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Abstract
Abstract
Diabetes mellitus is a global epidemic, with an estimated 171 million diabetic patients worldwide. 
Diabetic wound infections, particularly diabetic foot infections (DFI), are a major source of morbidity 
and their treatment consumes a significant amount of medical economic resources. In addition to 
debridement, the current first-line treatment for DFIs is antibiotic therapy. However, an increasing 
number of antibiotic-resistant DFI cases require alternative treatments. One potential alternative 
is bacteriophage therapy (BT). The purpose of this study is to develop and evaluate a topically-
delivered bacteriophage treatment protocol (including formulation and dosage regimen) with 
potential efficacy in diabetic wound infections.
The principles of wound infection management are discussed, and a comprehensive overview of 
DFI assessment and management is provided. The principles and current applications of BT are also 
examined, with particular regard to the potential for the inclusion of topical BT in the DFI therapeutic 
strategy.
In order to provide a thorough understanding of the epidemiology of DFI, a transversal observational 
multicenter study was conducted. Forty-nine hospitalized and ambulatory patients were enrolled, 
and 147 microbial isolates, comprising 43 different species, were cultured. This survey enabled 
the identification, characterization, and clinical correlation of the main bacteria involved, thus 
allowing the choice of the bacterial targets (Staphylococcus aureus, Pseudomonas aeruginosa and 
Acinetobacter baumannii). These targets were chosen not only because of their frequency but also 
because of their association with multi-drug resistance.
Following the epidemiological study, five previously morphologically and genetically characterized 
bacteria-specific lytic bacteriophages (S. aureus F44/10 and F125/10, P. aeruginosa F770/05 and 
F510/08, and A. baumannii F1245/05 bacteriophages) were tested against these strains. The 
bacteriophage spot test procedure was used, and their combination was shown to have broad host 
ranges for the different target bacterial species. Subsequently, the in vitro activity against planktonic 
cells and established biofilms was studied. Target bacteria during planktonic growth were challenged 
with their specific bacteriophages, which revealed effective, early killing at 4 hours, but this was 
followed by bacterial regrowth to pre-treatment levels within 24 hours. However, by using metabolic 
activity as a measure of cell viability within established biofilms, significant cell impairment following 
bacteriophage exposure was found when repeated treatment (every 4 hours) was applied. The 
greatest effects occurred in both planktonic and biofilm cells, showing a bacteriophage/bacterium 
input multiplicity (IM) of 10. These complementary studies on both planktonic cells and established 
biofilms allowed us to define a high IM (≥10) and a treatment protocol of multiple doses (every 4 
hours for 24 hours).
When in vitro testing showed the feasibility of the project and indicated the optimal dosage regimen, 
the opportunity to study the bacteriophage solutions led to the development of an animal model of 
diabetic wound infection, which was suitable for the evaluation of topical antimicrobial therapies. 
The Galiano et al. murine splinted, excisional wound-healing model was used as a template and 
further refined and adapted using male chemically induced diabetic Wistar rats. After every step of 
the procedure was optimized, a model was established, which accurately reproduced not only the 
healing of infected wounds in humans but also the current treatment standard of care, including 
sharp debridement. 
This led to the subsequent in vivo testing of the antimicrobial activity and wound-healing capability 
of the topically delivered bacteriophage protocol against wounds with S. aureus, P. aeruginosa, and 
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A. baumannii infections, using single strains of the bacteria, the aforementioned animal model, 
and a previously optimized pig wound infection model. In conjunction with sharp debridement, the 
bacteriophage treatment effectively decreased bacterial colony counts and improved planimetric 
and histological parameters in S. aureus and P. aeruginosa infections, but was not as effective 
against A. baumannii. Although the improvements were more significant in the rodent model than 
in the porcine model, our results suggested that topically administered bacteriophage treatment 
when applied in conjunction with wound debridement may be effective in resolving chronic wound 
infections. Incidentally, the results of the in vitro and in vivo studies were not only complementary 
but also yielded similar microbiological results, further highlighting the consistency and efficacy of 
the protocol across the tested scenarios.
However, this project is not without limitations. Only one strain each of the bacteria was used 
in the in vivo testing, which meant that the effectiveness of the treatment was limited to these 
strains and cannot be universally assumed to be effective against related, similar, or other untested 
strains. Moreover, although the animal models are appropriate in terms of their biological similarity 
to humans, they fail to account for the full complexity of human DFIs, which could influence 
the effectiveness of the protocol. Furthermore, only one type of BT protocol was tested. It was 
demonstrably effective, but it may not be the most efficacious form of BT protocol. Additionally, 
bacteriophage resistance was not examined or tested, so even if the BT protocol is effective, this 
study cannot predict outcomes for all scenarios in which the BT protocol may be used.
Nevertheless, collectively these studies show that a high IM (≥10) and multiple dose (every 4 hours 
for 24 hours), topical BT protocol may be an effective therapeutic approach to diabetic wounds 
infected with different pathogens, particularly those identified as antibiotic-resistant. These results 
represent the first step in the development of a fully regulated human clinical trial that explores the 
potential of BT in diabetic wound infections. The ultimate goal of this study is to transform BT into a 
viable, everyday strategy for treating DFIs.
xi
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Resumo
A diabetes mellitus configura-se hoje como uma epidemia global, com uma estimativa mundial de 
cerca de 171 milhões de diabéticos. As infeções de feridas em diabéticos, particularmente as infeções 
do pé diabético, são uma importante fonte de morbidade, e representam uma significativa fonte de 
consumo de recursos médicos e económicos. A par do desbridamento mecânico, o atual tratamento 
de primeira linha para as infeções do pé diabético é a terapêutica antibiótica. No entanto, são cada 
vez mais as infeções por bactérias resistentes aos antibióticos, o que incita ao desenvolvimento de 
terapêuticas alternativas. Uma alternativa potencial é a terapêutica bacteriofágica. O objetivo deste 
estudo foi o desenvolvimento e avaliação de um protocolo de terapêutica bacteriofágica tópica 
(incluindo a formulação e posologia) com potencial eficácia no tratamento de infeções de feridas de 
diabéticos.
São abordados os princípios gerais da terapêutica das infeções da pele e tecidos moles, com 
especial referência às infeções do pé diabético. Também os princípios gerais e as aplicações atuais 
e potenciais da terapêutica bacteriofágica são detalhados, destacando-se o potencial para a sua 
inclusão na estratégia terapêutica nas infeções do pé diabético.
A fim de proporcionar uma visão global da epidemiologia das infeções do pé diabético, conduziu-se 
um estudo observacional, multicêntrico e transversal. Foram recrutados 49 doentes de ambulatório 
e em hospitalização, tendo-se isolado 147 microrganismos, pertencendo a 43 diferentes espécies. 
Este estudo permitiu a identificação, caracterização e correlação clínica das principais bactérias 
responsáveis pelas infeções do pé diabético, permitindo, assim, a escolha dos alvos bacterianos 
(Staphylococcus aureus, Pseudomonas aeruginosa e Acinetobacter baumannii). Estes microrganismos 
foram escolhidos não só pela sua frequência, mas também pela sua associação à resistência aos 
antibióticos.
Na sequência do estudo epidemiológico, foram testados nestas estirpes cinco bacteriófagos líticos 
bactéria-específicos previamente caracterizados morfológica e geneticamente (bacteriófagos S. 
aureus F44/10 e F125/10, P. aeruginosa F770/05 e F510/08 e A. baumannii F1245/05), utilizando o 
procedimento de spot test para bacteriófagos. As combinações de bacteriófagos bactéria-específicos 
demostraram ter amplos host range para as diferentes espécies de bactérias-alvo. Posteriormente, 
a atividade destas combinações sobre células planctónicas e em biofilme maduro foi estudada in 
vitro. As bactérias-alvo em crescimento planctónico foram infetadas com diferentes combinações 
dos seus bacteriófagos específicos, obtendo-se eficácia inicial (nas primeiras 4 horas), porém, 
com recrescimento bacteriano para os níveis pré-tratamento em 24 horas. No entanto, em células 
de biofilmes maduros – usando a atividade metabólica como uma medida da viabilidade celular 
– obteve-se uma importante limitação da viabilidade após exposição repetida (a cada 4 horas) 
às diferentes combinações dos bacteriófagos específicos. Os maiores efeitos, tanto sobre células 
planctónicas como sobre as células em biofilme, ocorreu com uma input multiplicity de 10. Estes 
estudos complementares em células planctónicas e em biofilme maduro permitiram definir um 
protocolo terapêutico utilizando uma input multiplicity elevada (≥ 10) e múltiplas doses (a cada 4 
horas durante 24 horas).
Uma vez que os testes in vitro mostraram a viabilidade do projeto e indicaram a posologia 
ideal, a oportunidade de estudar as soluções de bacteriófagos levou ao desenvolvimento de um 
modelo animal de infeção da ferida diabética adequado para a avaliação das terapêuticas tópicas 
antimicrobianas. O modelo murino excisional de cicatrização de feridas com utilização de tala de 
Galiano et al. foi adaptado e aperfeiçoado, utilizando ratos Wistar machos com diabetes mellitus 
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induzida quimicamente. Depois de otimizar cada etapa do processo, foi estabelecido um modelo que 
não só reproduz com precisão o processo de cicatrização de feridas infetadas em seres humanos, mas 
que reproduz igualmente o atual protocolo de tratamento destas feridas, incluindo o desbridamento 
mecânico.
Isto levou ao subsequente ensaio in vivo – no modelo animal acima mencionado, bem como num 
outro modelo porcino de infeção de ferida previamente otimizado – da atividade antimicrobiana e da 
capacidade de cicatrização de feridas do protocolo de terapêutica bacteriofágica tópica em feridas 
infetadas por estirpes individuais de S. aureus, P. aeruginosa e A. baumannii. A terapêutica bacteri-
ofágica tópica, em conjunto com o desbridamento mecânico, resultou efetivamente na diminuição 
da contagem de colónias bacterianas bem como na redução da área de ferida e melhoria dos parâ-
metros histológicos em feridas infetadas por S. aureus e P. aeruginosa, não tendo sido demonstrada 
tanta eficácia nas infetadas por A. baumannii. Estes resultados, embora mais expressivos no modelo 
de roedor do que no modelo porcino, sugerem que a terapêutica bacteriofágica tópica, quando 
aplicada em conjunto com o desbridamento mecânico, pode ser eficaz na resolução de infeções de 
feridas crónicas. Aliás, os resultados dos ensaios in vitro e in vivo não só são complementares, como 
também apresentam resultados microbiológicos semelhantes, destacando a consistência e eficácia 
do protocolo entre os cenários testados.
No entanto, este projeto não é isento de limitações. Apenas uma estirpe de cada uma das bactérias 
foi usada no teste in vivo, o que significa que a evidência da eficácia terapêutica é limitada a estas 
estirpes, não podendo ser assumida como eficácia universal, nomeadamente em estirpes não 
testadas. Ademais, e independentemente da similaridade biológica dos modelos animais com os 
humanos, eles não conseguem dar conta de toda a complexidade das infeções do pé diabético que 
pode influenciar a eficácia do protocolo. Além disso, apenas um tipo de protocolo de terapêutica 
bacteriofágica foi testado. Apesar de ter demonstrado eficácia, pode não ser o protocolo mais eficaz. 
Por fim, também a resistência aos bacteriófagos não foi avaliada, o que significa que, mesmo que 
o protocolo seja eficaz, o estudo não pode prever os resultados para todos os cenários em que o 
protocolo possa ser utilizado.
Coletivamente, estes estudos demostram que um protocolo de terapêutica bacteriofágica tópica 
usando uma input multiplicity alta (≥ 10) e doses múltiplas (a cada 4 horas durante 24 horas) pode ser 
uma abordagem terapêutica eficaz para a terapêutica de feridas diabéticas infetadas por diferentes 
agentes patogénicos, especialmente aqueles associados a resistência aos antibióticos. Estes 
resultados representam um primeiro passo no desenvolvimento de um ensaio clínico controlado e 
regulamentado para a avaliação do potencial da terapêutica bacteriofágica nas infeções de feridas de 
diabéticos. O objetivo final deste estudo é transformar a terapêutica bacteriofágica numa alternativa 
viável para o tratamento das infeções do pé diabético.
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Aims and Thesis Outline
Aims
The main objective is the development of a topically delivered bacteriophage treatment protocol 
(including formulation and dosage regimen) with potential efficacy in diabetic wound infections.
The secondary objectives are the following:
– conduct an epidemiological survey of diabetic foot infections in Lisbon, allowing the 
identification and characterization of the main bacteria involved and their correlation with 
clinical data;
– investigate, in vitro, the antimicrobial activity of bacteriophage solutions against planktonic 
cells and established biofilms;
– develop an animal model of diabetic wound infection suitable for the evaluation of topical 
antimicrobial therapies, namely topical bacteriophage therapy; and
– investigate, in vivo, the antimicrobial activity and wound-healing capability of bacteriophage 
solutions delivered topically to wounds in an animal model of diabetic chronic wound infection.
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Thesis outline
This thesis is divided into three sections (A, B, and C). 
Section A includes the aims and outline of the thesis as well as the general introduction, which 
describes the context of the research, providing a theoretical foundation for the thesis. The General 
Introduction presents background information on chronic wounds, specifically diabetic foot 
infections, and provides the current framework for their diagnosis and treatment. In addition, it 
gives a general outline of bacteriophage biology and bacteriophage therapy, especially concerning 
topical therapy.
Section B, whose general outline is presented in Figure A0-1, is divided into four chapters. Chapter 1 
presents the epidemiological survey of diabetic foot infections in Lisbon, allowing the identification, 
characterization and clinical correlation of the main bacteria involved, and thus justifying the 
chosen bacterial targets. Chapter 2 presents a detailed characterization of the bacteriophages used 
with regard to their spectrum of activity, and their genetic and morphological structure. It also 
describes their activity against planktonic cells and established biofilms, justifying the posology and 
dosage regimen used in the animal studies. Chapter 3 presents the optimization of a new wound 
infection model in chemically induced diabetic Wistar rats, which is suitable for the evaluation of 
topical antimicrobial therapies, namely bacteriophage therapy. Chapter 4 presents the study of the 
antimicrobial and wound-healing capability of bacteriophage solutions delivered topically to wounds 
in two (rodent and porcine) animal models of diabetic chronic wound infection. Each chapter is 
introduced by a short text that frames it according to the general outline of the thesis.
Section C includes chapters on the general discussion and future research. The chapter on 
General discussion summarizes and discusses the main findings, as well as the implications and 
methodological limitations of the results obtained. The chapter on Future prospects presents 
future research directions that could provide the next steps along the path to a practical and widely 
applicable topical bacteriophage therapy. In addition, it also presents potential applications and 
future research directions outside the area of bacteriophage therapy.
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9Section A
General Introduction
Chronic wounds
Definitions and epidemiology
Chronic wounds, such as diabetic foot ulcers (DFUs), chronic venous leg ulcers, and pressure ulcers, 
are defined as wounds that have failed to proceed through an orderly and timely reparative process 
to produce anatomic and functional integrity over a period of 3 months (1). It has been estimated that 
around 1% of the population is affected by non-healing wounds, and the most affected population 
is over the age of 65 (2). Therefore, future aging trends in the world’s population are likely to lead 
to a significant increase in the incidence of these wounds over the next 20 years. This is of particular 
relevance because chronic wounds are a major source of pain and disability in patients, and their 
treatment involves considerable economic cost (3). 
Healing pathophysiology
Human skin is a complex and uniquely constructed organ with vital functions. Wounds occur when 
the integrity of the skin tissue is disrupted. In the acute wound setting, when this protective barrier 
is broken, the physiologic process of healing is immediately set in motion. In this classic model 
(4), wound healing is divided into three sequential but overlapping phases: (1) the inflammatory 
phase; (2) the proliferative phase (re-epithelialization, granulation and neo-angiogenesis); and (3) 
the remodeling phase (extracellular matrix remodeling). This complex, orchestrated biochemical 
cascade is characterized by signature events, cells, and their molecular regulators. For a complete 
review of the various cellular and inflammatory pathways involved in acute wound healing please 
refer to Schreml et al. (5).
Although most acute wounds heal in an uncomplicated fashion, following the aforementioned 
orderly and timely repair process, a large number of non-healing wounds fail to establish a sustained 
anatomic and functional result (6). Despite the differences in origin, non-healing wounds display 
common clinical features, include the following: the presence of necrotic tissue, lack of adequate 
blood supply, and excess exudate (7). Continuous bacterial clinical or sub-clinical infections (8) limit 
the cytokine-mediated switch to the later granulation tissue formation phase, resulting in prolonged 
inflammation and increased neutrophil infiltration with consequent protease activity. A persistent 
inflammatory phase is commonly witnessed by histopathology, which is associated with a delay in 
the formation of mature granulation tissue and failure of re-epithelialization (9).
Bacterial infection
As previously noted, clinical or subclinical infection is considered a common reason for impaired 
wound healing (10). Recent studies have emphasized both qualitative and quantitative aspects of 
wound microbiology, as well as the host’s immune response, as critical determinants of wound 
outcome. 
In relation to qualitative aspects, although important differences exist in the microbiology of 
various chronic wounds, some common concepts can be presented (Figure A1-1). Gram-positive 
cocci, namely Staphylococcus aureus, are the first microorganisms to colonize1 and acutely infect2 
breaks in the skin. Chronic wounds develop a complex polymicrobial microbiology, including aerobic 
gram-negative rods and anaerobes. Nonfermenting gram-negative bacilli are found in many patients 
1  Presence of multiplying bacteria in a wound but not causing tissue damage
2  Presence of multiplying bacteria in a wound causing tissue damage and clinical signs of infection
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with chronic or previously treated infections, and Pseudomonas aeruginosa is specifically associated 
with wounds treated with wet dressings (11). Anaerobes are rarely the sole pathogen, but they often 
participate in a mixed infection with aerobes, especially in cases of deep tissue infection (12). These 
mixed infections provide an optimal opportunity for microbial synergy, which increases the net 
pathogenic effect and hence the severity of infection (13). Thus, the presence of specific pathogens 
is less important than are the composition of the polymicrobial wound microbiota and the presence 
of additional potentiating factors, namely bacterial biofilms. Bacterial biofilms are formed when 
planktonic phenotype bacteria attach to the wound surface and colonize into highly organized 
structures composed of extracellular polymeric substance (EPS) produced by the microorganisms 
and the host’s surrounding tissues (14). Within the biofilm, both the protective outer coating and the 
altered bacterial phenotype contribute to the enhanced resistance of microorganisms to the host 
response, as well as to various antibiotic treatments. The described formation and behavior of the 
entire biofilm community is directed by signaling molecules that are produced when microorganisms 
reach a critical number—critical colonization3. This phenomenon is termed “quorum sensing,” and 
it has been shown to be a key regulator of the expression of virulence factors as well as a modulator 
of host immunity (15).
Figure A1-1 – Qualitative aspects of acute and chronic wounds. Gram-positive cocci, namely S. 
aureus, are the first microorganisms to colonize and acutely infect breaks in the skin. Chronic wounds 
develop a complex polymicrobial microbiota, including aerobic gram-negative rods and anaerobes.
Assuming that the qualitative microbiology remains constant, the probability of wound infection 
increases as the microbial load increases to a critical level, when infection or a failure to heal is 
considered almost inevitable (13). Breidenbach et al. (16) established this critical level in complex 
extremity wounds, as a bacterial tissue count >105 of colony-forming units (CFU)/g. However, there 
are exceptions to this rule of thumb because various organisms have different intrinsic virulence 
3  Presence of multiplying bacteria in a wound adversely affecting wound healing while not causing classical clinical sings of infection
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potentials. A good example is ß-hemolytic streptococci, which are able to induce tissue damage at 
102 CFU per gram of tissue, while greater counts of less pathogenic organisms may be of little clinical 
significance (17). 
Another critical factor is the efficacy of the host’s immune response in dealing with wound 
microbiota. Infection is facilitated by local potentiating factors, such as tissue necrosis and hypoxia 
(caused by poor local perfusion accentuated by the hypermetabolic state and microbial cellular 
metabolism), which impair the immune cell activity in the wound environment (18).
All these complex interactions have been systematized in the wound infection continuum (Figure 
A1-2). This concept describes the effects of increasing bacteria quantity and diversity in wound tissue 
and their relationship to the quality of the host’s immune response (19). 
Figure A1-2 – Wound infection continuum. Wound infection can be defined as the process by which 
organisms bind to tissue, multiply, and then invade tissue and elicit an immune response. It can be 
illustrated as an infection continuum or shown as an equation. The quantity of microbes representing 
the states of colonization, critical colonization, and infection are unique and related to the quality 
of the host immune response. At a certain quantity, these organisms may begin quorum sensing or 
communicating chemically, triggering the expression of virulence factors, namely the production of 
biofilm.
Wound infection management principles
Correctly identifying the etiology of a chronic wound, as well as the local and systemic factors that 
may contribute to poor wound healing, is essential to an adequate therapy and key in successful 
12
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wound management (1). However, regardless of the specific type of wound, general wound 
management principles exist for all chronic wounds (20) (Figure A1-3). 
The initial and most important step in the management of any chronic wound, infected or not, is 
to remove the necrotic material and debris until normal tissue appears. This is called debridement, 
which reveals the healthy tissue required for wound healing while the wound bed is cleansed of 
bacterial biofilms (21). Although there are several modalities of debridement, sharp debridement 
is generally regarded as fast and effective and, as elegantly demonstrated by Wolcott et al. (22), 
also opens a time-dependent antimicrobial therapeutic window. A serial debridement strategy 
further enhances this effect, by enabling the frequent disruption of the biofilm and increasing its 
vulnerability to treatment (23). This strategy is not only theoretical but also has been recognized 
as effective in a retrospective analysis of patients in a randomized controlled trial of growth factor 
therapy in DFUs (24).
Antimicrobial therapy may further enhance the reduction of the number of bacteria in chronic 
wounds (25). Although systemic infection is treated with systemic antibiotics (13), these do not 
effectively decrease bacterial levels in granulating wounds where, theoretically, topically applied 
antimicrobials (topical antibiotics or antiseptics) could be more effective (26). Irrespective of the 
definitions of antibiotics and antiseptics, for which a lack of consensus within the literature exists, 
these may be divided into two categories: antimicrobial solutions used to irrigate wounds and 
antimicrobial preparations designed for longer periods of contact time. The former usually have 
only a brief contact time with the wound surface and include hypochlorites and substances, such as 
potassium permanganate. The latter are normally developed as creams, ointments, and impregnated 
dressings, including most topical antibiotics (e.g. fusicidic acid) and silver-based products (e.g. silver 
sulphadiazine). Some products (available in different forms) fall into both categories: povidone 
iodine, chlorhexidine and hydrogen peroxide (27). Controversy has long surrounded the use of topical 
antimicrobial agents because of the lack of adequate proof of their efficacy, reports of cytotoxicity, and 
risk of antibiotic-resistance induction, which depends on the particular formulation, concentration 
of active ingredient, and duration of exposure (28). Most efficacy studies are suboptimal and have 
varied designs that are not easily comparable (28). Moreover, most have not considered or have 
even excluded debridement (27). However, a systematic review of controlled trials (29) showed 
that several topical substances hastened healing and induced a few improved outcomes. A recent 
Cochrane systematic review (30) concluded that evidence supported the use of a topical antiseptic 
in a specific chronic wound type. Regardless of the decision to initiate topical antimicrobial therapy, 
general consensus exists about its discontinuation when bacterial balance has been achieved 
because protracted courses of antibiotics may inhibit wound healing and promote the development 
of resistant organisms (20).  
After preparation of the wound bed by using debridement and antimicrobial agents, a moist 
environment, which has been accepted as the best topical environment for open wounds (20), should 
be maintained. If, despite all efforts of optimization, the wound fails to heal in a timely fashion, 
surgical closure is generally recommended. 
13
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Figure A1-3 – Common wound infection management principles. The initial and most important 
step in the management of any chronic wound is debridement, which opens a time-dependent 
antimicrobial therapeutic window. Antimicrobial therapy (topical antibiotics or antiseptics) may 
further enhance the reduction of the number of bacteria in chronic wounds. 
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Diabetic foot infections
Definitions and epidemiology
The world is facing a major epidemic of diabetes mellitus (DM). There are an estimated 171 million 
diabetic patients worldwide, and this number is expected to double by the year 2030 (31). All DM 
patients are at risk of developing a diabetic foot ulcer (DFU), which is a full-thickness wound below 
the ankle, irrespective of duration. Based on current studies, the annual population-based incidence 
is 1 to 4% with a prevalence of 4 to 10%, and the estimated lifetime risk is 25% (32). According 
to a study published by the Eurodiale study group (33), approximately 58% of DFU patients will 
become clinically infected. Patients with DM frequently require minor or major amputations of the 
lower limbs (15 to 27%), and in more than 50% of cases, infection is the preponderant factor (34). 
Major amputation is associated with significant morbidity and mortality (ranging from 13 to 40% 
at 1 year to 39 to 80% at 5 years (32)), in addition to immense social, psychological and financial 
consequences (35). The treatment of diabetic foot infections (DFI) accounts for up to one-quarter of 
all diabetic admissions in both Europe and the United States (US), making it the single most common 
reason for DM-related hospital admission (36). The solution to this predictable progression includes 
the development of structured screening tools to identify those at risk and the implementation of 
standardized education and prevention protocols. However, as stated by Lavery et al. (37), even 
with the best preventive standard of care, 9% of patients with DM will still develop a DFI, with the 
consequent risk of amputation. 
Pathophysiology
A prior DFU is an almost obligatory prerequisite for DFIs, even though, in some cases, the wound 
may have closed before DFI presentation (37). DFUs have a multifactorial nature, as numerous 
observational studies have indicated. It is well established that insulin deficiency (absolute or relative) 
is the basis of the biochemical abnormalities that lead to the organic complications of DM and the 
biological deficits of tissue healing and regeneration (38). DFUs result from a complex interaction of 
two major risk factors: neuropathy—both symmetric and bilateral, with varying degrees of alterations 
in autonomic, sensory and motor functions —plays the main role, while peripheral vascular disease 
resulting from atherosclerosis plays a secondary role (Figure A1-4). Approximately 50 to 60% of all 
DFUs can be classified as neuropathic. Signs or symptoms of vascular compromise are observed 
in 40 to 50% of all patients. The vast majority of patients have neuroischemic ulcers, and only a 
minority of patients have purely ischemic ulcers (39). However ulceration of the diabetic foot, either 
neuropathic or ischemic, does not occur spontaneously; it follows some form of extrinsic (e.g., low-
pressure trauma from ill-fitting shoes) or intrinsic trauma (e.g., from the atrophy induced by motor 
neuropathy of the foot’s intrinsic muscles) (40). 
Once the protective layer of skin is broken, deep tissues are exposed to bacterial colonization. In 
DFUs, in addition to the considerations discussed in the previous chapter, infection is facilitated by 
ischemia, the particular anatomy of the foot (i.e., it is divided into several compartments, which 
explains the rapid spread of infection), and intrinsic immunological deficits, especially in terms of 
neutrophil dysfunction (41). 
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Figure A1-4 – Diabetic foot infection pathophysiology. Diabetic foot ulcer results from the complex 
interaction of a number of risk factors. Neuropathy (with alterations in motor, sensation, and 
autonomic functions) plays the central role and causes ulcerations because of trauma or excessive 
pressure in a deformed foot without protective sensibility. Once the protective layer of skin is broken, 
deep tissues are exposed to bacterial colonization. Infection is facilitated by diabetes mellitus-
related immunological deficits, especially in terms of neutrophils, and it rapidly progresses to the 
deep tissues.
Bacterial infection
The microbiologic features of DFIs develop according to the already described microbiological 
principles of chronic wounds, with some specificities. Acute infections in patients who have not 
recently received antimicrobials are often monomicrobial (almost always with an aerobic gram-
positive cocci), whereas chronic infections are often polymicrobial (including gram-positive and 
gram-negative aerobes and anaerobes (18)). However, the impaired host’s defenses around necrotic 
tissue allow low-virulence bacteria, such as coagulase-negative staphylococci and Corynebacterium 
species, to assume a pathogenic role (11).
The intrinsic pathophysiological characteristics of DFIs, along with long periods of hospitalization, 
complex surgical procedures, and prolonged broad-spectrum antibiotic therapy, are also predisposed 
to infection with antibiotic-resistant organisms (e.g., methicillin-resistant S. aureus [MRSA] or 
vancomycin-resistant enterococci [VRE]) (18, 42).
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Assessment 
Recognizing important risk factors and making a logical treatment-oriented assessment of DFIs requires 
a consistent and thorough diagnostic approach. Such evaluation involves the careful assimilation 
of global medical foot and wound history, a systemized and detailed physical examination, and the 
results of complementary diagnostic procedures. Various systems have been proposed to classify DFUs, 
but none has gained widespread acceptance. The International Working Group of the Diabetic Foot 
developed the PEDIS classification system (43), which consists of internationally applicable guidelines 
that can reliably predict the outcome of diabetic foot management (44). The PEDIS system classifies 
all DFUs into the subcategories of five main parameters (perfusion, extent/size, depth/tissue loss, 
infection and sensation), according to strict criteria (Table A1-1). Although it was not developed as 
a guide for daily management or to predict the outcome of an individual patient, it considers all the 
potentially useful information obtained from the patient’s clinical history, foot examination, and 
diagnostic exams. Consequently, the use of this systematic examination ensures that important aspects 
are not overlooked. 
The assessment of DFIs based on the PEDIS classification has been reviewed elsewhere (45). In this 
chapter, we will consider only the evaluation of infection. The diagnosis of infection is clinical, based 
on the presence of symptoms and signs of inflammation (39), and it must always be confirmed and 
classified according to the depth of involvement. In the PEDIS grading system, three parameters are 
particularly relevant to clinical management and outcome: the involvement of skin only (Grade 2); the 
involvement of deeper structures (Grade 3); and the patient’s systemic inflammatory response (Grade 
4). To categorize the patient definitively into one of these groups, different diagnostic procedures are 
indicated. 
All patients should have a complete blood count with differential, erythrocyte sedimentation rate 
and c-reactive protein testing. However, caution must be exercised when interpreting laboratory 
tests because no marker is sufficiently sensitive or specific to confirm the diagnosis of DFI, and tests 
are often misleading, even in the case of severe lesions (46). In these patients, the most sensible sign 
of infection is often recalcitrant hyperglycemia, despite regular anti-hyperglycemic regimens. 
Another problem is determining the presence of osteomyelitis. The International Working Group 
on the Diabetic Foot has proposed consensus criteria (47) for diagnosing diabetic foot osteomyelitis; 
however, these remain to be validated by a properly designed trial. A positive probe-to-bone test 
(i.e., when a sterile metal probe reveals a hard and gritty surface compatible with bone) in the 
presence of DFI appears to have a relatively variable positive predictive value, while a negative test 
in a low-risk patient markedly decreases the likelihood of osteomyelitis (48). This simple technique 
may be complemented by imaging studies (e.g., plain radiographs and magnetic resonance imaging). 
However, the gold standard criterion for diagnosing osteomyelitis is a characteristic histopathology 
(acute or chronic inflammatory cells or necrosis) associated with a positive culture from a bone 
specimen ideally obtained at the time of surgical debridement or by fluoroscopic- or computed 
tomography-guided percutaneous biopsy (47). 
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Table A1-1 – PEDIS classification system. The International Working Group of the Diabetic Foot’s 
PEDIS system classifies all foot ulcers in subcategories of five main categories (perfusion, extent/
size, depth/tissue loss, infection and sensation), according to strict criteria. PaCO2: partial pressure 
of carbon dioxide in the arterial blood; TcpO2: transcutaneous oxygen pressure
Categories Grades Description
Perfusion
grade 1
No symptoms or signs of peripheral artery disease in the affected foot
   in combination with
– palpable dorsal pedal and posterior tibial artery or
– ankle-brachial index 0.9 to 1.10 or
– toe-brachial index >0.6 or
– TcpO2 >60 mmHg
grade 2
Symptoms or signs of peripheral artery disease but not of critical limb ischemia: 
– presence of intermittent claudication or
– ankle-brachial index < 0.9, but with ankle pressure >50 mmHg or
– toe-brachial index<0.6, but systolic toe blood pressure >30 mmHg or
– TcpO2 30-60 mmHg or
– other abnormalities on non-invasive testing, compatible with peripheral 
artery disease but with critical limb ischemia
grade 3
Critical limb ischemia:
– systolic ankle blood pressure <50 mmHg or
– systolic toe blood pressure <30 mmHg or
– TcpO2 < 30 mmHg
Extent     Wound size after debridement (measured in square centimeters)
Depth
grade 1 Superficial full-thickness ulcer, not penetrating deeper than the dermis
grade 2 Deep ulcer, penetrating to subcutaneous structures (fascia, muscle or tendon)
grade 3 Deep ulcer, penetrating any of the subsequent layers of the foot (bone or joint)
Infection
grade 1 No symptoms or signs of infection
grade 2
Infection involving the skin and the subcutaneous tissue only
   at least two of the following items must be present:
– local swelling or induration
– erythema >0.5 to 2 cm around the ulcer
– local tenderness or pain local warmth
– purulent discharge (thick, opaque to white or sanguineous secretion)
grade 3 Infection involving structures deeper than skin and subcutaneous tissues or
erythema >2 cm plus one of the items described above
grade 4
Foot infection accompanied by signs of systemic inflammatory response syndrome:
– temperature >38 ºC or <36 ºC
– heart rate >90 beats/min
– respiratory rate >20 breaths/min (or PaCO2 <32 mmHg)
– white blood cell count >12.000 or <4.000 cells/mm3 
(or 10% band forms)
Sensation
grade 1 No loss of protective sensation
grade 2
Loss of protective sensation 
   absence of perception of the one of the following tests:
– absent pressure sensation, determined with a 10-g monofilament   on two 
out of three sites on the plantar side of the foot or 
– absent vibration sensation, determined with a 128-Hz tuning fork tested on 
the hallux
18
General Introduction
 
In the absence of suspected osteomyelitis, bacteriological sampling, which must be done after 
mechanical debridement and cleansing of the wound with gauze soaked in sterile physiological 
saline, is indicated if infection is clinically suspected. The best sampling technique remains a matter 
of debate. While tissue biopsy and fluid aspirate are considered the gold standard for diagnosing 
wound infection (13), such invasive tests are infrequently performed for superficial wounds or in 
many practice settings, such as outpatient clinics, because of concerns about enlarging the ulcer 
or inducing pain (13, 49). Superficial swabbing of the wound is discouraged, but swabbing the 
base of the ulcer is acceptable if it is the only possible option (50). Independent of the sampling 
method, specimens must be placed in transport medium and be sent to the microbiology laboratory 
as quickly as possible. Assuming that at present, there are no completely reliable microbiological 
methods to distinguish between pathogenic and nonpathogenic microorganisms, microbiologists 
and clinicians must collaborate closely to interpret the results, taking into account the sampling 
conditions, transport time and conditions, and the type of bacteria isolated. 
Treatment 
When a DFI patient presents to the care team, a multidisciplinary management strategy should 
be rapidly implemented (Figure A1-5) because evidence suggests that this reduces the incidence 
of major amputation. The multidisciplinary team should include the following: a diabetologist, a 
surgeon with relevant expertise in managing DFI, a tissue viability nurse and ideally a podiatrist, as 
well as access to other specialist services (e.g., vascular surgeons and orthopedists) (50). 
The literature includes excellent, complete reviews on the current treatment strategies of DFIs (18, 
45), which is beyond the scope of this thesis. In this chapter, we will consider only infection control. 
Drainage and surgical debridement are two different but complementary surgical procedures that 
are essential in infection control. Drainage is the incision of an area of tissue phlegmon or abscess, 
and should be the first-line treatment for all DFIs, if these are present. Debridement, following the 
principles already described, should follow and be performed as soon as possible.
Randomized clinical trials have shown that systemic antibiotics selected according to the severity of 
infection are clinically valuable in DFIs (18, 51); as in the majority of infectious diseases, they must be 
provided as early as possible. However, as authoritative guidelines emphasize (18, 50) and a recent 
systematic review confirms (52), no particular antimicrobial regimen has been shown to be superior 
to others in DFI treatment. The initial empirical antibiotic therapy in DFIs should aim to cover the most 
common pathogens, based on the known local epidemiology of DFIs. Moreover, the therapy and should 
subsequently be refined according to clinical response and microbiological results (11). The optimal 
duration of antibiotic therapy has not been clearly established, but it could be 1 to 2 weeks for simple 
forms of infection, and 2 to 4 weeks for moderate to severe forms of skin and soft tissue infections 
(18). The application of topical antibiotics, although not currently advisable for most clinically infected 
chronic wounds, may be considered for a properly managed wound with subclinical infection that is 
failing to heal, or to help in the removal of biofilms that have been implicated in persistent infections 
(28). 
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Figure A1-5 – Management of diabetic foot infections. The multidisciplinary team must consider 
draining invasive infections, debriding necrosis, and promptly starting empirical antibiotic therapy, 
complemented by appropriate vascular reconstruction. Complete and permanent off-loading of 
the wound should follow. Accumulating evidence indicates that negative pressure wound therapy 
(NPWT) should be included in the treatment pathway. Assuming appropriate attention to all these 
steps, a wound that fails to improve should prompt the clinician to consider alternative and adjunctive 
therapies. Control of vascular risk factors and a biomechanically sound surgical reconstruction, with 
or without amputation, must be considered in the final common pathway of the treatment plan in 
order to minimize the risk of recurrent ulceration.
Once the infection has been controlled, revascularization must be immediately considered. The 
main objective in patients with DFIs is to obtain sufficient perfusion to control the infection and save 
the limb, in which the temporary improvement of perfusion obtained with endovascular therapy 
may be sufficient to promote healing and prevent amputation (53). 
After the wound has healed, the control of vascular risk factors should be addressed. In the 
presence of deformity, a biomechanically sound foot reconstruction must be completed to prevent 
the recurrence of foot ulceration. On the other hand, if the wound fails to improve despite repeated 
surgical interventions, alternative and/or innovative therapies should be considered (e.g., growth 
factors and hyperbaric oxygen therapy). However, if all these treatments fail or are not considered, 
amputation remains the only option in cases of severe infection, especially in the neuroischemic 
foot. Major (leg or thigh) amputations should be exceptional, occurring only in cases of uncontrolled 
life-threatening infection. 
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Bacteriophages
Introduction
Bacteriophages are viruses that consist of a genome contained within a protein coat and specifically 
infect bacteria. They are the most abundant entities on earth (the estimates range from 1030 to 1032 
(54) ), and they play key roles in regulating the microbial balance in every ecosystem where this has 
been explored (55). 
Bacteriophages were discovered independently by two microbiologists: in 1915 by the British Felix 
Twort (56) and in 1917 by the French-Canadian Felix d’Hérelle (57). Although Twort did not pursue 
his discovery, d’Hérelle systematically investigated the nature of bacteriophages (58) and explored 
their ability to function as therapeutic agents (59). 
Bacteriophage taxonomy
As viruses that infect bacteria, bacteriophages are genotypic and phenotypically different from viruses 
that infect archaea (archaeovirus) and eukarya (eukaryovirus). The name “bacteriovirus” was recently 
proposed as scientifically appropriate (60). The classification of bacteriophage was assigned to the 
International Committee for Taxonomy of Viruses (ICTV), which recognizes 14 families of bacteriophages 
(61).  Eleven of these families are not grouped in a superior taxonomical category, while the other three 
are included in the order Caudovirales. This comprises the vast majority of known bacteriophages (96 
%) and its members have in common deoxyribonucleic acid (DNA) genomes and a complex morphology 
with a capsid of regular symmetry (the head) and a DNA injection apparatus of helicoidal symmetry 
(the tail). The morphology of the tail defines the three families of the order: Myoviridae (with a long, 
contractile tail), Siphoviridae (with a long, non-contractile tail), and Podoviridae (with a short tail).
The ICTV classification is based mainly on morphological analysis, nucleic acid type, and host 
organism. This classification has been greatly criticized during the past few years because it is 
dependent on electron microscopic images and does not take into account the rapidly increasing 
amount of genomic and proteomic data (62). Furthermore, innumerable bacteriophages whose 
genomes have been completely sequenced—especially prophages of lysogenic bacteria and 
bacteriophages of non-cultivable hosts—for which no electron microscopic images are available. 
Because bacteriophage genomes are highly mosaic, it is now becoming clear that a strictly hierarchical 
taxonomy cannot represent the complex relationships between viral species. Thus, there is increasing 
consensus that bacteriophage classification should be based on genomic data (63).
Bacteriophage lifecycle
Lysis of the host cell by bacteriophages is a complex process consisting of a cascade of events 
involving several structural and regulatory genes. Moreover, not all bacteriophages replicate in a 
similar way, and there are significant differences in their replication cycles between strictly lytic4 
and temperate bacteriophages. However, for a specific group of bacteriophages, Caudovirales, 
morphogenesis is so similar that a standard process has been suggested (64). Bacteriophages do 
not have their own metabolism, and require the metabolism, energy resources, and materials of 
their hosts to replicate. Common steps in the replication process of bacteriophages can be properly 
correlated with the graphical representation of the one-step growth curve, which translates the 
experimental interaction between the bacteriophage and its host over time (Figure A1-6).
4 Strictly lytic (often described as virulent) bacteriophages are both lytic and incapable of displaying a lysogenic cycle. Throughout the text the term 
“lytic bacteriophage” refers only to “strictly lytic bacteriophage”.
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Figure A1-6 – Common steps of the bacteriophage lytic replication process properly correlated with 
graphical representation of the one-step-growth curve (a myovirus is used here as example). Once a 
bacteriophage encounters a target bacterium the process of bacteriophage replication takes place: 
(1) the bacteriophage adsorbs and ligates to bacterial surface receptors, then the sheath contracts 
and the hollow tail tube is thought to penetrate through the cell cytoplasmic membrane, injecting 
bacteriophage nucleic acid in the bacterial cytoplasm; (2) the genetic material of the bacteriophage 
takes up the biosynthetic machinery of the host and, during the eclipse period, mRNA expression 
occurs resulting in directed macromolecular biosynthesis; (3) during maturation, the previously 
synthesized bacteriophage structural proteins are assembled, and bacteriophage particles 
accumulate inside the cell; (4) at the end of the latent period, the accumulation of lytic proteins 
results in cell lysis and release of bacteriophages. The burst size corresponds to the average number 
of progeny bacteriophage particles produced per infected bacterium.
Cellular infection
Bacteriophages must encounter target bacteria before cellular infection occurs. This process 
of extracellular search occurs through diffusion and other means of movement (65, 66), which 
is followed by virion adsorption to the host bacteria. Adsorption is the process by which specific 
bacteriophage receptor binding proteins (tail fibers in Myoviridae), through the effects of diffusion 
and Brownian motion5, come into contact with specific and chemically complementary locations 
(bacterial receptors) on the bacterial surface. Generally, after an initial weak and reversible interaction, 
5  Random movement of microscopic particles suspended in a fluid resulting from the impact of molecules of the surrounding medium
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a strong and irreversible binding occurs between one or more components of the bacteriophage tail 
and a receptor of the cell surface (67). For this purpose, bacteriophages can use as specific receptors 
bacterial capsules, different parts of lipopolysaccharide, flagella, fimbriae, and many other surface 
proteins. The second step involves major structural rearrangements of the bacteriophage tail and 
tail/heath connector (tail contraction in the case of myoviruses), which culminate in the penetration 
(mechanic and/or enzymatic) of the tail apparatus through the host cell envelope (68). The third step 
is the injection of bacteriophage DNA into the bacterial cytoplasm.
 
Lytic cycle
After the injection of viral DNA, the genetic material of the bacteriophage takes up the biosynthetic 
machinery of the host (69). In the first phase, called the eclipse period, it is not possible to find 
bacteriophages inside or outside the cells. During this period, specifically ordered mRNA expression 
occurs, which results in directed macromolecular biosynthesis: (1) early protein synthesis, which 
constitutes a set of proteins required for replication of the bacteriophage genetic material; and (2) 
late proteins synthesis, corresponding to a set of structural proteins (comprising the capsid and the 
various components of the tail) and proteins required for the lysis step. The next phase is called 
maturation. During this period, the genetic material and the previously synthesized bacteriophage 
structural proteins are assembled, and bacteriophage particles accumulate inside the cell. The last 
phase, which corresponds to the end of the latent period, occurs because of the accumulation of 
lytic proteins and results in cell lysis and the release of bacteriophages (67, 69).
Temperate bacteriophages and lysogenic cycle
Temperate bacteriophages can multiply through the lytic cycle, or they may remain in a quiescent 
state inside the host cell. In this state, the bacteriophage genome (referred to as prophage) exists in 
a suppressed state, and the majority of genes are not transcribed. In many cases, the bacteriophage 
genetic material integrates into the host chromosome and is replicated and passed to daughter cells 
(67). 
Bacteriophage-biofilm interactions
Despite the increasing recognition of the importance of bacteriophage-biofilm interactions, the 
complex nature of those interactions is not yet conclusively understood (70). Biofilms are dynamic 
structures containing voids and passageways lined with bacteria, with ongoing balances between 
bacterial growth, microcolony differentiation, and bacterial release into the planktonic state (71). 
Biofilms pose barriers to extracellular search because of its intricate structure, and the movement 
of bacteriophages from the bulk fluid to the biofilm is dependent on particle concentration (72). 
Bacteriophages can further increase their mobility within the biofilm by deploying EPS-degrading 
depolymerases, which can modify the biofilm’s structure (73). The subsequent steps depend on the 
bacteriophage’s encounter with susceptible bacteria in microcolonies. This is followed by host infec-
tion cycles and progeny release with continuous additional EPS depolymerization (Figure A1-7).
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Figure  A1-7 – Bacteriophage-biofilm interactions (adapted from (70)). Considered is a lytic 
bacteriophage that is physically associated with an extracellular polymeric substance (EPS)-
depolymerase that interacts with an EPS-displaying biofilm: (A) a free bacteriophage diffuses and 
encounters a biofilm EPS, resulting in local digestion; (B) bacteriophage encounters and infects a 
susceptible bacterium in a microcolony, with subsequent progeny release; and (C) additional EPS 
depolymerization occurs along the path of a newly released single bacteriophage, which then 
encounters and infects a new microcolony associated bacterium, resulting in a progeny release 
that is followed by free-bacteriophage dissemination into bulk water toward subsequent biofilm 
acquisition. 
Bacterial resistance to bacteriophages
Genotypic resistance
Bacteria are constantly challenged by bacteriophages and rates of bacterial bacteriophage resistance 
can be as high as 10-3 per host-cell, but usually average 10-7 (74). This resistance to bacteriophage 
infection is accomplished by mutation and selection, and it depends on a variety of mechanisms. 
These include the following: (1) blocking bacteriophage adsorption; (2) inhibiting the injection of 
bacteriophage genomes; (3) preventing DNA integration by superinfection exclusion systems (Sie); 
(4) degradation of bacteriophage DNA by the Restriction-Modification (RM) defense system and 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); and (5) blocking bacteriophage 
replication, transcription, translation or virions assembly by the abortive-infection system (Abi) (74). 
However, the most common mechanism resistant to bacteriophage infection involves strategies to 
prevent a bacteriophage from attaching to the cell surface, such as the lack of receptor expression, 
an alteration of a receptor, and the masking or shielding of receptors (75). 
Evolutionary dynamics of bacteria and bacteriophage
It has been shown that bacteria and their corresponding lytic bacteriophages coevolve and 
establish equilibrium between their respective populations, in interactions that are analogous to 
those of a predator-prey model (76). Therefore, it is anticipated that natural bacteria-bacteriophage 
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populations, especially when in biofilm, will exhibit the coexistence of resistant and sensitive  bacterial 
clones (76). This can be caused solely by a mutation and selection process, resulting in a constant 
arms race between bacteriophage and its host (77). However, there is evidence for non-heritable 
mechanisms that lead to the coexistence of bacteria and bacteriophages. Four equally valid and 
non-mutually excluding theories have been presented (Figure A1-8): numerical refuge, physiological 
refuge hypothesis, spatial refuge, and shielding by bacterial debris. The numerical refuge theory (78) 
predicts that simple mass-action interactions between bacteriophages and sensitive and resistant 
bacteria determine the stability of the population, so when densities of sensitive bacteria are low, 
bacteriophage densities will also decline, allowing sensitive cells to increase again. The physiological 
refuge hypothesis (79) postulates that during certain stages of bacterial life cycles sensitive bacteria 
may become transitorily resistant to bacteriophage infection, which may occur for example if 
resistance is based not on a complete absence of receptors, but instead on a greatly reduced number 
of receptors. The spatial refuge theory (80) states that physical heterogeneity in the environment 
protects some sensitive bacteria from bacteriophage infection. Finally, the shielding by bacterial 
debris predicts that active bacteriophages adsorb into fragments of lysed cells (debris) and inject 
their genetic material in a suicidal manner discounting from the system as a bacteriophage (81). 
Figure A1-8 – Theories suggested to explain bacteria-bacteriophage coexistence and coevolution: 
(A) numerical refuges predicts that simple mass-action interactions between bacteriophages and 
sensitive and resistant bacteria determine the stability of bacteria and bacteriophage population; (B) 
physiological refuges postulates that during certain stages of bacterial life cycles, sensitive bacteria 
may become transitorily resistant to infection; (C) spatial refuges states that physical heterogeneity 
in the environment protects some sensitive bacteria from bacteriophage infection; and (D) shielding 
by bacterial debris predicts that active bacteriophages adsorb onto fragments of lysed cells (debris) 
and inject its genetic material in a suicidal manner discounting from the system as a bacteriophage.
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Biological basis of bacteriophage therapy safety
Bacteriophages are considered to have a tropism that is unique to bacteria (60) because adhesion 
is mediated only by bacterial ligands, and different metabolic pathways preclude bacteriophage 
replication in human cells. This is well established by molecular biology studies in which bacteriophages 
that were genetically manipulated to penetrate human cells had no replicative capacity within them 
(82). However, Merril et al. (83) conducted complicated experiments to demonstrate the possibility 
of the expression of a bacterial-derived viral gene in human cells. Nevertheless, this is so rare that it 
does not require serious consideration when accessing the safety of bacteriophages. 
The pathogenic potential of bacterial species is caused by the presence and expression of genes 
that encode for virulence factors. In a process called bacteriophage conversion, bacteriophage-
encoded virulence genes can convert their bacterial host from a nonpathogenic strain to a virulent 
strain by providing mechanisms for the invasion of host tissues and the avoidance of host immune 
defenses (84). Several temperate bacteriophages have been shown to carry such virulence genes, 
thus exerting roles in the various stages of pathogenesis: attachment and colonization (85, 86); host 
immune avoidance (87); cellular invasion (88); intracellular survival (89, 90); and toxin production 
(91-95). Nonetheless, lateral gene transfer may also occur in strictly lytic bacteriophages by a process 
known as generalized transduction. Although it should be recognized, this potential biosafety 
problem should not be overestimated (96) because of the following factors: (1) human commensal 
bacteria and their respective bacteriophages interact continuously in the body, causing greater 
lateral gene transfer than the one potentially induced by therapeutic bacteriophages; and (2) it is 
now generally accepted that antibiotic therapy by itself is a potential inducer (97) and enhancer (98) 
of lateral gene transfer.
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Bacteriophage therapy
Introduction
Bacteriophage therapy (BT) is the use of bacteriophages with the goal of reducing or eliminating 
pathogenic bacteria. It should be differentiated from bacteriophage biocontrol, which refers to 
the control of environmental pests or nuisance bacteria by bacteriophages (99). BT holds great 
promise as a means of controlling infections caused by antibiotic resistant bacteria (independently 
or synergistically with chemical antibiotics) or under circumstances where chemical antibiotics are 
otherwise ineffective (100). 
Historical perspective
The history of bacteriophage biology and BT (Figure A1-9) has been recounted in some depth 
and from various perspectives in a number of reviews (101-107). Not long after the discovery of 
bacteriophages, Felix d’Herelle used them to treat dysentery (59). The first publication on BT was 
performed by Bruynoghe and Maisin (108), who successfully used bacteriophages in the treatment 
of S. aureus skin infections. Several promising studies followed (109-111), and, encouraged by 
these results, d’Herelle and others continued their trials in BT. Additionally, in the 1930s, multiple 
companies (e.g., L’Oreal, Eli Lilly Company, E.R. Squibb & Sons and Swan-Myers-a division of Abbott 
Laboratories (112)) began the marketing of bacteriophage products that were active against various 
microorganisms, but not subjected to external evaluations to assess their clinical effectiveness (113).
However, the effectiveness of the preparations was controversial because of the lack of properly 
controlled studies, quality control, and sufficient understanding of the biology of bacteriophages 
(112)). Two negative reviews were ordered by the Council on Pharmacy and Chemistry of the US 
(114, 115). The advent of antibiotics resulted in the cessation of commercial production in much 
of the Western world by the 1940s. However, in Western Europe, some interest in BT remained 
and resulted in sporadic publications (116). In France, Dr. Jean-François Vieu of the “Service des 
Enterobacteries” of the Pasteur Institute of Paris used BT in selected cases during the 1970s (117), 
and in Vevey, Switzerland, Dr. Glauser Harrmann developed and marketed (with the approval of 
the National Pharmacy Commission) bacteriophage preparations for therapeutic application (118). 
Conversely, BT continued to be used, separately or synergistically with antibiotics, in Eastern Europe 
and the former Soviet Union (119). 
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Figure A1-9 – Timeline depicting the comparative evolution of bacteriophage therapy, discovery of 
antibiotics and the Staphylococcus aureus resistance profile, as an illustrative example of the bacterial 
resistance evolution. MRSA – Methicillin-resistant Staphylococcus aureus; VRSA – Vancomycin-
resistant Staphylococcus aureus
Bacteriophage therapy design
Baceriophage isolation, choice and purification
The first steps in all BT protocols involve some combination of bacteriophage isolation and selection 
(101, 120, 121). As it is practiced, BT relies on two possible, or even complementary, models of 
bacteriophage selection (Figure A1-10): large-scale uniform therapy (prêt-à-porter) and personalized 
therapy (sur-mesure) (122). The first involves mixtures (cocktails) of different bacteriophages that 
display a wider host range than their individual components do. The major advantages of this kind of 
application are the wider spectrum of activity and reduced resistance development in the short term. 
Hence, along with intellectual property issues, western pharmaceutical companies are pursuing 
this approach. Thus, the first modern, commercially available human therapeutic bacteriophage 
preparation will probably be based on this model (101).
In the second approach (personalized therapy), pathogenic bacteria are isolated from a specific 
patient and tested against a large, ideally well characterized collection of previously isolated 
bacteriophages. Although this is not compatible with the current licensing processes, the long and 
expensive regulatory pathways needed for the large-scale uniform therapy approach are forcing 
non-profit BT centers to opt for a sur-mesure concept, while adhering to standards of ethics, safety 
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and quality control (123). Significantly, evidence (124) has shown that these custom-designed 
bacteriophage preparations are more effective than the mainstream-production ones are.
Regardless of the bacteriophage model, the procedures by which bacteriophages are isolated from 
natural samples (e.g., sewage or river water) are similar and involve some form of bacteriophage 
enrichment (123). This strategy aims to isolate specific bacteriophages that are readily propagated in 
the laboratory. Isolation and laboratory amplification is followed by a purification procedure (120). 
While the simplest of bacteriophage purification protocols involves only clarification of lysed cultures 
via centrifugation or filtration, more stringent purification using ultracentrifugation are followed by 
a series of filtration and washing/buffer-exchange steps, or various forms of chromatography, which 
is always required when an invasive bacteriophage application is envisaged (101). 
Figure A1-10 – Bacteriophage therapy concepts: prêt-à-porter or sur-mesure (adapted from (122)). 
The large-scale uniform therapy (prêt-à-porter) model involves mixtures (cocktails) of different 
bacteriophages that display a wider host range than their individual components do. The major 
advantages of this kind of application are the wider array spectrum of activity and reduced 
resistance development in the short term. Hence, along with intellectual property issues, western 
pharmaceutical companies are following this approach. The personalized therapy (sur-mesure) 
model involves the isolation of pathogenic bacteria from a specific patient and testing against a 
large, ideally well-characterized collection of previously isolated bacteriophages. While this is not 
compatible with the current licensing processes, the long and expensive regulatory pathways needed 
for the large-scale uniform therapy approach are forcing non-profit bacteriophage therapy centers 
to opt for this concept, while adhering to standards of behavior, safety and quality control.
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Pharmacology
Pharmacology may be divided in two major components: pharmacokinetics (description of the 
body’s impact on a drug) and pharmacodynamics (description of a drug’s impact on the body). When 
considering antimicrobials as drugs, the concept of body includes both normal body tissues and 
the numerous symbiotic microorganisms that constitute the normal microbiota (microbiome), so an 
important component of antibacterial pharmacodynamics is the inhibition of the growth of target 
bacteria (66). The pharmacology of BT has been extensively reviewed with emphasis on various 
aspects of the subject (66, 125, 126). 
Bacteriophage application may be topical (applied directly where its action is desired and 
intending a local effect, including inhalation and enteric non-systemic applications), enteral (given 
via the digestive tract and intending a systemic effect), and parenteral (given by routes other than 
the digestive tract and intending a systemic effect) (66). However, this section concentrates on 
considerations related to topical applications because of its relative importance in this thesis and 
because it has been relatively under-considered in previous reviews.
Pharmacokinetics
Pharmacokinetics related to topical applications of drugs describes the time-dependent drug 
concentration following the application of the drug to the surface, which directly relates to its 
potential to reach concentrations that are sufficient to achieve primary pharmacodynamic effects 
(127). It also describes the drug’s absorption into the systemic circulation and consequent distribution 
(substance movement into other body tissues), metabolism (modification of drugs within the body) 
and excretion (movement of drugs out of the body). 
We will first focus our pharmacokinetic discussion on a specific bacteriophage characteristic: self-
amplification. This characteristic enables not only attaining but also, most importantly, sustaining 
the minimum bacteriophage density in the vicinity of the target bacteria, which is necessary to 
achieve the desired levels of eradication (66). The capability of bacteriophages to increase what 
in pharmacological terms would be their antibacterial dose leads to the concept of passive and 
active therapy (126, 128, 129). Passive therapy occurs when the initial dose and primary infection 
is sufficient to reduce bacterial numbers: this can be described as a pharmacologically conventional 
dosing. On the other hand, active therapy requires the ongoing replication of bacteriophages in 
order that the bacteriophage density reaches or is maintained at levels sufficient to control the 
multiplication of bacteria. However, active and passive therapies are not mutually exclusive and 
both can occur in the same treatment (Figure A1-11). To understand further the basic kinetic 
properties of BT, we must also appreciate the theoretical concepts of proliferation threshold and 
inundation threshold (126, 128, 129). The proliferation threshold represents the concentration that 
the bacterial population must exceed in order for the total bacteriophage numbers to increase. 
Similarly, the inundation threshold represents the minimum bacteriophage concentration above 
which the bacterial population declines. By integrating these concepts, we can understand that active 
therapy can occur only when the concentration of bacteria exceeds the proliferation threshold, and 
that passive therapy can occur only when the initial concentration of bacteriophage exceeds the 
inundation threshold. We introduce here the concept of clearance threshold that represents the 
bacteriophage titer required to reduce the density of a bacterial population to zero (129). Although 
these concepts are merely theoretical, there is now general consensus that BT protocols should be 
based on passive therapy using high initial bacteriophage titers approaching the clearance threshold 
(66, 130). While the attainment of sufficient titers solely via in situ bacteriophage replication (active 
30
General Introduction
 
therapy) should not be depended upon, bacteriophage replication nonetheless may provide a margin 
of safety in attaining BT efficacy (66). The initial high bacteriophage titers should be calculated based 
on the multiplicity of the 10 rule (99, 130), which states that if the goal is significant reduction 
in bacterial density, then we should strive for on the order of 10 bacteriophages adsorbed to the 
average bacterium. Finally, we should stress that bacteriophages display single-hit killing kinetics 
and that the clearance threshold is calculated based on the number of adsorbed bacteriophages, 
not the number of added bacteriophages (66). 
Figure A1-11 – Bacteriophage kinetics (adapted from (129)). Time plot of concentration of bacteria 
(solid lines) and bacteriophage (broken lines) representing a large inoculation before proliferation 
onset time, which results in mixed therapy: passive therapy followed by active therapy.
The discussion of absorption, distribution, metabolism, and excretion of bacteriophages following 
topical application is important mainly in safety considerations. Although several published animal 
studies concerned the BT of systemic and gastrointestinal infections (131-134), including the evaluation 
of pharmacokinetic parameters, there is no record of projects dedicated exclusively to topical therapy. 
However, from these published studies, we can extrapolate some data. A first important point is that 
even if some studies do not demonstrate systemic absorption of bacteriophages administered by 
non-parenteral routes (135, 136), bacteriophages applied topically have a propensity to circulate 
systemically (136-140). After topical application, systemic absorption takes place via the lymphatic 
system (141) as well as the blood (136), and it is dependent upon the intrinsic characteristics of the 
bacteriophage, the route of administration, as well as the characteristics of the initial dose, individual 
species, or host. Few studies have explored the differences among bacteriophages or the differences 
between individual patients in terms of bacteriophage absorption (66, 125). However, when 
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absorption occurs, it is very fast and nearly parallel to intravenous administration (142), resulting in 
the rapid distribution to the internal organs (143). The identification of bacteriophages in the brain, 
lung, kidney and spleen is possible after 3 hours, although titers are 102 lower than in the blood 
(136, 143). The organs of the mononuclear-phagocyte system (with special relevance to the liver) 
are the main site of the accumulation of bacteriophages (135, 144), and persistence is only relevant 
in the spleen (up to 12 days in rabbit (137)) with fast hepatic clearance (145). After administration 
and systemic absorption, bacteriophages show liver uptake and early excretion in feces (starting 
at 3 hours and ending 12 hours after adsorption (136, 146)) and urine (beginning 30 minutes after 
absorption (136)), although this occurs only with blood bacteriophage titers in excess of 105 PFU/mL 
(147). A final consideration is that because of the replicative capacity of bacteriophages, all these 
characteristics are dependent on the presence or absence of susceptible bacteria and their relative 
concentration (142), which makes it virtually impossible to design an in vivo pharmacokinetics curve. 
Toxicology
Bacteriophages are generally considered safe by the scientific community (148) and regulatory 
entities (149), based on different theoretical considerations and empirical and experimental 
evidence. Bacteriophages have been isolated from different human products (saliva (150), urine 
(151) and feces), constituting a major component of normal gastrointestinal microbiota (142, 152) 
because of its ability to replicate in symbiotic or pathogenic bacteria. Humans and other higher 
organisms are often exposed to interactions with bacteriophages, as shown by bacteriophages titers 
in ground  (estimated at 107 PFU/g (153)) and aquatic environments (estimated at 108 PFU/mL (54)). 
Although wastewater treatment plants contain high densities of bacteriophages, most of which 
have aerosolization potential and are capable of infecting human microbiota bacteria (154-156), 
no correlation between sewage bacteriophages and human diseases has been identified by public 
health agencies. Because bacteriophages are normal contaminants of food, it was proposed that the 
bacterial contamination of certain foods (e.g., carrots (157) and poultry (158)) may be established 
through counts of specific bacteriophages. Bacteriophages were also identified in commercial 
preparations of blood products (159, 160) and vaccines (161) for human parenteral administration. 
Because of concern about the safety of vaccines contaminated with bacteriophages, Milstien et 
al. (162) isolated and administered them (in high titer) in Rhesus monkeys, and did not observe 
any adverse reaction. Petricciani et al. (163) concluded that human vaccines contaminated with 
bacteriophages posed no real threat to public health. It is thus possible to conclude that the contact 
between humans and natural bacteriophages is not incidental but instead intense and constant 
(142), and that over millions of years, this relationship has never been deleterious. This is also 
supported by the fact that bacteriophage genes were never identified in the human genome (96), 
unlike the high level of integration of retroviral genetic material. However, there is the potential for 
this relationship to change when bacteriophages are applied on a massive scale, as in BT. 
The empirical evidence of the safety of bacteriophages is in studies of Western Asia and Eastern 
Europe countries, which may not meet current standards of clinical research (164), such as Poland 
(165-171) and Georgia (172), in which no adverse effects were identified with massive exposure 
(doses between 105 and 1011) by oral, rectal, topical and inhaled routes (173). Minor adverse effects 
(fever and hepatodynia) were identified only in the use of intravenous preparations, and even these 
were not attributed to bacteriophages, but instead to the bacterial contamination of the byproducts 
used (174, 175). Perhaps the most complete safety analysis results were found in two studies 
published by Bogovazova et al. where the pharmacokinetics and toxicology of bacteriophages specific 
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to Klebsiella spp. produced by the Russian firm ImmunopreparatTM were analyzed. In the first study 
(143), bacteriophages administered by intramuscular, intraperitoneal and intravenous injection to 
rats and guinea pigs resulted in no acute toxicity or macroscopic or histological changes, even at 
doses 3,500 times higher than those projected for humans. The second study (176) evaluated the 
safety (and efficacy) of a bacteriophage preparation in the treatment of a range of human patients 
infected with Klebsiella spp., which was considered non-toxic.
The safety of BT was also assured by the experimental evidence in studies meeting the current 
standards of clinical research, including studies of animal safety (135, 177). Recently, human studies 
were performed in accordance with experimental patterns in healthy volunteers (178, 179), patients 
with chronic renal failure (180), patients with congenital immunodeficiencies (179, 181, 182), and 
patients infected with the human immunodeficiency virus (183).
The recognition of safety is well expressed by authorization granted by the US Food and Drug 
Administration (FDA) and the US Environmental Protection Agency for the marketing of bacteriophage 
solutions to control microbial contamination of food: (1) P100 ListexTM to control Listeria spp. in meat 
and cheese (http://www.ebifoodsafety.com) by EBI Food Safety; (2) AgriPhageTM for tomato and 
pepper harvests by OmniLytics Inc. (http://www.omnilytics.com); and (3) ListShieldTM, EcoShieldTM, 
or SalmoFreshTM to control respectively Listeria spp., Escherichia coli O157:H7 and Salmonella enterica 
by Intralytix Inc. (http://www.intralytix.com). Of special importance is the fact that the Director of 
the Office of Food Additive Safety, Center for Food Safety and Applied Nutrition of the FDA in the 
approval declaration of ListexTM P100 (184) concluded that the use of bacteriophage products, either 
isolated or cumulatively, had no expected significant effects on the human environment, excepting any 
environmental impact assessment. In addition is Staph Phage Lysate, an immunotherapeutic agent 
containing high bacteriophage titers (108 to 109 PFU/mL), which was marketed by Laboratories Delmont 
for animal use. Its topical and systemic use in human therapy was approved by the National Institute of 
Health after safety and efficacy studies were conducted in the US (185). The preparation was considered 
very safe with only minor adverse events reported over a period of 12 years with more than 35,000 SPL 
doses administered (102). No case of anaphylaxis, even with intravenous therapy, was observed (185).
Efficacy
BT has been extensively studied in animal models used in veterinary medicine (186), and some of 
the strongest evidence of its efficacy comes from animal studies. The number of papers in the BT field 
has increased substantially in recent years; however, the number of papers dedicated specifically 
to the topical application of bacteriophages is limited (187). Because excellent reviews dedicated 
to animal research studies have been conducted in the past few years (188-190), we will attempt 
to address the gap in the current knowledge on topical BT by examining the previously published 
animal studies of the efficacy of using bacteriophages in topical application. For historical interest, 
we will first refer the studies of Smith et al. (131-134) at the Institute for Animal Disease Research 
in the United Kingdom, which reported the successful use of bacteriophages in the microbiological 
and clinical cure of E. coli gastrointestinal infections in multiple animal models (mice, calves, lambs, 
and piglets). These studies constitute the basis of the mathematical models underlying BT presented 
in the previous section (76, 188), and they impelled other researchers to investigate the effect of BT 
in different animal models (173). The first relevant animal experimental studies exploring the utility 
of BT in skin wounds were by Soothill et al. (191, 192), which reported the utility of bacteriophages 
in preventing and treating experimental disease in skin grafts of rodents infected with S. aureus and 
nonfermenting gram-negative bacilli. 
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Recently, experimental animal studies have focused on the effective concentrations of 
bacteriophage needed to eliminate bacterial infections and the timing of administration. A study 
by Goode et al. (193) used lytic bacteriophages to reduce the contamination of chicken skin by 
Salmonella and Campylobacter spp., and a study by Kumari et al. (194) used a specific bacteriophage 
for the treatment of K. pneumoniae B5055-induced burn wound infections. Both studies concluded 
that low-titer bacteriophage administration is unlikely to be successful, and that increasing the IM 
increases the success of BT by reducing bacterial numbers. Other experimental animal studies that 
explored topical BT for areas other than the skin (195, 196) drew similar conclusions. 
Some of these previous animal studies have been used to outline the optimal bacteriophage 
posology and other pertinent details considered important in designing subsequent human 
volunteer trials. Bogovazova et al. (143) evaluated the efficacy and delineated the optimal 
bacteriophage concentration and administration route of bacteriophages for the treatment of 
infections caused by Klebsiella spp., and they subsequently used these results to evaluate the safety 
and efficacy of the bacteriophages in human Klebsiella spp. infections (176). Recently, the BioControl 
company (recently acquired by Targeted Genetics of Seattle to form a new joint company, AmpliPhi 
Biosciences Corporation) developed a topical bacteriophage formulation for P. aeruginosa otitis. 
The microbiological and clinical efficacy of this formulation was accessed in a canine model (197), 
and the results were used to develop a double-blinded safety and small-number efficacy trial in 
human patients suffering chronic otitis caused by P. aeruginosa. Finally, we should stress that animal 
studies conducted to evaluate the efficacy of therapeutic or prophylactic non-topical application of 
bacteriophages help to corroborate the general efficacy of BT, regardless of the form of application. 
In this regard, we would like to point out Matsuzaki et al.’s (198) study, which demonstrated the 
prophylactic effect of bacteriophage ΦMR11 when it was administered before a lethal dose of 
S. aureus. Most importantly, this study included as a negative control a bacterial lysate that did 
not contain a viable bacteriophage, which did not exert any protective effect, and thus excluded 
unspecific primer immunogenic effects of some bacteriophage proteins.
Human applications 
Excellent reviews of various aspects of human BT are available (100-103, 199-202). Here we will 
focus on recent relevant studies, as well as Polish and Georgian historical experiences related to 
the topical BT of wounds. First, because of its historical importance we refer to studies by Slopek et 
al. (166-171), which constitute the most detailed documentation to date of the general application 
of bacteriophages for the treatment of human infections. This set of studies involved 550 patients 
from all age groups in 10 Polish medical centers: the Wroclaw Medical Academy Institute of Surgery 
Cardiosurgery Clinic, the Children’s Surgery Clinic and Orthopedic Clinic, the Institute of Internal 
Diseases Nephrology Clinic, and the Clinic of Pulmonary Diseases. All treatments were conducted 
in a research mode, and the bacteriophage formulations were prepared at the Bacteriophage 
Laboratory of the Institute of Immunology and Experimental Therapy of the Polish Academy of 
Sciences, using standard methods and tested for sterility. The treatment protocol included the 
use of bacteriophage-soaked compresses applied as dictated by localized infection, in addition to 
systemic (oral) BT. Bacterial levels and bacteriophage sensitivity were continually monitored, and 
therapy was generally continued for two weeks beyond the last positive bacterial culture. In the 
final summary paper, the investigators thoroughly analyzed the results and presented success 
rates ranging from 75% to 100% (92% overall), as measured by wound healing and microbiological 
improvement. However a more recent analysis, based on the retrospective data of 153 patients 
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 admitted for bacteriophage treatment between January 2008 and December 2010 at the Institute 
of Immunology and Experimental Medicine (203), showed a lower success rate (39.9%). This was 
at least partially, justified by more rigorous methods of monitoring and evaluating the patients. 
Nonetheless, this Institute continues active exploration of different human applications of BT (204-
207), with a strong focus on the immunologic consequences of bacteriophage treatment (152, 201, 
208, 209). 
BT is also part of the general standard of care in Tbilisi, Republic of Georgia, under the auspices 
of the Bacteriophage Institute. A recent publication by Chanishvili and Sharp (210) drew worldwide 
attention to the depth and extent of the work developed by this center. The chapter on dermatology 
reports on the treatment of deep forms of dermatitis, such as furunculosis and abscesses. The protocol 
included drainage of the abscess and debridement of devitalized tissue followed by injection of the 
bacteriophage solution into the lesion and surrounding areas, with a reported treatment success of 
94.4% in patients who had previously failed antibiotic treatment. 
We should stress that currently in the major tertiary care centers of Georgia, BT is a primary tool for 
the successful treatment of multi-resistant infections. However, the application of bacteriophages is 
integrated into a broader wound care protocol that includes drainage, debridement, and early wound 
closure. Bacteriophage can be applied by direct irrigation of the wound with liquid preparations, 
soaking of bandages in liquid preparations, or by ultrasonic debridement of the wound in the 
preparation. Preference is generally given to using Pyophage cocktail (a commercial cocktail directed 
against five different bacterial species, including P. aeruginosa), at its standard concentration of 105-
106 pfu/ml of each of the bacteriophage components (100).
Recently, Markoishvili et al. (211) reported on the use of PhagoBioDerm—a biodegradable 
matrix impregnated with bacteriophages (S. aureus, P. aeruginosa, E. coli, Streptococcus spp. 
and Proteus spp.), ciprofloxacin, and benzocaine—to treat infected venous stasis skin ulcers in 
patients that had failed to respond to other treatment approaches. This study showed promising 
results, which were later confirmed in another study of radiation burns infected by multiresistant 
S. aureus (212). However, both studies received much criticism because they took place in 
Georgia, were uncontrolled, and did not yield microbiological evidence in most cases. In 2008, at 
the Wound Care Center (213) in Lubbock, Texas, a successful, physician-initiated, FDA-approved 
phase 1 safety trial of BT used a special formulation of fully sequenced bacteriophages prepared 
by the Intralytix company, containing only two bacteriophages active against S. aureus, five 
against P. aeruginosa and one against E. coli for the treatment of infected venous ulcers and 
other chronic wounds. This study managed to demonstrate the safety of the formulation, but 
it has to be complemented by a phase 2 efficacy study because the posology (dose and dosing 
interval) used (those permitted by the FDA) did not agree with existing data  on bacteriophage 
pharmacokinetics. 
Finally, we refer to the Belgian experience, which explored the possibility of using bacteriophages 
for human therapy, particularly in burn applications. During this process they developed an extensive 
collaboration with bacteriophage biologists in both Moscow and Tbilisi. In addition, an international 
organization, the Phages for Human Applications Group Europe (P.H.A.G.E.), was created for the 
promotion of research and clinical trials in BT, integrated within a regulated framework (http://
www.p-h-a-g-e.org/). As a key step towards full clinical trials of BT, the group carried out a small 
clinical safety study in burn patients infected with P. aeruginosa and/or S. aureus at the Brussels 
Burn Wound Centre of the Queen Astrid Military Hospital in Brussels. This study, which was 
approved by a medical ethics committee, included 9 patients and was launched following a process 
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which has been published step-by-step (123, 214). The formulation (BFC-1 bacteriophage cocktail) 
consisted of three bacteriophages: a Myovirus and a Podovirus against P.  aeruginosa and a Myovirus 
against S. aureus. The genome and proteome analysis were consistent with the conclusions that the 
chosen bacteriophages were not temperate and that there was an absence of toxin-coding genes. 
The cocktail was purified of endotoxin, and an elaborate quality control was performed including 
stability (shelf life), determination of pyrogenicity, sterility, and cytotoxicity. In the human study, 
a section of a large burn on each patient was exposed to a single bacteriophage spray application 
and another section, distant from the previous and belonging to the same wound, was used as 
a control. Both regions were evaluated with tissue biopsies before application and between 2 
and 5 hours after the treatment application by bacterial quantitative culture. While no adverse 
events related to the application of bacteriophages were identified, some technical problems were 
encountered, which limited the evaluation of efficacy. Biopsy samples were found to be excessively 
cumbersome, leading to long periods between the detection of a candidate with bacterial burn 
wound colonization and the inclusion of this patient in the study. To address these problems, in the 
next phase of the trial, patients will be selected based on visual observation of burn wound infection 
by an experienced clinician, and swabs will be used to monitor burn wound colonization. This will 
mean the inclusion of all burn wound infections, not just those with P. aeruginosa and S. aureus. The 
posology will also be different, with frequent applications (at least once a day) of larger quantities of 
the bacteriophage formulation in a cream or gel-based product (100). This very active international 
consortium has now submitted a new study protocol to conduct a prospective randomized double 
blind trial comparing mupirocin and bacteriophage ISP for the nasal decolonization of MRSA. The 
complete microbiological and molecular analysis of this therapeutically important bacteriophage, 
which includes stability assays, genome and virion analysis and an extensive host range screening, 
has already been published (215).
Regulatory issues
One of the major challenges in the clinical application of bacteriophages in Western medicine 
is adapting the regulatory framework to fit these very different self-replicating and self-limiting 
antimicrobials. As described in the previous sections, BT products have already been marketed in 
European countries. In Poland, which is a member of the European Union, a short term interim 
solution was to consider BT as an experimental treatment within the responsibility and supervision 
of medical ethical committees, as covered by the Physician Practice Act (Polish Law Gazette N° 28 of 
1997) and World Medical Association Declaration of Helsinki (214, 216). However, this provisional 
solution is not a substitute for fully controlled clinical trials in accordance with the US FDA or the 
European Medicines Agency (EMA) regulatory framework. 
Recently, EMA placed BT under the Medicinal Product Regulation, specifically under the category 
of Biologicals (Commission Directive 2001/83/EC). In the US FDA, bacteriophage applications are 
handled by the Division of Vaccines and Related Product Applications of the Center for Biologicals 
Evaluation and Research. However, neither of these guidelines fully cover aspects that are specific to 
bacteriophages. EMA and US FDA might have to revise their rules as they did for influenza vaccines, 
which also require a rapid updating and licensing procedure (217). These regulatory hurdles, 
along with the absence of strong intellectual property protection, have hampered pharmaceutical 
companies in the worldwide marketing of bacteriophage preparations. To avoid the drug licensing 
pathway, some US-based bacteriophage companies decided to develop bacteriophage products 
first for the decontamination of food, plants, fields and livestock (218). The US FDA and the US 
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Department of Agriculture Food Safety and Inspection Service (USDA, FSIS) currently recognize 
commercial bacteriophage preparations as safe and approved their use in food consumed by humans 
(71 Fed. Reg. 47729; 2006).
Non-profit organizations, such as P.H.A.G.E., advocate that bacteriophages should not be categorized 
as classical medicinal products. In the specific case of the European Union, these organizations 
lobby competent authorities and policymakers for the creation of an optimal regulatory framework 
dedicated specifically to BT, in addition to the present Medicinal Products Directive 2001/83/EC 
(219).
Advantages and disadvantages of bacteriophage therapy relative to chemical antibiotics
Lytic bacteriophages have self-replicating and self-limiting antibacterial properties, which makes 
them compelling alternatives to chemical antibiotics. The majority of the advantages and limitations 
associated with BT have already been presented in previous sections. Here we will condense them 
into a coherent whole, especially with regard to topical therapeutic bacteriophage.
As extensively discussed, bacteriophages have a low potential for intrinsic toxicity (119) and, owing 
to their host specificity, their disruption of normal microbiota tends to be minimal (220). This is in 
contrast with many chemical antibiotics, which, even when used topically, have unfavorable toxicity 
profiles and broader spectrums of activity, making them prone to induce superinfections (221). 
While the narrow spectrum of activity ascribed to bacteriophages is an advantage with regard to 
safety, it also places a heavy burden on the effective identification of pathogenic bacteria, especially 
from the point of view of bacteriophage sensitivity (222).
Lytic bacteriophages are bactericidal agents with a specific mechanism of action. Conversely, 
many antibiotics are bacteriostatic and hence may more readily permit bacterial evolution towards 
resistance (223). Because antibiotics and bacteriophages as therapeutic agents have different 
mechanisms of action, there is an absence of cross-resistance. Consequently, BT can be readily 
employed to treat antibiotic-resistant infections (200, 224). 
Bacteriophages are also versatile in terms of formulation development (220), in addition to their 
suitability for most routes of administration (100, 200). Thereby, one of their major advantages in 
relation to chemical antibiotics is the feasibility of topical application. Systemic antibiotics may not 
penetrate sufficiently into the infectious focus to provide sufficient on site concentration to eliminate 
the infection. This is mainly because of tissue hypoperfusion arising from vascular occlusive diseases, 
tissue necrosis, or fibrotic barriers. Similarly, antibiotics administrated topically are unable to 
provide effective wound concentration because of dilution by inflammatory exudates, neutralization 
by enzymes and other inflammatory mediators, and the inability to penetrate adequately into 
the necrotic tissues. The reproductive ability of bacteriophages avoids this problem because they 
continue to replicate and penetrate into tissue as long as susceptible bacteria are present (66, 100). 
Similarly, it is now recognized that the overwhelming majority of bacteria in chronic wounds exist 
in a biofilm phenotype (225) and, as previously described, bacteriophages have the potential to 
penetrate biofilms actively. 
Finally, bacteriophages are easily discovered (often from sewage and waste waters) and, especially 
for external applications, can be prepared fairly inexpensively to facilitate their potential applications, 
especially in underserved populations (226).
The major disadvantages associated with BT have already been partially addressed and are 
enumerated as follows: (1) bacteriophages specificity implies that their lytic spectrum may be limited 
and that causative bacterial pathogens have to be identified prior to their administration; (2) the 
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lytic life-cycle of bacteriophages described in in vitro environments may not be maintained under 
normal physiological conditions found in the wound; (3) bacteriophages may have and express genes 
that encode for virulence factors; (4) resistance to bacteriophage infection may be accomplished by 
mutation and selection; (5) bacteriophages are complex organisms that may potentially induce a 
noxious immune response from the host (highly dependent of the on the route of administration and 
bacteriophage type); and (6) there are limited proofs of efficacy of BT and reported cases of inefficacy. 
These concerns, specifically those related to safety, should be manageable through a combination 
of proper bacteriophage selection, effective formulation, and the clinician’s understanding of and 
familiarity with product application (222). 
Bacteriophage applications for the treatment of diabetic foot infections
Because antibiotics still represent the standard first-line therapy against bacterial infections, the 
envisaged use of BT should focus on infections involving antibiotic-resistant bacteria and/or chronic 
infections in areas not accessible to antibiotic therapy. The role of microorganisms in chronic wounds 
and the systemic and topical antimicrobial therapy of chronic wounds have been discussed in the 
previous sections. However, the use of antibiotics is not risk-free, and antimicrobial resistance in the 
general population is a continuing and growing concern (227). However, a report from the European 
Centre for Disease Prevention and Control and the EMA pointed out that only two new antibiotic 
drugs are under development, and both are in the early stages (228). Therefore, infected chronic 
wounds constitute one of the best field models for the application of BT. Among infected chronic 
wounds, DFIs are of particular interest for BT because of some intrinsic adverse characteristics, 
including poor vascularization and the presence of biofilm-associated infections frequently caused 
by antibiotic-resistant microorganisms (18, 45). In addition, DFIs are a leading cause of morbidity 
and mortality worldwide, also affecting the working-age population. The use of BT in DFI is not 
unfamiliar in medicine and has been used in both Europe and the United States. However, BT is not 
part of accepted treatment modalities in the western world, and proof of its efficacy is mainly found 
in uncontrolled studies (165) and individual case reports (229). Thus, the medical implementation 
of BT as a fully accepted alternative therapy in DFIs requires the prior pharmacologically informed 
modeling and development of approaches—in vitro and in vivo—using appropriate animal models 
in compliance with regulatory frameworks.
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Specific framework
The first steps in all BT protocols involve some combination of bacteriophage isolation and selection 
(1-3). In our particular case, we already possessed a relatively large bacteriophage library because 
we were working directly with a company (TechnoPhage, S.A.) that develops bacteriophage-based 
products. However, we needed to develop an epidemiological study to choose bacterial targets and 
assemble a bacterial library against which we could test the bacteriophages. Therefore, we conducted 
a transversal observational study at four clinical centers in Lisbon (2 outpatient clinics, 1 general 
surgery ward and 1 vascular surgery ward) for a 6-month period. Clinical data was collected using a 
structured questionnaire (Annex B1.0-1) and microbiological products (aspirates, biopsies, or swabs 
collected using the Levine method) for clinically infected foot ulcers of patients with DM, as advised 
by current clinical guidelines (4). All health care providers (HCP) were instructed about the proper 
methods for the collection of culture material, and a written protocol was provided (Annex B1.0-
2). Microbiological analysis was done at the Microbiology Laboratory of the Faculty of Veterinary 
Medicine, University of Lisbon. Sample processing, isolation, quantification, and identification of 
aerobic and anaerobic bacteria as well as antimicrobial susceptibility testing of the aerobic isolates 
were performed using the standard methods (5, 6). As quantitative cultures were performed, 
clinically relevant tissue burden (CRTB; swab count of >105 CFU/cm2, tissue count of >105 CFU/g or a 
needle aspiration sample of >105 CFU/mL) was used as a potential indicator of the microorganisms’ 
relevance in clinically infected DFUs. All isolated strains were stored, and clinical and microbiological 
information was compiled in a centralized database and later analyzed (Figure B1.0-1).
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Figure B1.0-1 – Study outline of epidemiological survey of diabetic foot infections. All patients with 
diabetes mellitus and clinically infected foot ulcers presenting to any of four clinical centers in Lisbon 
were included in the study by their health care providers (HCP). A diabetic foot ulcer was defined as 
a full-thickness wound below the ankle in a diabetic patient, irrespective of duration (7). Infection 
was defined clinically by symptoms and signs of inflammation as described by the infection item 
on the PEDIS system (7). Medical histories, examination details, and investigation reports were 
recorded using a structured questionnaire. Specimens were collected as advised by current clinical 
guidelines (4). In the case of abscess with intact integument (and other closed lesions), the protocol 
suggested sampling by needle aspiration under strict aseptic technique. For ulcers and other open 
wounds, biopsy specimens were required, except in situations where the HCP considered that the 
invasive procedure could place the patient at risk (pain induction or risk of enlarging the ulcer). In 
either procedure, debridement of necrotic tissue and cleansing with simple saline before sampling 
was obligatory. In biopsies, shaving or punch techniques (8) were required. In swab sampling, HCPs 
were instructed in a standardized procedure (9), based on the Levine 1 cm2 swab method, using a 
flocked swab. Transport of all samples in specific transport media to the laboratory was assured 
by an on-call express courier. Sample processing, isolation, quantification, and identification of 
aerobic and anaerobic bacteria as well as antimicrobial susceptibility testing of the aerobic isolates 
were performed using the standard methods (5, 6). All isolated strains were stored, and clinical and 
microbiological information was compiled in a centralized database and later analyzed.
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Abstract
Aims: An epidemiological survey of diabetic foot infections (DFIs) in Lisbon, stratifying the bacterial 
profile based on patient demographical data, diabetic foot characteristics (PEDIS classification), ulcer 
duration and antibiotic therapy. 
Methods: A transversal observational multicenter study, with clinical data collection using a structured 
questionnaire and microbiological products (aspirates, biopsies or swabs collected using the Levine 
method) of clinically infected foot ulcers of patients with diabetes mellitus (DM). 
Results: Forty-nine hospitalized and ambulatory patients were enrolled in this study, and 147 
microbial isolates were cultured. Staphylococcus was the main genus identified, and methicillin-
resistant S. aureus (MRSA) was present in 24.5% of total cases. In the clinical samples collected from 
patients undergoing antibiotic therapy, 93% of the antibiotic regimens were considered inadequate 
based on the antibiotic susceptibility test results. The average duration of an ulcer with any isolated 
multi-drug resistant (MDR) organism was 29 days, and previous treatment with fluoroquinolones 
was statistically associated with multi-drug resistance. 
Conclusions: S. aureus was the most common cause of DFIs in our area. Prevalence and precocity 
of MDR organisms, namely MRSA, were high and were probably related to previous indiscriminate 
antibiotic use. Clinicians should avoid fluoroquinolones and more frequently consider the use of 
empirical anti-MRSA therapy.
Keywords: Epidemiology, Diabetic foot, Infection, Microbiology, Portugal
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Introduction
Diabetes mellitus (DM) is a serious health problem that is rapidly expanding worldwide (1). 
One of the more frequent diabetic complications is diabetic foot, which results from a complex 
interaction between a number of risk factors. Neuropathy (with alterations in motor, sensitive and 
autonomic functions) has a central role, causing ulcerations because of trauma or excessive pressure 
on deformed feet that lack protective sensitivity (2). Once the protective layer of skin is broken, 
the deep tissues are exposed to bacterial colonization. Infections are facilitated by immunological 
deficits (especially in neutrophils), which are related to DM, and they rapidly progress to the deep 
tissues. Patients with DM frequently require minor or major amputations of the lower limbs (15 to 
27%), and in more than 50% of cases, infection is the preponderant factor (2).
S. aureus is the most prevalent isolate in diabetic foot ulcers (DFUs), together with other aerobes 
(including Staphylococcus epidermidis, Streptococcus spp., P. aeruginosa, Enterococcus spp. and 
coliform bacteria) and anaerobes (3, 4). Because of the polymicrobial nature of diabetic foot infections 
(DFIs), Karchmer et al. (5) questioned the need for precisely defining the causative microorganism and 
suggested a treatment strategy based only on the knowledge of the general epidemiology. More recently, 
an increase in the incidence of multi-drug resistant (MDR) organisms, namely methicillin-resistant 
S. aureus (MRSA) and extended-spectrum β-lactamase (ESBL)-producing gram-negative bacteria, is 
threatening the outcome of anti-infectious therapy in the community and in hospitalized patients (4). 
Therefore, the current guidelines (6) and expert opinion (7) advise providers to obtain specimens for 
culture before initiating empiric antibiotic therapy to help with the selection of a definitive therapy.
Although Portugal has one of the highest prevalences of DM, lower extremity amputations (8) 
and MRSA skin and soft tissue infections (9) in Europe, there is virtually no data on the prevalence 
and characterization of DFIs. Therefore, we performed an epidemiological survey of DFIs in Lisbon, 
stratifying the bacterial profiles based on patient demographical data, characteristics of diabetic foot 
(PEDIS classification), ulcer duration and current and recent (≤3 months prior) antibiotic therapy.
Subjects, materials and methods
This transversal observational study was conducted at 4 clinical centers (2 outpatient clinics, 1 general 
surgery ward and 1 vascular surgery ward) in Lisbon from January 2010 to June 2010. A structured 
questionnaire was developed to record medical histories, examination details and investigation 
reports by health care providers (HCPs). Specimens were collected from patients with DM and 
clinically infected foot ulcers, as advised by current clinical guidelines (6). A DFU was defined as a 
full-thickness wound below the ankle in a diabetic patient, irrespective of duration (10). Infection was 
defined clinically by symptoms and signs of inflammation, as described by the infection item on the 
PEDIS system (10). Specimens were obtained from patients before the first dose of antibiotics or while 
under antibiotic therapy with progression of infection signs and clinical deterioration of the ulcer. 
This study was approved by the Faculty of Medicine of the University of Lisbon Research Ethics 
Committee and the Portuguese Data Protection Authority, and written informed consent was 
obtained for every patient.
Clinical characterization 
For clinical characterization, 9 study factors were recorded for each patient: age, gender, DM duration 
(from diagnosis), last HbA1c value (accepted if collected in the last 3 months), hypertension and dyslipidemia 
(as defined according to the American Diabetes Association (ADA) guidelines for the diabetic population 
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(11)), active tobacco abuse (defined as ≥20 packs in the previous year), presence of ischemic heart disease 
(defined as previous history of myocardial infarction, coronary artery bypass graft or percutaneous 
transluminal coronary angioplasty) and chronic renal failure (defined as calculated glomerular filtration 
rate <30 mL min-1 1.73 m-2, permanent renal replacement therapy or previous transplant). 
Diabetic foot characterizations 
For characterization of diabetic foot, we used the International Working Group of the Diabetic Foot PEDIS 
system (10), which classified all foot ulcers in subcategories of five main categories (perfusion, extent/size, 
depth/tissue loss, infection and sensation), according to strict criteria. For the definition of osteomyelitis, 
a minimum of a positive probe-to-bone test (12) was accepted, but clinicians were encouraged to 
substantiate their diagnosis with the appropriate imaging studies. The number of previous ulcers and 
previous minor (toe or part of the foot) or major (above the ankle) amputations was also recorded.
Antibiotic therapy 
HCPs were asked to register all current and recent (over the previous 3 months) antibiotic therapies. 
Collection of samples 
All HCPs were instructed on the proper methods for the collection of culture material, and a written 
protocol was provided. In the case of abscess with intact integument (and other closed lesions), the 
protocol suggested sampling by needle aspiration under strict aseptic technique. For ulcers and 
other open wounds, biopsy specimens were required, except in situations where the HCP considered 
that the invasive procedure could place the patient at risk (pain induction or risk of enlarging the 
ulcer). In only these situations, superficial swab samples were accepted, in strict accordance with 
the National Institute for Health and Clinical Excellence diabetic foot guideline (6). For either of the 
procedures, debridement of necrotic tissue and cleansing with simple saline before sampling was 
obligatory. For biopsies, shaving or punch techniques, as previously described (13), were required. 
For swab sampling, HCPs were instructed on a standardized procedure (14), based on the Levine 1 
cm2 swab method, using a flocked swab (ESwab Collection System, Copan).
Transport 
Aspirates were transported in buffered isotonic agar with reduction agent media (Port-A-Cul Vial, BD 
BBL), and biopsies and swabs were transported in modified liquid Amies medium (ESwab Preservation 
System, Copan). Transport to the laboratory (Microbiology Laboratory, Faculty of Veterinary Medicine, 
Technical University of Lisbon) within 2 hours of collection was assured by an on-call express courier. 
Processing and microbiological analysis of wound specimens 
Standard methods for sample processing and isolation and identification of aerobic and anaerobic 
bacteria were used (15). Biopsy samples were weighed to the nearest milligram in sterile Petri dishes 
and homogenized in PBS using a pearl jar. A 100-µL volume of the homogenate was used for serial 
dilutions in PBS. For aspirate samples, a 100-µL volume of the recovered fluid was directly used for 
serial dilutions in PBS. Swab samples were vortexed with the swab inside for 5 seconds, and then a 
100-µL volume of the suspension was used for serial dilutions in PBS. Quantification was performed 
using the 10-fold serial dilution method (15), and 100 µL of each dilution was inoculated onto 
MacConkey agar (Merck)/Columbia ANC agar with 5% sheep blood (BioMérieux) and, in duplicate, in 
Schaedler agar with 5% sheep blood (BioMérieux). The first two plates were incubated under aerobic 
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conditions at 35°C for 24 to 48 hours, and the two Schaedler plates were incubated under anaerobic 
conditions (Anaerocult A, Merck) for 48 to 96 hours. Additionally, samples were inoculated in Brain 
Heart Infusion Broth (Difco, BHIB) to allow recovery of fastidious or low-concentration organisms. 
Isolates were identified by standard methods (15). In some instances, unusual strains were identified 
using partial 16S rRNA gene sequencing (16). Antimicrobial susceptibility testing of the aerobic 
isolates was performed using the standard disc diffusion method, as recommended by the Clinical 
and Laboratory Standards Institute (17). Quantitative results were expressed in CFU/mL for needle 
aspiration samples, CFU/g for biopsy samples and CFU/cm2 for swab samples. Consistent with the 
study by Bill et al. (18) and the results of a recent systematic review (19), a swab count of >105 CFU/
cm2 was considered equivalent to a tissue count of >105 CFU/g or a needle aspiration sample of >105 
CFU/mL; all of these values are considered to represent a clinically relevant tissue burden (CRTB). 
  
Multidrug resistance profiles 
Methicillin-resistant S. aureus (MRSA), methicillin-resistant Staphylococcus epidermidis (MRSE) 
and other coagulase-negative Staphylococcus spp. (MRCN) were defined as strains phenotypically 
resistant to cefoxitin (by the disc diffusion method). Vancomycin-resistant Enterococcus spp. (VRE) 
were defined as strains that were phenotypically resistant to vancomycin. (ESBL)-producing gram-
negative strains were phenotypically confirmed using the cephalosporin/clavulanate combination 
disk test (20). Multi-drug resistant (MDR) P. aeruginosa and Acinetobacter baumannii strains 
were defined as those resistant to at least three of six antibiotics, including amikacin, gentamicin, 
ciprofloxacin, piperacillin, ceftazidime and imipenem. Pan-drug resistant (PDR) P. aeruginosa and 
A. baumannii/calcoaceticus strains were defined as those sensitive only to colistin (21). All of 
these strains (MRSA, MRCN, VRE, [ESBL]-producing gram-negative bacteria, and MDR and PDR P. 
aeruginosa and A. baumannii/calcoaceticus) were considered to be MDR organisms.
Statistical analysis
Qualitative variables were expressed as percentages, and quantitative variables are expressed as 
means ± SD (standard deviation). Significance of the study variables was tested using Student’s 
t-test, the Chi-square test or Fisher’s exact test, where appropriate. A two-tailed p value of <0.05 was 
considered to be statistically significant. Additionally, the ulcer duration (in days) was stratified by 
microbial isolate and visually summarized in a box plot, with the boxes representing the lower and 
upper quartiles, the vertical line the median, the bars the minimum and maximum data points, and 
the solid diamond symbol the mean.
Results
A total of 49 patients (mean age of 62.7 ± 12.7 years and a male-to-female ratio of 6.8) were admitted 
during the study period. Their clinical and diabetic foot characteristics, stratified in accordance with 
the sample collection method, are shown in Table B1.1-1. Among these patients, the mean duration 
of DM was 23.0 ± 12.8 years, 26.5% had HbA1c levels <58 mmol/mol (<7.5%), >90% had hypertension 
and/or dyslipidemia, and 30.6% and 10.2% had ischemic heart disease and chronic renal failure, 
respectively. Two-thirds of the patients had undergone recent antibiotic therapy, and one-third was 
currently undergoing antibiotic therapy. The majority of the samples came from outpatients (65.3%), 
and swabbing was the most commonly used method (63.3%) for sample collection. However, 92.8% 
of hospitalized patients and all clinically suspected osteomyelitis patients had samples collected 
by an invasive technique. There were statistically significant differences in the  isolation rates of 
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microorganisms from deep tissue samples and superficial swabs, with fewer aerobes per sample, 
in particular gram-positive bacteria (2.3 ± 1.0 vs. 1.3 ± 1.2), isolated from swabs, but there was no 
difference in the isolation rate of anaerobes or MDR organisms. 
Table B1.1-1 – Clinical and microbiological characteristics of DFIs stratified  
by the sample collection method
total
(n = 49)
swab samples
(n = 31)
deep tissue samples 
a
(n = 18)
Hospitalization (%) 34.7% 12.9% 72.2%
Demographical data
 Age (years) 62.7 ± 12.7 60.2 ± 13.5 67.0 ± 10.1
 Male gender (%) 83.7% 87.1% 77.8%
Diabetes mellitus
 Control of diabetes (HbA1c <7%) 20.4% 16.1% 17.8%
  Duration (years) 23.0 ± 12.8 22.5 ± 12.8 23.7 ± 13.1
Co-morbidities
 Hypertension (%) 93.9% 96.8% 88.9%
 Dyslipidemia (%) 95.9% 93.4% 100%
 Active tobacco abuse (%) 38.7% 32.2% 50.0%
Organ lesions
 Ischemic heart disease (%) 30.6% 35.5% 22.2%
 Chronic renal failure (%) 10.2% 12.9% 5.6%
Diabetic foot characterization
 Number of previous ulcers 1.6 ± 1.5 1.9 ± 1.6 1.2 ± 1.2
 Previous amputation (%)
  major
  minor
46.9%
10.2%
38.8%
51.6%
9.7%
45.2%
38.9%
11.1%
27.8%
 Duration of present ulcer (days) 30.6 ± 31.9 33.4 ± 25.9 25.7 ± 40.5
 Neuroischemic (%) 53.1% 54.8% 50.0%
 Osteomyelitis (%) 30.6% 0.0% 83.3%
 PEDIS
  Perfusion  1 (%) 44.9% 43.9% 46.6%
      2 (%) 40.8% 40.7% 41.0%
      3 (%) 14.3% 19.3% 12.4%
  Extent (cm2) 13.3 ± 56.9 1.2 ± 0.6 34.3 ± 91.7
  Depth  1 (%) 18.4% 29.0% 0.1%
      2 (%) 51.0% 71.0% 16.6%
      3 (%) 30.6% 0.0% 83.3%
  Infection 2 (%) 61.2% 87.1% 16.6%
      3 (%) 36.7% 12.9% 77.7%
      4 (%) 2.0% 0.0% 5.4%
  Sensation 2 (%) 100% 100% 100%
Antibiotic therapy
 Previous (%) 65.3% 67.7% 61.2%
 Current (%) 30.6% 23.0% 43.7%
Isolates
        Monomicrobial (%) 16.3% 12.9% 22.1%
 Total number (per sample) 3.0 ± 1.4 3.2 ± 1.3 2.7 ± 1.4
    Aerobes 2.5 ± 1.1 2.7 ± 0.9 2.3 ± 1.3
   Gram-positive 2.0 ± 1.0 2.3 ± 1.0 1.6 ± 1.1
   Gram-negative 0.6 ± 0.6 0.5 ± 0.5 0.7 ± 0.7
    Anaerobes 0.4 ± 0.6 0.4 ± 0.6 0.3 ± 0.6
    MDR organisms 0.6 ± 0.9 0.5 ± 0.8 0.9 ± 1.0
a biopsies (n = 14) and aspirates (n = 4) MDR – multi-drug resistant
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Out of the 49 patients enrolled in this study, 147 microbial isolates (comprising 43 species) were 
cultured, which represents an average of 3.0 ± 1.4 organisms per sample. Systematic results are 
presented in Table B1.1-2. Aerobes were present in 98.0% of cases, with gram-positive bacteria 
comprising 66.0% of the total number of isolates. Staphylococcus was the main genus identified, 
with S. aureus present in 51% of the samples and in 94.1% of the cases with a CRTB. Coagulase-
negative Staphylococcus spp. were the second most frequently encountered aerobic gram-positive 
isolates, with Staphylococcus epidermidis and Staphylococcus lugdunesis commonly associated with 
a CRTB. Corynebacterium spp. and other uncommon gram-positive bacteria were also identified but 
not in clinically significant quantities. Streptococcus spp. were infrequently (4.1%) isolated. Gram-
negative aerobes comprised 19.0% of the isolated organisms, while P. aeruginosa, the single most 
predominant species, was isolated in only 12.2% of cases. Proteus spp. were the next most frequently 
recovered gram-negative bacteria, although largely (75.0%) in non-CRTB cases. A. baumannii/
calcoaceticus were identified in 8.2% of the cases and were the non-PDR species found exclusively 
in the non-CRTB cases. Anaerobes were found in 30.6% of patients, with Peptostreptococcus spp. 
accounting for 55.0% of all anaerobic isolates, followed by the Bacteroides fragilis group, which 
accounted for 25% of these isolates, but this last group was more frequently identified in non-CRTB. 
Candida spp. were infrequently encountered, representing only 1.4% of the total isolates.
MDR organisms were present in 38.8% of cases, while MRSA was found in 24.5% of patients, 
thereby making it the predominantly isolated pathogen. MRSE and other methicillin-resistant 
coagulase-negative Staphylococci were also identified but accounted for only 4.8% of the isolates. 
Gram-negative MDR organisms were identified in a total of 18.9% of the patients. Of the isolated 
Acinetobacter baumanni and P. aeruginosa strains, 38.5% were PDR, and the remainder were MDR. 
Although a longitudinal study using sequential microbiological samples was not performed, visually 
representing the relationship between the microbial isolates and ulcer duration in a box plot graph 
(Figure B1.1-1) revealed a pattern: gram-positive bacteria appeared in ulcers of short duration, while 
anaerobes associated with either gram-positive or -negative organisms appeared in ulcers of longer 
duration. This finding was independent of previous or current antimicrobial therapy. The average 
duration of an ulcer with any isolated MDR organism was 29 days.
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Table B1.1-2 – Distribution of the DFI isolates
n %
%
(/patients)
CRTB
Aerobes 125 85.0% 98.0% 63.2%
  Gram-positive 97 66.0% 95.9% 64.9%
    Staphylococcus spp. 54 36.7% 79.6% 66.7%
        S. aureus (MRSA) 32 (17) 21.8% (11.6%) 51.0% (24.5%) 93.8% (94.1%)
        Staphylococcus epidermidis (MRSE) 7 (3) 4.8% (2.0%) 14.3% (4.1%) 42.9% (66.7%)
        other coagulase-negative Staphylococcus spp. 
(MRCN) a
15 (3) 10.2% (2.0%) 20.4% (4.1%) 20.0% (33.3%)
    Streptococcus spp. b 6 4.1% 12.2% 100%
    Enterococcus spp. c (VRE) 13 (1) 8.8% (0.7%) 20.4% (2.0%) 76.9% (100%)
    Corynebacterium spp. d 12 8.2% 28.6% 50.0%
    other Gram-positives e 12 8.2% 22.4% 41.7%
  Gram-negative 28 19.0% 51.0% 57.1%
    Enterobacteriaceae 16 10.9% 16.3% 56.3%
        Escherichia coli 1 0.7% 2.0% 100%
        Klebsiella spp.  (ESBL) 2 (1) 1.4% (0.7%) 4.1% (2.0%) 100% (100%)
        Proteus spp. f 8 5.4% 16.3% 25.0%
        other Enterobacteriaceae g 5 3.4% 4.1% 80.0%
    nonfermenting negative bacilli 12 8.2% 20.4% 58.3%
        MDR P. aeruginosa (PDR-PA) 7 (2) 4.8% (1.4%) 12.2% (4.1%) 71.4% (100%)
        MDR A. baumannii/calcoaceticus (PDR-AB) 5 (3) 3.4% (2.0%) 8.2% (6.1%) 40.0% (66.7%)
Anaerobes 20 13.6% 30.6% 75.0%
    Peptostreptococcus spp. 11 7.5% 22.4% 100%
    Bacteroides fragilis group 5 3.4% 4.1% 20.0%
    Other anaerobes h 4 2.7% 4.1% 75.0%
Yeasts i 2 1.4% 4.1% –
in brackets are the multi-drug resistant (MDR) organisms of each species; CRTB – clinically relevant 
tissue burden; MRSA – methicillin-resistant S. aureus; MRSE – methicillin-resistant Staphylococcus 
epidermidis; MRCN – methicillin-resistant coagulase-negative Staphylococcus spp. other than 
Staphylococcus epidermidis; VRE – vancomycin-resistant Enterococci; ESBL – extended-spectrum 
beta-lactamases producing Enterobacteriaceae; MDR – multi-drug resistant; PDR-PA / PDR-AB – 
pan-drug-resistant A. baumannii / pandrug-resistant P. aeruginosa
a Staphylococcus lugdunensis (n = 2) and other coagulase-negative Staphylococcus spp. (n = 13); b 
Streptococcus agalactiae (n = 3), Streptococcus mitis group (n = 1) and Streptococcus dysgalactiae 
(n = 2); c Enterococcus faecalis (n = 9) and Enterococcus faecium (n = 1); d Corynebacterium 
amycolatum/striatum (n = 9) and other Corynebacterium spp. (n = 3); e Dermabacter hominis (n = 1), 
Leuconostoc spp. (n = 1), Arcanobacterium spp. (n = 2), Arthrobacter spp. (n = 1), Kocuria varians/
rosea (n = 2), Cellulomonas spp. / Micrococcus spp. (n=1) and Brevibacterium spp. (n=4); f Proteus 
mirabilis (n=4) and Proteus vulgaris (n=4); g Enterobacter spp. (n = 1), Serratia marcescens (n = 2) and 
Morganella morganii (n = 2); h Fusobacterium spp. (n = 1), Prevotella spp. (n = 1), Eggerthella spp. 
(n = 1) and Veinonella spp. (n = 1); i Candida albicans (n = 1) and Candida parapsilosis (n = 1) 
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Figure B1.1-1 – A box plot representing the ulcer duration data (in days), stratified by the microbial 
isolate (the boxes represent the lower and upper quartiles, the vertical line the median, the bars the 
minimum and maximum data points, and the solid diamond symbol the mean).
MDROs – multi-drug resistant organisms, GP – gram-positive aerobes, GN – gram-negative aerobes, 
A – anaerobes 
In the clinical samples collected from patients undergoing antibiotic therapy (Table B1.1-3), which 
corresponded mainly to hospitalized patients with osteomyelitis, 93% of the antibiotic regimens 
were considered inadequate based on the antibiotic susceptibility test results. Quantitative and 
qualitative differences were found in these samples, with fewer microorganisms identified (2.1 ± 
0.9 vs. 3.4 ± 1.3); in particular, fewer gram-positive (86.7 vs. 100%) and anaerobic (6.7% vs. 41.2%) 
bacteria were identified; however, there was a higher prevalence of MDR organisms (66.7% vs. 
26.5%). Although all the clinical variables were examined, multi-drug resistance was only statistically 
associated with current antibiotic treatment (with any class of antibiotics) and with previous 
fluoroquinolone treatment (Table B1.1-4).
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Table B1.1-3 – Distribution of the DFI isolates in relation to current antibiotic therapy
total
(n = 49)
not under antibi-
otic therapy
(n = 34)
under antibiotic 
therapy
(n = 15)
p a
Hospitalization (%) 34.7% 17.6% 73.3% <0.01
Isolates
 Total number (per sample) 3.0 ± 1.4 3.4 ± 1.3 2.1 ± 0.9 <0.01
 Aerobes
  Number present per sample 2.5 ± 1.1 2.9 ± 1.0 1.9 ± 1.0 <0.01
  Samples with ≥1 (%) 98.0% 100% 93.3% NS
   Gram-positive
    Number present per sample 2.0 ± 1.0 2.3 ± 1.0 1.5 ± 1.1 0.02
    Samples with ≥1 (%) 95.9% 100% 86.7% 0.03
   Gram-negative
    Number present per sample 0.6 ± 0.6 0.6 ± 0.6 0.4 ± 0.6 NS
    Samples with ≥1 (%) 51.0% 58.8% 33.3% NS
 Anaerobes
  Number present per sample 0.4 ± 0.6 0.5 ± 0.6 0.1 ± 0.5 NS
  Samples with ≥1 (%) 30.6% 41.2% 6.7% 0.01
 MDR organisms
  Number present per sample 0.6 ± 0.9 0.4 ± 0.7 1.1 ± 1.0 <0.01
  Samples with ≥1 (%) 
 
38.8% 26.5% 66.7% <0.01
Antibiotic therapy covers isolated pathogens – – 7.0% b –
a not under antibiotic therapy vs. under antibiotic therapy 
b of the total of patients current undergoing antibiotic therapy
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Table B1.1-4 – Relationship between MDR organisms and recent (≤3 months) or current antibiotic 
therapy
non-MDR
(n = 30)
MDR a
(n = 19)
P b
Previous antibiotic therapy 63.3% 73.7% NS
 Penicillins 
 (including associations with b-lactamase inhibitors)
63.3% 79.0% NS
 Cephalosporins 13.3% 26.3% NS
 Carbapenems 10.0% 5.3% NS
 Aminoglycosides 0.0% 0.0% NS
 Sulphamides 13.3% 15.8% NS
 Fluoroquinolones 23.3% 63.2% <0.01
 Glycopeptides 6.7% 5.3% NS
 Oxazolidinones 0.0% 5.3% NS
 Others 3.3% 5.3% NS
Current antibiotic therapy 16.7% 52.6% <0.01
 Penicillins 
 (including associations with β-lactamase inhibitors)
6.7% 0.0% NS
 Cephalosporins 0.0% 0.0% NS
 Carbapenems 10.0% 15.8% NS
 Aminoglycosides 0.0% 5.3% NS
 Sulphamides 3.3% 0.0% NS
 Fluoroquinolones 10.0% 15.8% NS
 Glycopeptides 3.3% 5.3% NS
 Oxazolidinones 0.0% 5.3% NS
 Others 0.0% 5.3% NS
 Covers the isolated pathogens 40.0% 0.0% 0.03
a MRSA, MRSE, MRCN, VRE, ESBL-producing negatives, PDR P. aeruginosa and PDR A. baumannii/
calcoaceticus 
b non-MDR vs. MDR
Discussion
DFIs are common, complex, and costly. They account for the largest number of proximate 
nontraumatic lower extremity amputations (2). This public health problem is particularly important 
in the underdiagnosed and undertreated diabetic Portuguese population (8). To our knowledge, 
this is the first published epidemiological study that reports the infectious microbiota and clinical 
characteristics of diabetic foot in patients located in Portugal. This study reflects the clinical profiles 
of inpatients and outpatients in the Lisbon area, but because the sample was relatively small, the 
study population was heterogeneous, and some controversial methodological issues were utilized 
(notably, the use of swabs and quantitative results), care must be taken when interpreting these 
results. 
The baseline characteristics of the sample population are in line with those previously reported 
by European DFU studies (22), except for the high percentage of male patients and low percentage 
of patients with controlled DM (as evaluated by HbA1c). This can be partially explained by the 
hypothesis of a recent study (23) that reported that male gender and poor glycemic control are 
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 independent risk factors for infection and non-healing DFUs. The high prevalence of co-morbidities 
is due to the low cut-offs used in the definitions. 
Clinical guidelines (6) use infection severity and other clinical characteristics of DFUs as the basis for 
selecting an appropriate treatment approach, including antibiotic therapy. Our study used the PEDIS 
classification, and there were no statistical relationships between the diabetic foot characteristics, 
other than the duration of the ulcer and a clinical suspicion of osteomyelitis, and specific pathogens. 
We cannot be certain that the lack of significant associations was due only to the small sample size, 
however.
It is well documented in the literature (3, 4) that DFIs are polymicrobial in nature. In the present 
study, polymicrobial cultures were obtained from 83.7% of patients with a rate of isolation of 3.0 ± 
1.4 bacteria per patient, independent of the sampling method, which is similar to the results seen 
in previous studies. In agreement with published western studies (3, 4), we isolated predominantly 
aerobic gram-positive cocci from acute infections, while a more complex flora, including gram-
negative and anaerobic bacteria was obtained from chronic wounds. 
We also found that S. aureus, either alone or as a component of a mixed infection, to be the 
most frequently isolated pathogen. Coagulase-negative Staphylococcus spp. were also frequently 
found, often with a methicillin-resistance phenotype. Streptococcus spp., which are well-recognized 
pathogens in DFIs, were infrequently isolated. This can be partially justified by the high prevalence 
of present and recent antibiotic therapy. Enteroccoccus spp., considered low-virulence commensal 
organisms, except in diabetic and other compromised patients, were identified in 20.4% of patients, 
which is in accordance with other studies (3, 4). 
In strict accordance with other western studies (3, 4), but unlike studies from India and other Asian 
countries (24), we isolated relatively few aerobic gram-negative organisms. In our study, the high 
percentage of P. aeruginosa and low percentage of Proteus spp. isolates with a CRTB was consistent 
with the view that the first species can cause severe tissue damage in DM patients and should be 
regarded as significant in that population, while the latter are most commonly non-pathogenic (7).
Independent of the sampling method, anaerobes were isolated in one-third of the patients and 
almost always in mixed culture. This is in contrast to the findings of several other studies that failed 
to isolate anaerobes, possibly because of suboptimal study protocols (25). The anaerobes isolated 
from our study are consistent with other reported studies (26), in which Peptostreptococcus spp. 
were the predominant isolates. Although the exact role of anaerobic bacteria in DFIs is still under 
debate, our study is in line with the expert opinion (7) that suggests that anaerobes are more likely 
to be isolated from long-standing infections.
Other important factors to consider when interpreting the results of our study are that DFI is a 
clinical diagnosis and that both the quantitative and qualitative aspects of wound microbiology are 
critical determinants of an infection’s course. All the patients enrolled in our study had clinically 
infected DFUs, and we based our conclusions on a qualitative microbiological analysis, considering 
the diversity of the microorganisms and the potential for microbial synergy, and on quantitative 
microbiological analysis, which provided a good indication of the microbial load. Assuming that the 
qualitative microbiology remains constant, the probability of wound infection increases with the 
microbial load, up to a critical level at which infection or a failure to heal is considered to be almost 
inevitable. In this paper, CRTB represented the quantitative aspect of wound microbiology and was 
used only as a potential indicator of the microorganisms’ relevance in clinically infected DFUs. 
One of the main limitations of our study is that the quantitative and qualitative microbial 
evaluations were predominantly performed using swab samples. While tissue biopsies and fluid 
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aspirates are considered the gold standard for diagnosing wound infections (25), these invasive tests 
are performed infrequently with small wounds and in many practice settings, such as outpatient 
clinics, due to concerns over enlarging the ulcer or inducing pain (14, 25, 27). In our study, we 
introduced a standardized procedure that was strictly consistent with the current clinical guidelines 
(6). Our method used quantitative aerobic and anaerobic swab cultures as an alternative method 
when the HCP believed an invasive procedure would place the patient at risk. While this decision 
was based on the microbiological experimental and clinical evidence supporting the hypothesis 
that the results form quantitative swabs are highly correlated with those from invasive procedures 
(sensitivities from 93.5% to 100% and specificities from 76.3% to 94.2% have been previously reported 
(14)), this hypothesis is not consensual in the scientific community. Some authors have reported 
consistency between swab and deep tissue biopsy sample cultures (28, 29), while others believe 
that superficial swab cultures of DFIs only complicate patient evaluation by sampling the superficial 
wound compartment, which may contain colonizing organisms rather than true pathogens. These 
divergent conclusions may be explained by different and non-standardized protocols. While we 
acknowledge that a standardized quantitative swab sampling protocol may be an imperfect and 
difficult-to-implement method in the clinical setting, it clearly has merits in the research field, at 
least in a setting with a high prevalence of the multi-drug resistance setting such as in our study; 
when properly interpreted, they can provide useful information (27). 
We had a surprisingly high number of swab samples (mainly from outpatient clinics) from 
patients with small superficial ulcers. There were statistically significant differences between the 
superficial and deep samples, probably due to swab-associated and impossible-to-eliminate wound 
contamination by members of the endogenous microbiota (mainly gram-positive aerobes). This 
result may explain the high prevalence of Corynebacterium spp. and other low-virulence colonizers 
(e.g., Dermabacter hominis and Leuconostoc spp.), which were mainly cultured from swab samples.
In the present study, MDR organisms were cultured from 38.8% of the patients, the majority (24.5%) 
of which were MRSA. Most of the other international studies that have reported a similarly high 
percentage of MDR organisms were single-center, hospital-based studies (24). The high prevalence 
in such studies may be explained by the institution’s use of broad spectrum antibiotics, resulting in 
a pathogen-selective survival advantage. In our multicenter study, we did not find any statistically 
significant differences between the inpatients and outpatients, and the mean duration of ulcers with 
isolated MDR organisms was short (29 days). 
We also found a high percentage of patients (65.3%) who had received antibiotics in the previous 
three months and a statistical association between the presence of MDR organisms and previous 
fluoroquinolone therapy. This class of antibiotics has been widely used in Portugal for many years 
(30), and others have described (31) how they use correlates with the spread of MDR organisms, 
particularly MRSA. Therefore, our results suggest that multi-resistance in our area is widespread 
in diabetic patients with foot ulcers, and fluoroquinolone abuse (including inadequate dosing or 
suboptimal therapy duration) in the community could be a potential cause. 
We also evaluated samples from DFI patients receiving antibiotic therapy, mainly hospitalized 
patients with osteomyelitis, who had signs of infection progression and clinical deterioration of their 
ulcers. Microbial isolation was significantly influenced by systemic antibiotic therapy, with fewer 
microorganisms (mostly anaerobic bacteria) identified but with a significantly greater prevalence 
of MDR organisms. This finding may be explained by selective pressure because the majority of 
these patients were under broad-spectrum antibiotic therapy, mostly with carbapenems. There are 
surprisingly few published clinical trials on antibiotic therapy for DFIs, and the available data do 
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not allow current guidelines to recommend any specific antibiotic regimen. In 2010, however, the 
Portuguese Directorate-General of Health (32) published a clinical guideline suggesting the use of 
isoxazolylpenicillins or clindamycin for superficial infections, aminopenicillins with a β-lactamase 
inhibitor or fluoroquinolones combined with clindamycin for deep infections, and carbapenems 
or ureidopenicillins with a β-lactamase inhibitor for more severe infections. The same guideline 
also considered the potential use of cotrimoxazole, vancomycin, linezolid or tigecycline if MRSA 
was suspected but did not mention any suspicion criteria. Although these guidelines are typically 
considered by HCPs, our study showed that the initial empirical antibiotic therapy covered the isolated 
pathogens of patients with clinically deteriorating ulcers in only 7.0% of the cases. Therapeutic failure 
was related to the presence of MDR organisms, namely MRSA. 
In conclusion, our observational study provides a unique picture of the DFI pattern in our region. 
Both the prevalence and precocity of MDR organisms were alarmingly high and were probably related 
to indiscriminate antibiotic use. Fluoroquinolones, because of their pharmacological characteristics, 
safety and proven clinical effectiveness, are among the antimicrobial agents currently recommended 
by authoritative DFI guidelines. However, resistance has been directly linked to the use of these 
compounds, and the present study describes a statistical association that should encourage 
clinicians, and ultimately health authorities, to avoid their widespread use. By contrast, due to the 
high prevalence of MRSA in DFIs in our area, we suggest empirical anti-MRSA therapy followed by 
de-escalation to rationalize care and improve outcomes.
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Chapter 2: In vitro design of the bacteriophage cocktail
Specific framework
The development of an effective BT protocol is a toilsome, multi-step process (1). Once the target 
bacteria are defined, it is necessary to isolate and select the appropriate bacteria-specific lytic 
bacteriophages. These must then be morphologically and genetically characterized, mainly because 
of safety issues. Thereafter, as in any antibiotic development, in vitro studies precede in vivo studies 
and are employed to design a pharmacologically-informed dosage regimen. Several in vitro studies 
using multiple bacteriophages with diverse bacterial hosts intended for human applications have been 
published (2-4). The majority of these studies combine two or more bacteriophages (bacteriophage 
cocktails) in order to achieve effectiveness under a greater diversity of conditions and/or target 
more bacterial strains. Some also present associated in vivo efficacy studies (5). However, most 
report only the morphological and/or genetic characterization of the bacteriophages used, excluding 
pharmacological information of the diverse formulations. There are also relevant data available 
about preparations developed for non-clinical applications (6, 7). In our case, Technophage, S.A., had 
already isolated S. aureus, P. aeruginosa and A. baumannii/calcoaceticus specific-bacteriophages 
from environmental samples. Their morphological and genetic structures were investigated, and 
they were tested against clinical isolates (including 44 DFIs isolates from the epidemiological study) 
using the bacteriophage spot test procedure (8). Subsequently, their activity against planktonic cells 
and established biofilms was studied, and these data were used to design a dosage regimen for use 
in future studies (Figure B2.0-1). 
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Figure B2.0-1 – In vitro design of a lytic bacteriophage cocktail with therapeutic potential against 
organisms causing diabetic foot infections. S. aureus, P. aeruginosa, and A. baumannii-specific lytic 
bacteriophages were isolated from sewage water from the Lisbon area by employing standard 
methods. To produce bacteriophage stocks in sufficient quantities for the experiments, a standard 
protocol of amplification, concentration by high-speed centrifugation, and purification on a cesium 
chloride gradient was used. Final concentrations were determined with double agar overlay plaque 
assays and further diluted to achieve a working solution titer of 1010 pfu/mL prior to the assays. 
For the morphological characterization, all the bacteriophages were analyzed by transmission 
electron microscopy at the Félix d’Hérelle Reference Center for Bacterial Viruses. For the genotypic 
characterization, the DNA of each of the 5 bacteriophages was isolated using a standard phenol/
chloroform extraction and precipitation protocol, sent for commercial sequencing, and analysed by 
extensive bioinformatics evaluation. All bacteriophages were subsequently tested against clinical 
isolates (including 44 DFI bacterial isolates from the epidemiological study) using the bacteriophage 
spot test procedure. In order to determine bacteriophage activity against planktonic cells in vitro, a 
kinetic time-kill assay was performed using a modified protocol. A quantification model based on the 
reduction of alamarBlue by metabolically active cells was then used to investigate the effect of the 
different bacteriophage combination on the preformed bacterial biofilms. 
75
Section b
References
1. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol. 2010 
Jan;11(1):28-47.
2. Vandersteegen K, Mattheus W, Ceyssens PJ, Bilocq F, De Vos D, Pirnay JP, et al. Microbiological 
and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS 
One. 2011;6(9):e24418.
3. Kesik-Szeloch A, Drulis-Kawa Z, Weber-Dabrowska B, Kassner J, Majkowska-Skrobek G, 
Augustyniak D, et al. Characterising the biology of novel lytic bacteriophages infecting multidrug 
resistant Klebsiella pneumoniae. Virol J. 2013;10:100.
4. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, et al. Quality-
controlled small-scale production of a well-defined bacteriophage cocktail for use in human 
clinical trials. PLoS One. 2009;4(3):e4944.
5. Chan BK, Abedon ST. Phage therapy pharmacology phage cocktails. Adv Appl Microbiol. 
2012;78:1-23.
6. Sillankorva S, Neubauer P, Azeredo J. Pseudomonas fluorescens biofilms subjected to phage 
phiIBB-PF7A. BMC Biotechnol. 2008;8:79.
7. Shen Y, Liu Y, Zhang Y, Cripe J, Conway W, Meng J, et al. Isolation and characterization of Listeria 
monocytogenes isolates from ready-to-eat foods in Florida. Appl Environ Microbiol. 2006 
Jul;72(7):5073-6.
8. Armon R, Kott Y. A simple, rapid and sensitive presence/absence detection test for bacteriophage 
in drinking water. J Appl Bacteriol. 1993 Apr;74(4):490-6.

77
Section b
In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms 
causing diabetic foot infections
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Abstract
In patients with diabetes mellitus, foot infections pose a significant risk. These are complex infections 
commonly caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter 
baumannii, all of which are potentially susceptible to bacteriophages. Here, we characterized five 
bacteriophages that we previously determined to have antimicrobial and wound-healing potential 
in chronic S. aureus, P. aeruginosa, and A. baumannii infections. Morphological and genetic features 
indicated that the bacteriophages were lytic members of Myoviridae or Podoviridae and did not 
harbor any known bacterial virulence genes. Combinations of the bacteriophages had broad host 
ranges for the different target bacterial species. The bacteriophages’ activity against planktonic cells 
revealed effective, early killing at 4 hours, followed by bacterial regrowth to pretreatment levels by 
24 hours. By using metabolic activity as a measure of cell viability within established biofilms, we 
found significant cell impairment following bacteriophage exposure. Repeated treatment every 4 
hours caused a further decrease in cell activity. The greatest effects on both planktonic and biofilm 
cells occurred at a bacteriophage/bacterium input multiplicity (IM) of 10. These studies on both 
planktonic cells and established biofilms allowed us to better evaluate the effects of a high IM 
and a multiple-dose treatment protocol, and the findings support further clinical development of 
bacteriophage therapy. 
Keywords: bacteriophage therapy, Staphylococcus aureus, Pseudomonas aeruginosa, Acinetobacter 
baumannii, diabetic foot infections, in vitro, posology 
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Introduction
Diabetes mellitus affects an estimated 171 million patients worldwide (1) and has become a major 
world epidemic. Even with the best preventive care, 9% of patients will develop a diabetic foot infection 
(DFI), which brings the consequent risk of amputation (2). Qualitative and quantitative aspects of wound 
microbiology are critical determinants of the wound outcome. Gram-positive microorganisms are the 
first to colonize and acutely infect breaks in the skin, whereas chronic wounds develop a more complex 
polymicrobial microbiology, including aerobic Gram-negative rods (3). These microorganisms aggregate 
in communities encased within extracellular polymeric substances on the wound surface. Such an 
entity is defined as a biofilm, which shows increased resistance to immunological and antimicrobial 
attack (4). In current clinical practice, DFI treatment includes debridement and systemic antibiotics 
(3). The increased incidence of antibiotic-resistant bacterial strains, such as methicillin-resistant 
Staphylococcus aureus and pandrug-resistant, non-fermenting Gram-negative bacilli, threatens the 
efficacy of antimicrobial therapy (5). Thus, it is necessary to identify new therapeutic strategies for DFIs. 
Bacteriophages are viruses that consist of a genome contained within a protein coat and that 
specifically infect bacteria. In contrast to filamentous bacteriophages, the multiplication of tailed 
bacteriophages and release of the newly formed virus particles always involves lysis of the host 
bacterial cell. However, among tailed bacteriophages some may not immediately follow this lytic 
pathway. The genome of these so called temperate bacteriophages may instead reside in the host 
cell (integrated in the bacterial chromosome or in a plasmid-like form in the cytoplasm) and be 
propagated for several bacterial generations without lysis. In contrast, strictly lytic phages do not have 
this option and usually undergo the lytic pathway once inside the bacterial host (6). Bacteriophage 
therapy (BT) is the use of lytic bacteriophages to reduce or eliminate pathogenic bacteria. BT 
has become a broadly relevant technology for veterinary, agricultural, and food microbiological 
applications; however, the treatment of human infections with BT attracts the greatest interest (7). 
The use of bacteriophages as antibacterial agents for suppurative infections began shortly after 
the discovery of bacteriophages. Bruynoghe and Maisin first demonstrated BT, using bacteriophages 
to treat S. aureus skin infections (8). However, following the discovery and general application of 
antibiotics, interest in the therapeutic uses of bacteriophages waned. Recently, the increase in 
antibiotic-resistant bacterial strains has reinvigorated enthusiasm about these bacteria-specific 
viruses (9). This interest is particularly true in cases in which bacteriophages can be applied externally 
(topical application), as is the case for DFIs.
The development of an effective BT is a multi-step process consisting of (1) bacteriophage isolation 
and assessment for antibacterial activity against specific bacterial strains, (2) bacteriophage 
characterization and screening for undesirable traits, (3) in vitro posology and dosage regimen 
design, (4) preclinical animal efficacy and toxicology studies, and (5) regulated human clinical trials. 
Although the use of bacteriophages to treat DFIs is promising, difficulties in any of these steps can 
hinder widespread clinical application (10).
Recently, we demonstrated the antimicrobial activity and wound-healing capability of a topically 
delivered bacteriophage suspension against wounds chronically infected with chronic S. aureus, 
Pseudomonas aeruginosa, and Acinetobacter baumannii in two animal models of diabetes mellitus 
(11). In the current study, we present a characterization of the bacteriophages used in the previous 
study. We examined their spectrum of activity, genetic and morphological structures, and activity 
against planktonic cells and established biofilms. Collectively, the findings justify the posology and 
dosage regimen used in the animal studies.
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Materials and methods
Bacterial strains
The S. aureus 743/06, P. aeruginosa 433/07, and A. baumannii 1305/05 host strains were isolated 
from human clinical samples that were collected and identified in hospitals in the Lisbon area. The 
three strains were previously characterized as biofilm producers (12). Bacterial clinical isolates used 
for bacteriophage host-range investigation included S. aureus (n = 132), P. aeruginosa (n = 93), and A. 
baumannii (n = 103) from wound specimens. Of these isolates, 44 were from DFIs. The epidemiology, 
clinical details, and specific microbiology of our collection of DFI isolates have been previously 
described (5). All isolates were stored in tryptone soy broth (TSB; Biokar Diagnostics, Pantin Cedex, 
France) with 15% glycerol (w/v) at -70°C until needed. For the experiments, single bacterial colonies 
were grown in TSB at 37°C. After a 24-hour incubation, the bacterial cells were suspended in saline 
and adjusted to McFarland’s scale 0.5 (bioMérieux, Craponne, France), producing a final working 
suspension of approximately 5.0 × 108 cfu/ml.
Bacteriophages
Bacteriophage isolation, amplification, and purification
S. aureus F44/10 and F125/10, P. aeruginosa F770/05 and F510/08, and A. baumannii F1245/05 
bacteriophages were isolated from environmental water samples from the Lisbon area. Standard 
methods for bacteriophage isolation (13) were employed for all five bacteriophages using the host 
strains described above. The obtained bacteriophage plaques were purified by repeated single 
plaque isolation to ensure that each contained only one type of bacteriophage.
To produce bacteriophage stocks in sufficient quantities for the experiments, a previously 
described protocol of amplification, concentration by high-speed centrifugation, and purification 
on a cesium chloride gradient (14) was used for all five bacteriophages. Briefly, a final lysate of each 
bacteriophage was centrifuged at 10,000 × g for 20 minutes at 4°C. The pellet was discarded, and 
the supernatant fraction was concentrated overnight at 8,000 rpm (rotor JA-14, Beckman Coulter, 
Fullerton, USA). The bacteriophage pellet was resuspended in SM buffer (5.8 g l-1 NaCl, 2 g l-1 MgSO4 
× 7 H2O, 50 ml 1 M Tris, pH 7.5). This concentrated bacteriophage suspension was loaded onto a 
discontinuous CsCl gradient and centrifuged at 30,000 rpm for 5 hours at 4°C in a Beckman L-90 
ultracentrifuge with an SW41Ti rotor (Beckman Coulter, Fullerton, USA). The banded bacteriophage 
particles were collected and thoroughly dialyzed against SM buffer. Final bacteriophage titers were 
determined using double agar overlay plaque assays (15). Purified bacteriophages were stored at 
4°C and further diluted in SM buffer to achieve a working suspension of approximately 2 x 1010 pfu/
ml prior to the assays.
Bacteriophage features
Morphology
The morphology of each of the five bacteriophages was analyzed by transmission electron microscopy 
at the Félix d’Hérelle Reference Center for Bacterial Viruses, Laval University, Québec, Canada. Briefly, 
a 200-mesh Formvar carbon-coated copper grid (Pelco International, Redding, USA) was deposited 
face down on 10 μl of staining suspension (2% uranyl acetate, pH 7.0, for all bacteriophages except 
for F770/05, which was stained with 2% phosphotungstic acid, pH 7.0). After 30 s, 10 µl of the 
bacteriophage suspension was mixed with the stain. After 2-3 minutes, the grid was deposited face 
up on blotting paper. The grid was dried for 5 minutes and then observed at 80 kV using a JEOL 1230 
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transmission electron microscope (JEOL, Peabody, USA). These data were integrated with the genomic 
analysis, and the bacteriophages were classified according to the Ackermann classification (16).
Genomic analysis
The DNA of all five bacteriophages was isolated using a standard phenol:chloroform extraction and 
DNA precipitation protocol (17). The purified nucleic acid was sent to Macrogen, Inc. (Seoul, Korea), 
for commercial sequencing. In brief, pyrosequencing of the sample DNA was performed using the GS 
FLX Titanium General Library Preparation Kit (Roche 454 Company, Branford, USA) according to the 
manufacturer’s instructions. The assembly of quality-filtered reads was performed using Genome 
Sequencer De Novo Assembler software (Newbler) version 2.5.3. An extensive bioinformatics 
evaluation was conducted to analyze the sequences and identify regions of similarity with entries in 
databases, which yield clues about structure and function. Each genome sequence was scanned using 
the NCBI BlastN and BlastX bioinformatics tools (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Prediction 
of open reading frames (ORFs) was performed by integrating the results obtained by the programs 
GeneMark.hmm (http://exon.gatech.edu/genemark/eukhmm.cgi) and MetaGeneAnnotator (http://
metagene.cb.k.u-tokyo.ac.jp). Protein homology searches were performed with the BlastP program 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) using the NCBI non-redundant protein 
sequence database. The genome sequences were deposited in the patent division of GenBank 
(specific patent numbers: WO2010090542 and WO2012036580).
Host range
The five bacteriophages were tested against a panel of clinical isolates using the bacteriophage 
spot-test procedure (18). Briefly, 3 ml of top-0.7% tryptone soy agar (TSA; Biokar Diagnostics, Pantin 
Cedex, France) was added to 200 μl of an overnight culture of each clinical isolate and poured 
over TSA. The agar was allowed to solidify, after which 5 μl of each bacteriophage suspension 
(approximately 108 pfu) was spotted on the bacterial lawn of each different isolate. The drop was 
allowed to dry, and the plates were incubated overnight at 37°C. Specific bacteriophage-sensitive 
isolates showed clear areas where the bacteriophage suspensions had been spotted.
Bacteriophage activity against planktonic cells
To determine the bacteriophages’ activity against planktonic cells in vitro, a kinetic time-kill assay 
(19) was performed using a modified protocol. Briefly, 1 ml of the host bacterial suspension (5 
× 108 cfu) was diluted in 9 ml of TSB, yielding a final concentration of 5 × 107 cfu/ml. For single-
bacteriophage studies, 100 μl (5 × 109 pfu) of the specific bacteriophage was added, yielding a 
final concentration of 5 × 108 pfu/ml (bacteriophage-to-bacterium ratio or input multiplicity (IM) 
of 10). For combination studies, 100 μl (5 × 109 pfu) of each bacteriophage suspension was added, 
resulting in a final concentration of 5 × 108 pfu/ml (IM of 10) for each of the bacteriophages. An 
additional kinetic assay was performed for P. aeruginosa 433/07, in which 10 μl (5 × 108 pfu) of 
the bacteriophage F770/05 suspension was added (yielding an IM of 1), alone or in combination 
with the bacteriophage F510/08 at an IM of 10. Control experiments were performed in parallel 
using bacteriophage buffer instead of a bacteriophage suspension. All mixtures were incubated at 
37°C with agitation, and 100 μl aliquots were collected at 0, 1, 3, 5, and 24 hours post-infection. 
Bacterial quantification was performed using the 10-fold serial dilution method (20). All experiments 
were conducted in triplicate. The results are presented as the mean ± standard deviation and are 
expressed as logarithm-transformed values (log (cfu/ml)) over time. 
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Combined bacteriophage activity against established biofilms
The bacteriophages’ activity against established biofilms was examined using a modification of 
previously described protocols (21, 22). Briefly, 1 ml of each of the host bacterial suspensions (5 
× 108 cfu) was diluted in 9 ml of TSB, and 100 µl of this dilution (5 × 106 cfu) was added to a 96-
well flat-bottom polystyrene microtiter plate (Orange Scientific, Braine-l’Alleud, Belgium) and 
incubated at 37°C for 24 hours to allow biofilm formation. After incubation, the planktonic bacteria 
were carefully removed with a sterile pipette. The number of biofilm cells at 24 hours has been 
previously demonstrated to be approximately 107 cfu/well for all bacterial species (12). Then, 150 
μl of bacteriophage suspensions (IMs of 10 and 100) diluted in TSB was added to the wells. The 
following bacteriophage suspensions were used for each bacterium: for S. aureus, a 1:1 combination 
of F44/10 and F125/10; for P. aeruginosa, a combination of F770/05 and F510/08 at a 1:10 ratio; 
and for A. baumannii, F1245/05 alone. Biofilms treated with TSB alone served as positive controls in 
measurements of cell metabolic activity (see below).
The microplates were incubated at 37°C for either 4 or 24 hours. At each time point, the wells were 
processed according to a previously described protocol (21) using alamarBlue (AB; Thermo Scientific, 
Madrid, Spain), and their absorbances at 570 nm and 600 nm were measured using a SpectraMax 
340PC microplate reader (Molecular Devices, Sunnyvale, USA). A second assay was performed in 
which, after biofilm formation, planktonic bacteria were removed from the wells and replaced with 
a bacteriophage suspension every 4 hours over a 24-hour incubation period. In the positive-control 
group, planktonic bacteria were removed from the wells and replaced with TSB every 4 hours. These 
plates were then processed as described (21). 
Biofilm susceptibility experiments were performed a minimum of three times. All results are 
presented as the percent variation of AB ± standard deviation. This value was calculated using the 
manufacturer’s formula, with one exception: the media-only negative control in the formula was 
replaced by a more robust negative control that consisted of media plus bacteriophage at each IM 
(i.e., IMs of 10 and 100). Strong antimicrobial suppression was defined as a ≥ 50% reduction in AB 
compared with the positive control. 
Statistical analysis
For all data sets, comparisons between groups were performed using two-tailed Student’s t tests, 
and P-values < 0.05 were considered significant. All data were entered into a spreadsheet program 
(Excel, Microsoft, Redmond, USA) for statistical analysis. Analytical statistics were performed using 
Analyse-it, version 2.21 Excel 12+ (Analyse-it Software, Leeds, United Kingdom), a statistical add-in 
program for Excel.
Results
Bacteriophage features
After purification, the selected bacteriophages were initially characterized according to plaque 
morphology. The S. aureus F44/10 and F125/10, P. aeruginosa F770/05 and F510/08, and A. baumannii 
F1245/05 bacteriophages produced clear lytic plaques ranging from 1.5-5 mm in diameter. Plaques 
produced by the bacteriophages F770/05, F510/08, and F1245/05 were surrounded by growing 
opaque halo zones. The morphological and genomic characteristics of the five bacteriophages are 
presented in Figure B2.1-1. 
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Figure B2.1-1 – Morphological and genomic characteristics of the bacteriophages used for 
bacteriophage therapy. Five bacteriophages previously shown to successfully treat infections in 
vivo were characterized using transmission electron microscopy. Representative images are shown. 
The genomes were sequenced by pyrosequencing and analyzed extensively using BlastN, BlastX, 
GeneMark.hmm, MetaGeneAnnotator, and BlastP. ICTV = International Committee on Taxonomy of 
Viruses.
Morphology
To classify the purified bacteriophages based on their virion morphology, we used transmission 
electron microscopy. The staphylococcal bacteriophages F44/10 and F125/10 appeared to be 
composed of a contractile tail and an isometric head, with a baseplate structure also discernible at the 
tip of the F44/10 tail. These features, along with their genomic properties (see below), allowed us to 
classify F44/10 and F125/10 as Myoviridae. The Pseudomonas bacteriophages F770/05 and F510/08 
and the Acinetobacter bacteriophage F1245/05 had short tails and were classified as Podoviridae. 
The Podoviridae family consists of different subgroups. Although there are certain morphological 
similarities between the bacteriophages F510/08 and F1245/05 and the φKMV-like group (23, 24), 
definite morphological assignment of F1245/05 could not be performed due to the uncharacteristic 
morphology of these virion particles.
Genomic analysis
Bacteriophages were characterized at the genomic level by determining and analyzing their genome 
sequences. The bacteriophages F44/10 and F125/10 had the largest genomes and hence a greater 
number of putative genes and ORFs, which is in agreement with the characteristic features of viruses 
belonging to the Myoviridae family (25). The genomes of the bacteriophages F44/10 and F125/10 
displayed high similarity (up to 98% nucleotide sequence identity, 80-90% genome coverage) to those 
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of a group of highly related staphylococcal myoviruses, which includes bacteriophages K (26), A5W (27), 
and GH15 (28). The bacteriophages F510/08 and F770/05 shared high sequence identity (up to 98% 
nucleotide sequence identity, 83-98% genome coverage) with Pseudomonas �KMV-like and N4-like 
viruses, respectively (29). Examples of �KMV-like viruses are the bacteriophages �KMV and LUZ19 
(30, 31) and of N4-like viruses are LIT1 and LUZ7 (29). The bacteriophage F1245/05 presented no 
significant similarity at the DNA level with any known bacteriophage in the databases, except for a 
few short segments with up to 4% nucleotide sequence identity and 81% genome coverage.
The deduced products of the predicted genes of all bacteriophages were compared with sequences 
in the NCBI non-redundant protein sequence database using BLASTP. No significant similarity with 
known virulence or toxin proteins or with elements typically associated with lysogeny (integrases, 
repressors, and antirepressors) could be found. Finally, the protein similarity searches did not reveal 
potential exopolysaccharide depolymerase genes. 
Bacteriophage host range
To gain insight into the host range of selected bacteriophages, the susceptibility of three panels of 
clinical isolates of S. aureus (n = 132), P. aeruginosa (n = 93), and A. baumannii (n = 103) was tested 
for each species-specific bacteriophage. There was a degree of variability in the host range of each 
bacteriophage (Table B2.1-1). All tested staphylococcal strains were susceptible to both S. aureus 
bacteriophages (F44/10 and F125/10). In contrast, when examined individually, the P. aeruginosa 
bacteriophages F770/05 and F510/08 lysed only 63.4% and 68.8% of the tested isolates, respectively. 
However, when these results were considered together, we observed that 80.6% of the P. aeruginosa 
isolates were infected by at least one of the bacteriophages, whereas 51.6% were susceptible to 
both bacteriophages. Finally, of the tested A. baumannii strains, 74.8% were susceptible to the 
bacteriophage F1245/05. 
Table B2.1-1 – Susceptibility of wound bacterial isolates to candidate bacteriophages for bacteriophage 
therapy.
S. aureus P. aeruginosa A. baumannii
F44/10 F125/10 F770/05 F510/08
F770/05
+ F510/08
F1245/05
Number of bacte-
rial strains tested
132 93 103
Bacterial strain’s 
susceptibility
100% 100% 63.4% 68.8% 80.6%* 74.8%
*Percentage of P. aeruginosa isolates that were susceptible to at least one of the bacteriophages 
(only 51.6% of the isolates were susceptible to both)
Bacteriophage activity against planktonic cells
To evaluate the activity of the selected bacteriophages against planktonic cells, liquid cultures of 
the different bacterial hosts were exposed to the corresponding bacteriophages, both individually 
and in combination, and cell growth/viability was monitored over time with constant agitation. The 
time-kill curves are presented in Figure B2.1-2. S. aureus 743/06, when challenged with either F44/10 
or F125/10 at an IM of 10, showed impaired growth, with reductions in cell counts of 2.3 ± 0.3 log 
(cfu/ml) and 2.2 ± 0.2 log (cfu/ml), respectively, 3 hours post-infection. However, after 24 hours, the 
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cultures recovered to near-control levels. The reduction in the number of viable cells observed at 3 
hours was significantly enhanced when the two bacteriophages were used in combination (3.4 ± 0.2 
log (cfu/ml); P < 0.01). Still, there was no difference in the recovery of growth at 24 hours.
At an IM of 10, the P. aeruginosa bacteriophage F510/08 caused a 3.9 ± 0.4 log (cfu/ml) reduction 
in the viability of P. aeruginosa 433/07 at 3 hours post-infection. This reduction was more modest 
(0.7 ± 0.4 log (cfu/ml)) for F770/05 at the same IM and time point. When the two bacteriophages 
were combined, the kill curve was not different from that of F770/05 for the first 5 hours; however, 
the combination provided a statistically significant reduction relative to the control at 24 hours (1.3 
± 0.3 log (cfu/ml); P < 0.01). When the IM of F770/05 was reduced to 1, combined with F510/08 at 
an IM of 10, the initial 3-hour reduction was more pronounced (2.5 ± 0.4 log (cfu/ml); P < 0.01). 
Similarly, this combination caused a statistically significant reduction (1.7 ± 0.3 log (cfu/ml); P < 0.01) 
relative to the control at 24 hours. A. baumannii 1305/05 suffered an initial 2.7 ± 0.2 log (cfu/ml) 
reduction at 3 hours after single-bacteriophage (F1245/05) challenge. Although this bacterial strain 
recovered by 24 hours, it did not reach control levels of viability.
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Figure B2.1-2 – Time-kill curves of the target bacteria during planktonic growth when challenged 
with their specific bacteriophages (alone or in combination). Bacterial strains were grown in TSB 
with constant agitation and with or without bacteriophages. Growth was monitored and quantified 
by calculating cfu/ml at 0, 1, 3, 5, and 24 hours. In the left panel (input multiplicity, IM 10/10), assays 
were performed on S. aureus 743/06, P. aeruginosa 433/07, and A. baumannii 1305/05 in which the 
specific bacteriophage suspensions were added to provide an IM of 10. In the right panel (IM 10/1), 
an additional assay was performed on P. aeruginosa 433/07 in which the bacteriophage F770/05 
suspension was added to provide an IM of 1, alone or in combination with the bacteriophage 
F510/08 at an IM of 10.
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Bacteriophage combinations’ activity against established biofilms
We also studied the ability of the bacteriophages to eliminate cells in established biofilms by 
treating biofilms with species-specific bacteriophage combinations. AB, which quantitatively 
measures cell metabolic activity using an oxidation-reduction indicator that changes color in the 
presence of metabolically active cells, was used to measure cell viability in biofilms with and without 
treatment. The viability of cells within a biofilm is one of the most important aspects when evaluating 
the effectiveness of antimicrobial agents; therefore, we used a quantification method based on 
metabolically active cells, as determined by AB. This assay is a reliable and reproducible method 
for evaluating biofilm susceptibility and is considered to be preferable over the viable plate-count 
method, as it is very difficult to recover all surviving adherent bacteria as single cells using the latter 
method (21). The AB-based assay has been used to identify antimicrobials with enhanced efficacy 
against certain clinically important bacterial biofilms (21, 32).
Figure B2.1-3 shows the percentage of AB reduction in control and treated biofilms at 4 and 24 
hours using different IMs and frequencies of application. At 4 hours, the tested bacteriophage 
preparations strongly reduced the cell viability of all bacterial hosts, independent of the IM. There 
was only a statistically significant difference between IMs for A. baumannii; the higher IM resulted 
in a greater reduction in metabolic activity (71.9 ± 5.8% vs. 88.7 ± 3.1%; P < 0.01). 
At 24 hours, after a one-time bacteriophage preparation application, the cell viability of all bacterial 
strains was less suppressed than at 4 hours but still significantly different from that of the control. 
At 24 hours, there were no statistically significant differences between IMs except for S. aureus, for 
which the higher IM resulted in a greater reduction in cell viability (34.8 ± 8.5% vs. 52.6 ± 7.7%; P < 
0.01). In experiments using multiple bacteriophage treatments, a greater reduction in cell viability 
was observed compared with the reduction following one-time bacteriophage treatment. This trend 
was found for S. aureus and P. aeruginosa, but not for A. baumannii. 
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Figure B2.1-3 – Analysis of the bacteriophages’ activity against bacterial biofilms. Bacteria were 
grown for 24 hours to establish biofilms, and bacteriophages were then added. The following 
bacteriophage suspensions were used for each bacterium: for S. aureus, a 1:1 combination of F44/10 
and F125/10; for P. aeruginosa, a combination of F770/05 and F510/08 at a 1:10 ratio; and for A. 
baumannii, F1245/05 alone. Cell metabolism was quantified with alamarBlue (AB) and reported as 
the percent reduction relative to growth in untreated controls. C = negative control, T = treated with 
bacteriophage, IM = input multiplicity, 1x = one-time bacteriophage suspension application, 6x = 
bacteriophage suspension application every 4 hours for 24 hours. * P < 0.01 (dendritic lines establish 
the comparison between the different groups).
Discussion 
Effective bacteriophage preparations for therapeutic purposes require careful design through 
a multi-step research process of bacteriophage characterization, cocktailing, and dosing. This 
process includes in vitro studies, such as those presented here, and in vivo studies, which have 
been previously  published (11). Ideally, the characterization of bacteriophages for BT should be as 
thorough and complete as possible. However, in certain cases, it may be more practical to minimize 
this process and to focus the characterization on particular traits that are the most desirable for 
a specific application. Combining different bacteriophages in the same preparation (mixtures of 
two or more bacteriophages within a given formulation) frequently results in a broader spectrum 
of antibacterial activity and/or lytic efficacy and may allow targeting of bacteria under different 
conditions or in different environments (33). Finally, in vitro experiments such as those described in 
this work are useful for evaluating the direct interaction between a drug and bacteria, which enables 
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the selection of candidate bacteriophages. These studies also provide valuable information for the 
determination of optimal posology (34).
Integration of the information emerging from the morphological and genomic analyses revealed 
that the bacteriophages used here were all tailed bacteriophages (order Caudovirales), with two 
belonging to the Myoviridae family and three to Podoviridae. Genome sequence analysis did not 
identify any known genes related to lysogeny or traits that might enhance the virulence of the 
target bacteria, which is an important observation regarding the bacteriophages’ safe use. Another 
important selection criterion for bacteriophages for BT is their host range, which should be as broad 
as possible, particularly including clinically prevalent bacterial species (35). In this study, members 
of Myoviridae exhibited the broadest spectrum of lytic activity, whereas the Podoviridae viruses 
exhibited a narrower spectrum, and particularly the pseudomonal bacteriophages. The spectrum 
of activity of the staphylococcal bacteriophages was relatively broad as expected, given their 
high relatedness to bacteriophages K and A5W, both of which have been previously described as 
polyvalent bacteriophages (36, 37). Still, the host ranges of the Pseudomonas and Acinetobacter 
bacteriophages are remarkable compared with those of other species-specific bacteriophages (38, 
39). The overall morphology, genomic characterization, and host range results suggest that these 
bacteriophages are very good candidates for BT. However, care must be taken when generalizing these 
results, because the bacterial clinical isolates used for the  bacteriophage host-range investigation 
reflect only the microbiological profile of diabetic foot ulcers in a particular geographical area, and 
these vary worldwide. Also the sensitivity of the spot test must be taken into account. While the use 
of high bacteriophage titers (108 PFU per spot) for host range analysis is routine when considering 
bacteriophages for BT (40), it should be noted that the use of lower titers may reduce host range. In 
our host-range investigation the use of bacteriophage stock dilutions up to 103 PFU per spot yielded 
differences from the presented results up to 23% (unpublished data).
Time-kill curves provide detailed information about antimicrobial efficacy against planktonic 
bacteria as a function of time. These curves are often used to study the antibacterial effect of single 
and combination drug compounds and dosing regimens before in vivo efficacy studies (19). In the 
current study, following bacteriophage exposure, all bacteria had an initial bacterial reduction to 
nadir between 1 and 3 hours post-infection, followed by regrowth that was noticeable after 5 hours 
and even more pronounced after 24 hours. The Pseudomonas bacteriophage combination resulted 
in a significantly greater reduction in bacteria compared with the reduction stimulated by most active 
single bacteriophage 24 hours after bacteriophage exposure. However, the decrease was insufficient 
to be considered as a synergic effect, defined as a ≥ 2 log (cfu/ml)-fold decrease by a combination 
compared with the most active single agent (19). In the Pseudomonas combination study, when an 
IM of 1 of the Pseudomonas F770/05 bacteriophage was used instead of an IM of 10, we observed 
greater initial bacterial reduction after 3 hours, but similar results were obtained at 24 hours. This 
interaction was not specifically analyzed in our study, and there is no obvious explanation for this, 
but clearly, further studies would be of interest.
The study presented here has certain limitations. First, only a single bacterial inoculum was used. 
This value was carefully selected based on several lines of evidence. A higher inoculum (107 cfu/ml) 
was used than the normal 105 cfu/ml inoculum used in previous time-kill studies testing antibiotics 
(19) because we wanted to mimic a worst-case scenario, similar to that found in wounds (41). In a 
previous epidemiological study (5), microbiological products (aspirates, biopsies or swabs collected 
using the Levine method) of clinically infected foot ulcers in patients with diabetes were found to 
have a maximum bioburden of 107 cfu/gram of tissue (or cm2 of ulcer area). Additionally, the most 
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recent study using a previously optimized rodent model (11) tested this bacteriophage cocktail on 
infected wounds with a known average wound bioburden of 7.54 ± 0.19 log (cfu) per ulcer.
Second, the IM in nearly all experiments was 10 (fixed IM). The final chosen IM was selected based 
on the “multiplicity of 10 rule,” which states that if the goal is significant reduction in bacterial density, 
then one should strive for on the order of 10 bacteriophages adsorbed to the average bacterium 
(42, 43). Previous studies on infected animal and human burn tissue have concluded that low-titer 
bacteriophage administration (IMs lower than 10) is unlikely to be successful (44, 45). Furthermore, 
increasing the IM increases the success of BT by reducing bacterial numbers. 
Third, we observed regrowth in planktonic cells exposed to bacteriophages within 24 hours. This 
observation may be indicative of the development of resistance, as in vitro resistance is frequent 
in both BT and antibiotic therapy. For example, a study (46) previously found in vitro resistance 
frequencies of 10-6-10-4 for single-phage treatments and 10-6 for double-phage or triple-phage 
cocktails against Escherichia coli O157:H7. Similarly, resistance to fusidic acid can readily be 
selected from an initial high inoculum, with an average frequency of 10-6-10-8.This resistance has not 
limited the antibiotic’s topical use and does not appear to be a clinical problem (47, 48). However, 
these observations do not imply in vivo resistance. According to certain studies, the rate of the 
development of resistance to bacteriophages is approximately 10-fold lower than the rate of the 
development of antibiotic resistance (49). Nonetheless, as observed here, in vitro studies show 
that bacteriophage resistance can evolve within hours, independently of the use of bacteriophage 
combinations. However, the evolution of bacteriophage resistance in vitro does not seem relevant 
to in vivo scenarios, in which bacteria replicate more slowly and are challenged by more difficult 
environmental conditions. A previous study (50) found an average resistance frequency of 1.2 × 10-8 
for S. aureus treated with bacteriophages in vitro. However, the researchers were unable to isolate 
any bacteriophage-resistant S. aureus strains in vivo. Indeed, even though the resistance of bacteria 
to the bacteriophage cocktails used here was not specifically studied, we previously found that the 
presence of residual bacteria did not globally hinder planimetric or histological improvement (11). In 
the current study, the greatest reduction in bacterial counts occurred at 3 hours, and regrowth was 
observed at 5 hours, which enabled us to conclude that the best time to give a “boost” application 
of bacteriophage would be between these two time points.
A previous study (unpublished data) found that the plaques of the bacteriophages F770/05, 
F510/08, and F1245/05 were surrounded by growing opaque halo zones, which could be related to 
the presence of a virion-associated exopolysaccharide depolymerase (51). This and related enzymes 
have been found to enhance the biofilm-eradicating activity of bacteriophages compared with non-
depolymerase-producing bacteriophages (52). Based on genomic analysis, none of our bacteriophages 
seemed to produce any obvious extracellular polysaccharide or exopolysaccharide depolymerase. 
However, because bacteriophages that do not produce depolymerases have also been used in biofilm 
elimination (53), we sought to investigate the effect of bacteriophage combinations on the viability 
of target bacterial cells in preformed biofilms at 4 and 24 hours. Here, assays using an IM of 10 
produced nearly identical results as assays using an IM of 100, with two exceptions. First, we observed 
different results between an IM of 10 and an IM of 100 after 4 hours for A. baumannii; however, this 
discrepancy may have arisen because only one bacteriophage was used. When previous experiments 
used a combination of two bacteriophages, the IM doubled, producing synergistic results (34). Second, 
differences between IMs were observed after 24 hours for S. aureus. This result may have occurred 
because the receptor for the bacteriophage F44/10, which we speculate to be N-acetylglucosamine in 
the cell-wall teichoic acid, is very frequent (relative to other receptors) in both live cells and bacterial 
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debris. This property means that active bacteriophages may adsorb to fragments of lysed cells, (debris) 
instead of live cells, at a higher rate. This phenomenon may ultimately lead to injection of the genetic 
material in a suicidal manner, eliminating the bacteriophage from the system (54). Increasing the IM 
amplifies the probability of bacteriophage-bacterium interaction, resulting in a true cell infection. 
Moreover, in vivo a bacteriophage dose sufficiently in excess of the target bacterium population (IM 
≥100) should be given to account for bacteriophage loss, dilution (associated with absorption and 
distribution), decay and/or inefficiencies of bacteriophage adsorption to bacteria (e.g. inefficiencies 
in penetration into biofilms in vivo).It is well known that bacterial regrowth occurs after biofilms have 
been exposed to antibiotics (55). One possible way to limit this regrowth is through multiple dose 
applications. Our results using multiple dose applications, as opposed to single-application dosing, 
are similar to the results observed in Georgia, where BT is the current standard of clinical care, and 
in Poland, where BT is used as an experimental treatment under a compassionate-use regulatory 
provision (7, 56, 57). These results were also corroborated experimentally in previously published 
animal studies (50). This implies that a significant proportion of the bacteria in biofilm do not have 
genotypic resistance, but rather some form of phenotypic resistance, which is reversible by the 
modification of the causal environmental factors. Various equally valid and non-mutually excluding 
theories have been presented, that could explain the possible coexistence dynamics of bacteriophages 
and susceptible bacteria: numerical refuge, physiological refuge, and shielding by bacterial debris. The 
numerical refuge theory (58) predicts that simple mass-action interactions between bacteriophages 
and sensitive and resistant bacteria determine the stability of the population. So, in our study, when 
new bacteriophages were added (creating a higher bacteriophage density), a decline in the number 
of sensitive cells resulted. The physiological refuge hypothesis (59) postulates that during certain 
stages of bacterial life cycles sensitive bacteria may become transitorily resistant to bacteriophage 
infection. In the present study, fresh medium was then added. This altered the life cycle of the present 
sensitive bacteria (e.g., from stationary to logarithmic), thereby potentially converting them from a 
temporarily resistant state into a susceptible state. Finally, the shielding by bacterial debris theory 
(54) predicts that active bacteriophages adsorb into fragments of lysed cells (debris) and inject their 
genetic material in a suicidal manner discounting from the system as a bacteriophage. In the present 
study, as new bacteriophages were added dead cells were removed, thus reducing nonproductive 
binding as described. None of these observations was noted for A. baumannii, perhaps because this 
was the only case in which we used a single bacteriophage, limiting the importance of non-heritable 
mechanisms in the reduction in resistance induced by mutation.
In conclusion, we prepared, purified, and characterized bacteriophage cocktails with a broad 
spectrum of activity against S. aureus, P. aeruginosa, and A. baumannii strains that commonly cause 
DFIs. The complementary studies on both planktonic cells and established biofilms allowed us to 
better evaluate the effects of a high IM (≥ 10) and a multiple-dose treatment protocol (every 4 
hours for 24 hours). We believe that this work takes an important step toward the future clinical 
application of BT.
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Chapter 3: Rat model of diabetic wound infection
Specific framework
The clinical application of BT requires both in vitro and in vivo experimental validation. As 
experimental models, in vitro tests fail to reproduce the physiologic and pathogenic complexity of 
an organism, making in vivo models a crucial tool for ensuring clinical relevance (1). Therefore, when 
in vitro testing has shown the feasibility of a project and indicated the optimal dosage regimen of 
a treatment modality, the next logical step is to investigate the preparation using an animal model. 
Researchers have studied in vivo wound healing in a variety of species, including pigs (2), rabbits (3), 
rats (4-6) and mice (7, 8), by using different incisional, excisional, and granulation wound models 
in animals rendered diabetic through genetic modification or chemical induction. Animal models 
of infected cutaneous wounds have also been published (9, 10). In all these models, the kinetics 
of wound closure is evaluated by a combination of macroscopic and/or histologic data (Figure 
B3.0-1). The microbial burden may be evaluated by invasive or non-invasive methods. However, 
there is no appropriately standardized in vivo model to facilitate the screening of BT preparations 
or other topical antimicrobial therapy (TAT) agents and their impact on wound healing. None of 
the published models fully reproduces the current clinical practice treatment protocols of chronic 
wound infections, which include debridement, antimicrobials, and dressings (11). Mechanical 
debridement is particularly pivotal in this strategy because it converts the molecular and cellular 
environment of a chronic wound to that of an acute healing wound by removing scabs and debris 
(10, 12, 13). Sharp debridement, as elegantly demonstrated by Wolcott et al. (12), also opens a 
time-dependent therapeutic window for TAT. Thus, there is currently no clinical or experimental 
rationale for using TAT products in its absence. Hence, we needed to develop a new diabetic wound 
infection model optimized for testing TAT agents – namely BT preparations – accurately reproducing 
the pathophysiology of infected diabetic wound healing while using the current standard treatment, 
debridement.
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Figure B3.0-1 – Wound kinetics as quantified by planimetry and histology. (A) Planimetry: Wounds 
are photographed from standard height by using a mounted digital microscope in the beginning and 
at the end of the study, and wound area is expressed as a percentage of the initial wound area. (B) 
Histology: After animal euthanasia, harvested wounds can be examined histologically for both the 
epithelial gap (EG; distance between the advancing edges of clear, multiple-layer neoepidermis), 
dermal gap (DG; distance between uninjured dermis on both sides of the wound) and granulation 
tissue area (GT area; as calculated by computerized morphometric analysis).
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Abstract
Diabetes mellitus is an epidemic multisystemic chronic disease that frequently is complicated by 
complex wound infections. Innovative topical antimicrobial therapy agents are potentially useful for 
multimodal treatment of these infections. However, an appropriately standardized in vivo model 
is currently not available to facilitate the screening of these emerging products and their effect 
on wound healing. To develop such a model, we analyzed, tested, and modified published models 
of wound healing. We optimized various aspects of the model, including animal species, diabetes 
induction method, hair removal technique, splint and dressing methods, the control of unintentional 
bacterial infection, sampling methods for the evaluation of bacterial burden, and aspects of the 
microscopic and macroscopic assessment of wound healing, all while taking into consideration 
animal welfare and the ‘3Rs’ principle. We thus developed a new wound infection model in rats that 
is optimized for testing topical antimicrobial therapy agents. This model accurately reproduces the 
pathophysiology of infected diabetic wound healing and includes the current standard treatment 
(that is, debridement). The numerous benefits of this model include the ready availability of 
necessary materials, simple techniques, high reproducibility, and practicality for experiments with 
large sample sizes. Furthermore, given its similarities to infected-wound healing and treatment in 
humans, our new model can serve as a valid alternative for applied research.
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Introduction
The world is facing a growing diabetes mellitus (DM) epidemic, and diabetic foot ulcers, with an 
estimated lifetime risk of 25%(1), constitute one of the most common complications of this disease. 
About 58% of ulcers become clinically infected (2), often leading to amputation. Diabetic wounds 
(3, 4)  do not follow the precisely orchestrated course of events observed in normal healing, and 
bacterial colonization or infection further disrupts this process (5). In current clinical practice, once 
an adequate blood supply is assured, the treatment of diabetic foot infections includes debridement, 
systemic antibiotics, and dressings (6).  Mechanical debridement is pivotal to this strategy, because it 
not only significantly reduces the bioburden but also opens a time-dependent therapeutic window 
for topical antimicrobial therapy (TAT) (7). TAT agents consist of an active antimicrobial molecule 
associated with a vehicle or base, thereby delivering a high and sustained antibiotic concentration 
directly to the site of infection while avoiding systemic toxicity (8).
Several new TAT agents are under investigation, and a phased strategy of efficacy and toxicity 
testing is required before they can be made widely available for human use. None of the presently 
available in vitro or in vivo models of wound healing is optimal. As experimental models, in vitro 
tests fail to reproduce the physiologic and pathogenic complexity of an organism, making in vivo 
models a crucial tool for ensuring clinical relevance (9). Researchers have studied in vivo wound 
healing in a variety of species, including pigs (10), rabbits (11), rats (12-14) and mice (3, 15), by using 
different incisional, excisional, and granulation wound models in animals rendered diabetic through 
genetic modification or chemical induction.
For most researchers, rodents are the model of choice because they are inexpensive, easy to 
handle, require little space, and have accelerated healing compared with humans, thereby yielding 
for faster results (9).  The excisional wound model accommodates the broadest assessment of the 
mechanisms involved in wound healing, including epithelialization, granulation, and angiogenesis 
(16). In addition, this model supports the evaluation of new topical pharmacologic interventions 
because medications can be applied directly to the wound bed (13, 15).  All models of excisional 
wound healing are based on the same principles (Figure B3.2-1) (9). However, these models have 
been criticized because the main mechanism of wound healing in rodents is contraction (17) due 
to the presence of the panniculus carnosus muscle in the subcutaneous tissue; in contrast, humans 
heal more through reepithelialization (5). One rodent excisional wound healing model minimizes 
wound contraction by the use of silicone splints that are fixed to the skin by using immediate-
bonding adhesive and nylon sutures (17). Although potentially useful for evaluating diabetic wound 
bacterial infections, this model has not been tested or validated in this context. Other published 
animal models of infected cutaneous wounds (18, 19) fail to afford the optimal characteristics of the 
model cited previously (17). Still, this model (17) is not without disadvantages, namely the difficulty 
of applying and maintaining the dressing (and splint) while maintaining stringent infection control.
Because, to our knowledge, better in vivo models are not available for the evaluation of TAT in 
diabetic wound infections, we refined and adapted the previous murine model (17)  to develop a 
useful and cost-effective model for this purpose.
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Figure B3.2-1 – Schematic representation of diabetic rodent models of excisional wound healing. (1) 
Genetically modified or chemically induced diabetic animals are used. (2) Hair is removed (various 
techniques are available). (3) A full-thickness wound extending through the panniculus carnosus is 
created in the interscapular region of the upper back, typically by using a punch biopsy instrument. (4) 
Some models use a silicone splint fixed to the skin, for minimizing wound contraction while allowing 
the normal granulation and reepithelialization. (5) The wound is covered with a semiocclusive 
dressing. Various macroscopic and microscopic methods are available for the evaluation of wound 
closure.
Materials and methods
This study was approved locally by the Animal Ethics Committee of the Instituto de Medicina 
Molecular and nationally by the Portuguese General Directorate of Veterinary Services (Direcção 
Geral de Veterinária), in accordance with Portuguese law. All animals were maintained in accordance 
with European Directive 86/609/EC (20), Portuguese law (Portaria 1005/92) (21), and the Guide for 
the Care and Use of Laboratory Animals (22).  This study included the refinement and optimization 
of several sequential procedures. The animals used and the DM induction protocol were the same 
for all study groups. The final optimized wound-infection model study was preceded by 3 sequential 
optimization studies: hair removal (optimization study 1); prevention of unintentional critical 
colonization (optimization study 2); and assessment of wound bioburden (optimization study 3). To 
reduce the number of study groups, and therefore the total number of animals, each subsequent 
optimization study incorporated the findings of previous studies.
Animals
Specific pathogen-free male Wistar rats (Crl:WI[Han]; weight, 250 to 350 g; age, 8 to 10 wk) were 
obtained from Charles River Laboratories (L’ Arbresle Cedex, France) and kept in an approved animal 
care center. The rats were maintained in microisolation caging in a room with controlled humidity 
(50% to 70%) and temperature (20 to 22 °C), a 14:10-h light:dark cycle, and free access to pelleted 
rodent chow (RM3, Special Diet Systems, Essex, UK) and filter-sterilized water. Initially housed in 
groups of 2, rats were housed individually after hair removal to preserve skin and dressing integrity.
Induction of DM
DM was induced chemically as described previously (23). Briefly, after a 12-h fast, rats received a 
single intraperitoneal injection of streptozotocin (65 mg/kg; Merck Chemical, Darmstadt, Germany) 
freshly prepared in 0.1 M sodium citrate buffer (pH 4.5). At 8 d after streptozotocin injection, blood 
glucose measurement was performed on tail-vein blood by using a glucometer (Accu-Chek Aviva 
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Nano, Roche Diagnostics, Penzberg, Germany). Rats whose fasting blood glucose levels exceeded 250 
mg/dL (13.9 mmol/dL) were considered diabetic. Water intake and weight were monitor throughout 
the study, and to confirm the diabetic state, fasting blood glucose measurement was repeated on 
the day of euthanasia.
Optimization study 1: hair removal
On the day of DM confirmation, 9 diabetic rats were anesthetized by intraperitoneal injection 
of xylazine hydrochloride (10 mg/kg) and ketamine hydrochloride (25 mg/kg), and their dorsal 
surface hair was trimmed with an electric clipper. Rats then were divided into 3 groups depending 
on the method used to remove any remaining hair: straight razor; 2) depilatory cream (Opilca, 
GlaxoSmithKline Consumer Healthcare, Copenhagen, Denmark); and 3) cold wax (Veet cold wax 
strips, Reckitt Benckiser, West Ryde, Australia). The dorsum of all rats was rinsed with a 10% povidone-
iodine solution and, after drying and cleansing, a liquid film-forming acrylate (Cavilon Skin Cleanser, 
3M Health Care, Saint Paul, MN) was applied evenly to cover the hair removal area. A photograph 
of the dorsum of the rat was taken from a 1.5 cm standard height (ES65 digital camera, Samsung, 
Beijing, China), and the rats were placed on a 37 °C heating pad to minimize hypothermia. All rats 
received sterile sodium chloride to prevent dehydration. After fully recovering from anesthesia, rats 
were placed in individual cages. Photographs of nonanesthetized rats were taken on days 4 and 14 
after hair removal and used by 3 independent observers for evaluation of the hair-density index 
(scale: 1 [no hair] to 5 [normal amount of hair]) and skin-damage index (scale: 1, intact skin; 2, 
erythematous skin; 3, epidermal injury; 4, dermal injury; and 5, subcutaneous layer injury). Hair 
density and skin damage scores are expressed as the median (first and third quartiles).
Optimization study 2: prevention of unintentional critical colonization
Based on the findings of the previous optimization study, 18 Wistar rats with chemically induced DM 
were epilated by using cold wax and anesthetized by intraperitoneal injection of xylazine-ketamine 
4 d thereafter.
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Figure B3.2-2 – Illustration of specific techniques. (A) The oval-shaped silicone splint and its 
dimensions. (B) Application of a jacket made from adhesive tape to prevent dressing loss. (C) Bacterial 
inoculation of the wound bed by inserting a 27-gauge, 19-mm needle attached to a 1-mL disposable 
syringe through the silicon splint at a 45° angle. (D) Wounds photographed from a standard 1.5 cm 
height by using a mounted digital microscope.
Decontamination protocols
All surgical procedures were performed in a sanitized surgery room by using autoclave-sterilized 
instruments. Because the procedures were repeated in multiple rats, 2 sets of instruments were 
used. Between uses, instruments were cleaned thoroughly to remove all organic debris, disinfected 
with a multipurpose disinfectant (Virkon, Antec International Limited, Suffolk, UK), and resterilized 
by using a glass bead sterilizer (FST 250, Fine Science Tools, North Vancouver, Canada) according to 
the manufacturer’s guidelines. The surgeon wore clean scrubs, mask, and hair cap and used fresh 
sterile gloves for each rat.
Wounding, splinting, and dressing
The anesthetized rats were separated into 3 groups depending on the method of decontamination 
of the dorsal skin: thorough washing with sterile saline only; thorough washing with sterile saline 
followed by disinfection with 10% povidone-iodine; and sterile saline plus povidoneiodine (10 min 
contact time) followed by 70% isopropyl alcohol. A punch biopsy instrument (diameter, 6 mm; 
Accu-Punch, Acuderm, Fort Lauderdale, USA) then was used to create a full-thickness round wound 
extending through the panniculus carnosus in the interscapular region of the upper back of each 
rat, and the skin flap was excised by using iris scissors. An oval-shaped silicone splint (Figure B3.2-2 
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A) was adapted from a self-adhesive corn cushion (Comforsil, Toledo, Spain). Immediate-bonding 
cyanoacrylate glue in a disposable single-dose package (Loctite, Henkel Corporation, Westlake, OH) 
was used to fix the splint to the skin, followed by interrupted 3-0 nylon sutures to ensure its position. 
Liquid film-forming acrylate was applied to the epilated area, and the wound and surrounding area 
were covered with a previously tailored, semiocclusive, nonwoven polyester dressing (Fixomull 
Stretch, BSN Medical, Hamburg, Germany). The splint and dressing were maintained in place 
throughout the entire course of the experiment by the use of a jacket (Figure B3.2-2 B) made from 
adhesive tape (Leukoplast surgical tape, BSN Medical).
Debridement of the ulcer and  assessment of contamination
Four days after wounding, the semiocclusive dressing was removed, and a scab, defined as a 
crust of dried blood, serum, and exudate (19), was noted over each wound. By using strict aseptic 
technique, the ulcer was debrided by simple mechanical removal of the scab. The ulcer then was 
photographed as previously described, and a liquid Amies elution swab (eSwab Collection and 
Preservation System, Copan, Corona, CA) was used to collect and transport swab cultures. Bacteria 
collection was performed by using the one-point method (24).  Briefly, by using the sterile swab, the 
center surface of each wound was scrubbed carefully by rotating the swab 3 times clockwise with 
enough manual pressure to produce a small amount of exudate. The inoculated swab was inserted 
into a tube containing 1 mL liquid Amies transport medium and transported to the laboratory for 
immediate processing. The swab collection tube was vortexed (with the swab inside) for 5 s, and a 
100-µL aliquot of the suspension was used for serial dilutions. Quantification of the viable bacteria 
present in the swab was performed by using the 10-fold serial dilution method (25), and 100 µL 
of each dilution was plated onto tryptone soy agar (Biokar Diagnostics, Pantin Cedex, France). The 
plates were incubated under aerobic conditions at 37 °C for 24 h, after which colonyforming units 
were counted. The wound and surrounding area again were covered with a previously tailored, 
semiocclusive, nonwoven polyester dressing. Because all of these procedures are considered to be 
painless and noninvasive, they were performed on unanesthetized rats. A surgical drape was placed 
over the head of the rat to reduce stress and ensure immobilization. The entire procedure (including 
debridement) was repeated on days 5, 8, and 11. Rats were evaluated twice daily for the integrity 
of the adhesive jacket, which was reinforced whenever deemed necessary. On day 11, the rats 
were euthanized by intraperitoneal injection of pentobarbital (200 mg). Quantitative microbiologic 
results were expressed as the number of colony-forming units per swab and, on the basis of previous 
studies (26) and the results of optimization study 3, rats with more than 103  cfu/swab  on any given 
day were considered to be critically colonized. Results are presented as unit values and percentages.
Optimization study 3: assessment of wound bioburden
For this experiment, 14 Wistar rats with chemically induced DM were epilated by using cold wax, 
and an incision was made in each rat, splinted, and dressed as previously optimized and described. 
These ulcers were inoculated with bacterial suspensions of either S. aureus or P. aeruginosa. Clinical 
strains of S. aureus and P. aeruginosa that previously had been isolated from patients with chronic 
skin ulcers and cryopreserved at −70°C were grown on tryptone soy agar. After 24 h, bacterial 
cultures were harvested, and a bacterial suspension was prepared and compared with a McFarland 
standard (bioMérieux, Craponne, France). The inoculation dose was approximately 2.0 × 107  cfu/ 
mL. The rats were divided into 2 groups of 7 animals each (S. aureus and P. aeruginosa). After 
application of the dressing and with the rat still anesthetized, the wound bed was inoculated with 
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100 µL of cultured bacteria (approximately 2.0 × 106 cfu) resuspended in sterile saline by inserting 
a 27-gauge, 19-mm needle attached to a 1-mL disposable syringe through the silicon splint at a 45° 
angle (Figure B3.2-2 C).
At 4 d after wounding, rats were euthanized by intraperitoneal injection of pentobarbital (200 
mg), the semiocclusive dressing was removed, the ulcer was debrided, and a swab was obtained 
as described previously. Then, by using sterile surgical scissors, each wound was harvested in its 
entirety and placed in a sterile tube. Swabs and tissue samples were transported to the laboratory 
for immediate processing. The swabs were processed as previously described, and tissue samples 
were homogenized in 5 mL sterile saline in a pearl jar, vortexed for 20 s, and sonicated for 90 s at 35 
MHz (Transsonic T570, Elma, Singen, Germany) to disaggregate bacteria (this procedure had been 
optimized previously to minimize cell disruption). A 100-µL volume of the homogenate was used for 
the serial dilutions. Quantification was performed by using the 10-fold serial dilution method (25); 100 
µL of each dilution (either swab or tissue) was inoculated onto selective media (Chapman mannitol 
salt agar [Biokar Diagnostics] for S. aureus or cetrimide agar [Merck Chemical] for P. aeruginosa). The 
plates were incubated under aerobic conditions at 37 °C for 24 h, after which colony counts were 
performed. The isolates grown on Chapman mannitol salt agar were presumptively identified as S. 
aureus based on colony morphology and mannitol salt agar fermentation (27). The isolates grown 
on cetrimide agar were presumptively identified as P. aeruginosa based on colony morphology (28). 
Quantitative results are presented as the mean and standard deviation and expressed as logarithm-
transformed values (log[cfu/swab] for swab samples and log[cfu/ulcer] for tissue samples). The data 
were compared by using a logarithmic scale owing to the wide variations in number of colony-forming 
units between cultures. Correlations were evaluated by the Pearson correlation coefficient, and the 
Fisher r-to-z method was used to calculate P values. A P value of less than 0.05 was considered 
significant. All data was entered into a spreadsheet program (Excel, Microsoft, Redmond, WA) for 
statistical analysis. Analytical statistics were performed by Analyse-it version 2.21 Excel 12+ (Analyse-
it Software, Leeds, UK), a statistical add-in program for the spreadsheet program.
Optimized final rodent wound-infection model
General protocol and wound-closure kinetics
After every step of the procedure had been optimized, a final study (Figure B3.2-3) was designed 
by using 36 Wistar rats with chemically induced DM that were epilated by using cold-wax strips. 
Incisions were made, splinted, and dressed as previously described. Wounds were photographed 
from a 1.5-cm standard height by using a mounted digital microscope (SuperEyes 200× USB Digital 
Microscope, Shenzhen Tak and Assistive Technology, Shenzhen, China; Figure B3.2-2 D), and the 
rats were divided randomly into 3 groups: inoculated with S. aureus (n = 12), inoculated with P. 
aeruginosa (n = 12), and negative control (n = 12). The ulcers of the animals in the infected groups 
were inoculated with either S. aureus or P. aeruginosa as previously described, whereas the ulcers 
of the negative control group were inoculated with sterile saline. On day 4 after wounding, the 
semiocclusive dressing was removed, the ulcer debrided and photographed, and a swab was 
obtained as previously described. The entire procedure, including debridement, was repeated on 
days 5, 8, and 11, and the splint chamber was filled twice daily with sterile saline from day 5 until 
the end of the study. Wound kinetics were quantified by using image-processing software (ImageJ, 
US National Institutes of Health, Bethesda, MD) to measure the wound area by planimetry; wound 
area was expressed as a percentage of the initial wound area. Results are expressed as the mean of 
the percentage in area of the original wound size. Comparisons between groups were performed 
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by using 2-tailed Student t tests, and a P value of less than 0.01 was considered significant. All data 
were entered into the spreadsheet program, and analytical statistics were performed as described 
previously. 
Figure B3.2-3 – Final study design: optimized rodent wound infection model. Wistar rats each 
received a single intraperitoneal injection of streptozotocin; 8 d after injection, rats considered to be 
diabetic (fasting blood glucose greater than or equal to 250 mg/dL)  were epilated by using cold-wax 
strips. At 4 d after epilation (study day 1), skin was disinfected, wounded, splinted, and photographed 
from a standard height. In addition, rats were divided randomly into 2 infected groups (inoculated 
with either S. aureus or P. aeruginosa) and 1 negative control group (inoculated with sterile saline). 
On study days 4, 5, 8, and 11, ulcers were (1) debrided, (2) swabbed, and (3) photographed. From 
day 5 until the end of the study, splint chambers were filled twice daily with sterile saline. On study 
days 9 and 11, half of the animals in each group were (4) euthanized, and each ulcer was processed 
for histologic analysis.
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Histologic analysis
For each group, 6 rats each were euthanized by intraperitoneal injection of pentobarbital (200 mg) 
on days 9 and 11, and each ulcer (including a 0.5-cm skin border) was harvested in its entirety by 
using sterile surgical scissors and placed in a tube. The sample was fixed overnight in 10% buffered 
formalin solution, after which the tissue was trimmed and cut through at the widest margin, 
embedded in paraffin, and sectioned in 3-µm increments. Sections were made perpendicular to 
the anterioposterior axis and perpendicular to the surface of the wound. For each wound, 2 serial 
sections were placed on a slide and stained with hematoxylin and eosin. Under light microscopy, the 
sections were photographed by using an upright brightfield microscope equipped with a color camera 
(model DM2500, Leica Microsystems, Wetzlar, Germany) at 50× magnification. Panoramic cross-
sectional digital images of each wound were prepared by using professional image-editing software 
(Photoshop CS2, Adobe Systems, San Jose, CA). The images were analyzed for epithelial gap (EG), 
dermal gap (DG), and total granulation tissue (GT) area by using image-processing software. EG was 
defined as the distance between the advancing edges of clear, multiple-layer neoepidermis (9, 17), 
and its size was measured in millimeters, with an EG of 0 representing a completely reepithelialized 
wound. DG was defined as the distance between uninjured dermis on both sides of the wound (9, 17) 
and was measured in millimeters. GT area was calculated by computerized morphometric analysis 
(17)  and expressed in square millimeters. The results are presented as mean ± SEM. Comparisons 
between groups were performed by using 2-tailed Student t tests, and a P value of less than 0.05 was 
considered significant. All data were entered into the spreadsheet program and analytical statistics 
were performed as described previously.
Results
Animals and induction of DM
We induced diabetes in 98 male Wistar rats with a success rate of 81.6%. Of the 80 successfully 
induced rats, 3.8% died prior to the end of the study; at necropsy, no significant gross pathology 
was noted. There was no mortality during the optimized final study. For the final study, 77 animals 
(78.6% of the number of rats induced initially) were used. At the time of euthanasia, all rats were 
confirmed to have fasting glucose levels of at least 250 mg/dL, and the mean weight loss was 18.10% 
± 2.35%.
Optimization study 1: hair removal
Depilation by using a straight razor gave the worst hair density and skin damage results throughout 
the 15 d of the experiment (Figure B3.2-4). Although cold wax tended to cause increased immediate 
(day 1) epithelial injury, as measured by the skin-damage index, compared with that from the 
depilatory cream, this pattern was completely reversed by day 4. Epilatory hair removal by using cold 
wax achieved more prolonged results than did the depilatory methods (straight razor or depilatory 
cream), as evaluated by using the hair-density index, with less skin damage after day 4, which was 
the optimal day for infection.
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Figure B3.2-4 – Results of the hair-removal optimization study. After dorsal hair trimming, rats 
were divided into 3 groups: straight razor, depilatory cream, and cold wax. Photographs were 
taken immediately, 4 d, and 14 d after removal procedures; 3 independent observers evaluated 2 
parameters: hairdensity index (HDI) and skin-damage index (SDI). Results are expressed as median 
(first and third quartiles).
Optimization study 2: prevention of unintentional critical colonization. 
This experiment examined methods for preventing unintentional critical bacterial colonization. The 
use of a combined approach (washing with sterile saline, followed by disinfection with povidone-
iodine and washing with isopropyl alcohol after 10 min contact time) produced the best results 
(Table B3.2-1), with only 1 of the 6 control wounds having a swab colony count that exceeded 3 logs 
(4.6 × 105  cfu/swab). No dressing or splint was lost during the experiment.
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Table B3.2-1 – Evaluation of 3 strategies for preventing unintentional critical colonization (bacterial 
count >103 cfu/swab on any given study day). Note that the combined approach (washing with sterile 
saline, followed by disinfection with povidone-iodine and washing with isopropyl alcohol after 10 
minutes contact time) produced the best results.
unintentional 
bacteria count
sterile salinea 
(n = 6)
sterile saline + povidone-
iodineb
(n = 6)
sterile saline + povidone-
-iodine + isopropanolc
(n = 6) 
≤ 103 (3 log) 2 (33.3 %) 3 (50.0 %) 5 (83.3 %)
> 103 (3 log) 4 (66.7 %) 3 (50.0 %) 1 (16.7 %)
a washed with sterile saline
b washed with sterile saline followed by disinfection with 10 % povidone-iodine
c washed with sterile saline followed by disinfection with 10 % povidone-iodine and washing with 70 % 
isopropanol after 10 minutes contact time
Optimization study 3: assessment of wound bioburden 
The average colony count in swab samples (Table B3.2-2) was similar between the 2 species: 5.67 ± 
0.16 log(cfu/swab) for S. aureus and 5.65 ± 0.26 log(cfu/swab) for P. aeruginosa. The colony counts 
in tissue samples differed between the 2 species by 0.16 log(cfu/ulcer) but this difference was not 
statistically significant (2-tailed t test, data not shown). The one-point quantitative swab method 
underestimated the number of bacteria in the wound bed by 1.79 ± 0.10 log(cfu) for S. aureus and 
1.97 ± 0.16 log(cfu) for P. aeruginosa. The Pearson correlation coefficient (r) between swab and 
tissue colony counts was 0.810 (95% confidence interval, 0.143 to 0.971; P = 0.025) for S. aureus 
and 0.780 (95% confidence interval, 0.065 to 0.966; P = 0.037) for P. aeruginosa, suggesting a strong 
relationship between the 2 independent measures. This statistical correlation was not observed 
when data from the 2 infected groups were combined.
Table B3.2-2 – Bacterial colony counts (log[CFU]) from tissue or swab culture of wounds infected 
with S. aureus or P. aeruginosa. The variation between the two techniques (Δ swab/ulcer) is also 
presented. Note there was a statistical correlation for the individual groups but not when both 
of the infected groups were combined.
ulcer
log(CFU/ulcer)
swab
log(CFU/swab)
Δ swab/ulcer
log(CFU)
R
Pa
(95 % CI)
S. aureus
(n = 7)
7.46 ± 0.17 5.67 ± 0.16 1.79 ± 0.10 0.810
0.025
(0.143-
0.971)
P. aeruginosa
(n = 7)
7.62 ± 0.18 5.65 ± 0.26 1.97 ± 0.16 0.780
0.037
(0.065-
0.966)
TOTAL
(n = 14)
7.54 ± 0.19 5.66 ± 0.21 1.88 ± 0.16 0.743 N.S.
aP value as calculated by the Fisher r-to-z method
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Optimized rodent wound-infection model
Wound-closure kinetics
In the final wound-infection model study, the control group showed continuous reduction of the 
wound area that was enhanced after mechanical debridement (Figure B3.2-5). During the first 
4 d after infection, the wound area increased on average to 110.6% of the original size in the P. 
aeruginosa group and 102.3% of the original size in the S. aureus group. After the first debridement, 
the wound area began to decrease, paralleling a decrease in the microbial load. There was a 
statistically significant difference (P < 0.01) in wound area between the negative control and both 
infected groups on days 8 and 9; on day 11, only the difference between the negative control and P. 
aeruginosa groups remained significant. Microbial load was similar between the 2 infected groups 
(5.66 compared with 5.54 log[CFU/swab]) on day 4 and did not differ significantly on days 5, 8, and 
11.
Figure B3.2-5 – Results of the final wound-infection model study. The line graph illustrates wound 
healing kinetics of the infected (S. aureus or P. aeruginosa) and negative control groups. Each point 
represents the mean of the percentage in area of the original wound size. After day 4, wound area 
decreased progressively and was enhanced after mechanical debridement. Wound area differed 
significantly (*, P < 0.01) between the negative control and both infected groups on days 8 and 9 and 
between the negative control and P. aeruginosa-inoculated groups on day 11. The bar graph illustrate 
microbial load (from quantitative swab-sample cultures and expressed in no. of cfu per swab [log 
scale]) between the 2 infected groups on days 4, 5, 8, and 11. The S. aureus-inoculated group showed 
a trend (0.05 < P < 0.10) toward increased microbial load on days 5, 8, and 11. The lower panel 
contains macrophotographs of wounds from a representative rat in each group at each time point.
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Histologic analysis
Both EG and DG decreased (P < 0.01) as the GT area increased in all groups from day 9 to day 11 
(Figure B3.2-6). On day 9, EG closure was significantly delayed in infected groups compared with 
controls (S. aureus, 0.12 ± 0.06 mm; P. aeruginosa, 1.3 ± 0.15 mm; control, 1.55 ± 0.15 mm; P < 
0.01). By day 11, all wounds were completely reepithelialized, except for a single ulcer in the rats 
inoculated with P aeruginosa. GT area did not differ between groups on either day 9 or 11. However, 
DG closure followed wound contraction, as evaluated by digital planimetry. Wounds of infected rats 
showed significantly less DG closure than did those of control rats on days 9 (S. aureus, 1.88 ± 0.09 
mm; P. aeruginosa, 2.93 ± 0.08 mm; control, 3.17 ± 0.15 mm; P < 0.01) and 11 (S. aureus, 1.30 ± 0.16 
mm; P. aeruginosa, 2.20 ± 0.15 mm; control, 2.43 ± 0.06 mm; P < 0.01). DG closure did not differ 
significantly between infected groups.
Figure B3.2-6 – Quantitative histologic evaluation of epithelial gap (EG), dermal gap (DG), and granulation 
tissue (GT) area in the negative control and both infected (S. aureus or P. aeruginosa) groups on days 9 
and 11. On day 9, EG closure in both infected groups was significantly (*, P < 0.01) delayed compared 
with that in the control group. On days 9 and 11, wounds in the infected groups showed significantly 
(*, P < 0.01) less DG closure than did the control group. Original magnification, ×50.
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Discussion
The impairment of wound healing by DM, which is potentiated by infection, causes a significant 
amount of human morbidity and mortality worldwide (5, 29)  and has prompted the investigation of 
new TAT approaches. Although swine are thought to be the ideal large animal model for cutaneous 
disease (30)  the use of rodents overcomes several of its disadvantages (for example, size, cost, 
housing, husbandry, and reagent validation). Therefore, rodents are still the model of choice for 
research purposes in this area. However, there are no standardized wound-infection models for 
testing TAT.
One well-known rodent model (17)  is a splinted, excisional wound-healing model that involves 
genetically diabetic mice (db/db mice). In contrast, we used male Wistar rats in which DM had 
been chemically induced as a rodent model. Rats are a widely used biomedical research animal 
and currently the primary model for many preclinical tests, including those in the DM field (31). 
Although the use of rat models has declined in the last decade, mainly due to broad advances in the 
development of mouse genetic technologies, rats still afford many advantages over mice, primarily 
in regard to size and behavioral characteristics (32). In our case, the adhesive-tape jacket needed 
to prevent dressing loss and subsequent unintentional critical colonization would be impossible 
to adapt to a smaller rodent. Moreover, we expected our studies to involve frequent, nonpainful 
procedures. Rats often are easier to train and handle than are mice (33), obviating the need for 
inhalant anesthesia before procedures and reducing the associated time, distress, and mortality 
risks. Except for during the initial epilation and wounding procedures, the rats in our current study 
were restrained simply by placing a surgical drape over the rat’s head to maintain immobilization in 
the absence of any identifiable behavioral stress signs.
We have used streptozotocin-induced diabetic Wistar rats rather than one of the available rat 
genetic models. Although genetic models offer some undisputed advantages, they are of limited 
availability and are expensive for regular screening studies of wound healing related to DM (34). 
Further, the most common and readily available of genetically diabetic rats are obese to the point 
that excisional wound closure is impeded not only by physiologic dysfunction but also by excess 
subcutaneous fat (35).
Streptozotocin targets and inhibits pancreatic β-cell function without affecting the exocrine 
function and produces a DM type 1 phenotype with residual insulin secretion that enables animals 
to live longer than do genetic models before insulin treatment is needed. However, in addition to 
this biochemical deficit, this chemical agent causes other effects, such as altered T cell function and 
decreased macrophage phagocytosis, which also may contribute to impaired healing (9, 36, 37). 
Nevertheless, the streptozotocin model is one of the most suitable for use in wound healing studies, 
allowing accurate quantification of the main aspects of a healing wound such as wound closure, 
reepithelialization, and GT formation. In addition, we used male rats, whose pancreatic islet β cells 
are more prone to streptozotocin-induced cytotoxicity than are those of female rats (23) and which 
have 40% stronger skin than do female rats, due to a much thicker dermis (16). Our DM-induction 
rate exceeded 80%, as expected for the protocol (23), and the postinduction mortality rate was low 
(less than 5%).
The silicone splint was used in previous models because it minimized wound contraction 
without affecting the rate of reepithelialization, thus better recapitulating the repair mechanisms 
underlying human wound healing (16).  In our current study, the splint had the additional benefit 
of creating a sealed artificial chamber over the wound, maintaining sterility at the wound site 
and allowing the establishment of a monoculture infection while enabling the application of 
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products in a liquid vehicle. We filled this chamber twice daily with sterile saline, which provided 
a wet wound microenvironment beneficial to wound healing (38). Sterile saline is also the most 
frequently used negative TAT control. The influence of the splint and dressing maintenance on 
wound closure has been reported as a problem (9, 17). When the dressing is breached, the wound 
becomes contaminated, and splint loss is easier. Once animals lose the splint, wound closure occurs 
more rapidly. All of these factors can lead to the exclusion of animals from the study; therefore, 
meticulous application and maintenance of the dressing that protects the splint is an essential 
aspect of model standardization. To prevent dressing loss, we introduced a jacket made from 
adhesive tape. With twice-daily evaluation for the integrity of the adhesive-tape jacket and the 
addition of reinforcement whenever deemed necessary, we had a 100% success rate of maintaining 
the dressing and splint to the end of the experiment. The jacket seemed to be well tolerated by the 
rats, which exhibited no overt signs of distress.
Rodent skin is covered with dense hair that undergoes a defined cycle of hair growth similar to 
that of human hair (35). Although hair removal protocols are described in detail only infrequently in 
studies, hair regrowth has been reported as an impediment to splint and dressing skin adherence, 
resulting in the failure of skin contraction restriction and consequent exclusion of animals from the 
study (39). This problem is particularly important in wound infection models, because razor shaving 
produces microscopic cuts in the epidermis, and hair growth around the wound site acts as a wick, 
both of which increase the risk of wound contamination. Cold waxing, as indicated by the hair-density 
index we used here, was more effective than were shaving or chemical depilatories because waxing 
removed the hair from beneath the skin surface (40). This improvement in limiting hair growth was 
made at the expense of persistent skin lesions. However, although cold wax tended to cause more 
immediate (day 1) epithelial injury, as measured by the skin-damage index, than did depilatory 
cream, this effect was completely reversed by day 4. This outcome is consistent with previous skin 
electrical potential studies (40), which showed that waxing causes stratum corneum damage with 
an immediate loss of cutaneous barrier function and has a rapid and apparently complete recovery 
by the fifth day after treatment. From our optimization study and based on the previously cited skin 
electrical potential study (40), we decided to use cold waxing epilation in our final study at 4 d before 
wounding. This strategy prevented regrowth of hair throughout the course of the experiment and 
maintained the barrier function of the healthy surrounding skin.
The conversion of an excisional wound model to a wound-infection model is simple enough. The 
addition of a known concentration of virulent bacteria to the wound bed establishes infection in the 
test group (30),  but the most difficult problem to solve is the prevention of unintentional critical 
colonization or infection. Although sterilization of the wound is impossible, the use of strict measures 
can prevent colonization by pathogenic or normal skin flora microorganisms beyond a certain 
threshold, above which there may be impairment to wound healing. We and others (26, 41) consider 
this limit to be a tissue microbial load of 105 cfu/g tissue or 103 cfu/swab. A bioburden below this 
threshold does not seem to impair tissue repair and frequently has a positive effect on wound healing 
(42).  One potential criticism of our current study is that we did not include a chlorhexidine-based 
antiseptic solution test group; this type of antiseptic is considered to be ideal for wound infection 
prevention because of its persistent activity that prevents regrowth of microorganisms for at least 24 
h (43). This characteristic was the reason we did not include this type of disinfectant in our model: 
we would have had to pretreat the infection test group with the antiseptic solution, and its residual 
antiseptic activity might have limited the development of infection. We chose to use 10% povidone-
iodine and 70% isopropyl alcohol, because these agents have an immediate bactericidal action but 
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minimal residual activity (44). This strategy has been adopted in another animal model of diabetic 
wound infection (45).
One of the greatest controversies in wound management is the usefulness of quantitative swab 
cultures for predicting the presence of wound infection. This method has received criticism because 
it is thought to estimate wound-surface microbial numbers only and not deep-tissue numbers (41). 
However, several studies in humans and animals have demonstrated high sensitivity (93.5% to 100%) 
and good specificity (76.3% to 94.2%) and accuracy (approximately 90% to 99%) when compared 
with tissue-biopsy quantitative cultures (24, 46).  In an experimental acute-wound rat model, a 
tissue count of 105 cfu/g was equivalent to a count of 103  cfu/mL obtained from a moist swab 
(47);  another study (24) demonstrated that compared with biopsy cultures, one-point quantitative 
swab cultures detected similar types of microorganisms but underestimated bacterial numbers by a 
factor of 2 logs. These studies suggest that the quantitative swab method of collection and culturing 
is acceptable, given its correlation with the invasive method. The invasive method was strongly 
contraindicated in the model we developed because our study required serial evaluations of the 
bioburden, along with planimetry by digital photography and a final histologic evaluation. Because 
these measures constituted the final endpoints and would have been influenced by the wound-bed 
trauma induced by serial biopsies, we opted for swabbing.
Many methods (48) have been described for swab collection (10-point diagonal method, 1-cm2-
area sampling method, and one-point rotation method), but none has gained universal acceptance. 
In the current study and in accordance with others (24), we selected the one-point method because 
of the relatively small size of the wounds and to better avoid contamination with periwound flora. In a 
murine DM wound-healing model using quantitative cultures and transmission electron microscopy 
studies (19),  the majority of bacteria were in the scab above the wound bed rather than in the 
wound tissue. In addition, ulcer debridement (that is, the removal of the scab), which is essential to 
the model we developed, reproduced the current clinical practice of wound debridement previous 
to microbiologic sampling (41) and theoretically provided an improved estimate of deep-tissue 
bacterial numbers. Although the numbers of colonies obtained from swab and tissue samples 
varied, both samples were correlated logarithmically for each bacterium. Our data indicated that 
the one-point swab culture yielded an average 1.9 log(cfu) under-estimation of colony counts 
compared with those of the tissue cultures, consistent with the results of several other clinical and 
experimental studies (24, 47, 49). Surprisingly, we found that when P. aeruginosa and S. aureus 
groups were pooled before evaluation, this correlation could not be reestablished. Our results, 
which show underestimation of P. aeruginosa swab samples relative to S. aureus swab samples, may 
be explained by differential distribution of the 2 bacteria in the wound. This notion is in line with a 
previous study (50), in which confocal laser scanning microscopy of clinical wound-biopsy specimens 
demonstrated that the distance from P. aeruginosa aggregates to the wound surface was greater 
than that of S. aureus aggregates, leading to underestimation of P. aeruginosa in swab samples. 
This result supports the possibility that factors intrinsic to each pathogenic bacteria contribute, 
as does sampling technique, to the differences reported in studies comparing swab and tissue-
sample quantitative cultures. Finally, the choice of selective media (cetrimide or Chapman mannitol 
salt agar) is important, because using the proper medium is essential for the correct evaluation 
of target pathogens (41) and to prevent concurrent colonization by other microorganisms. The 
noninvasiveness of the quantitative swab, which allowed concomitant debridement and revealed 
a strong correlation with tissue sampling, made this method ideal for use in our rodent wound-
infection model.
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After optimizing each step of the process, we designed a protocol allowing the simultaneous and 
serial assessment of microbial load (by using quantitative swab-sample cultures) and the kinetics 
of wound closure (through digital photography and computerized planimetry software) and a well-
defined and easily repeatable quantitative histologic evaluation. It was our requirement that the model 
not only accurately paralleled the healing of infected wounds in humans but also the current treatment 
standard of care. Sharp debridement is standard procedure in wound management, and there is no 
clinical or experimental rationale for using TAT products in its absence (8). Debridement converts the 
molecular and cellular environment of a chronic wound to that of an acute, healing wound through the 
removal of scabs and debris. Many studies (7, 19, 51)  indicate that debridement plays an important 
role in removing bioburden and enhancing cicatrization, and its frequency is directly related to the rate 
of healing (52).  Furthermore and most importantly, debridement has been shown in several models 
to open a time-dependent window for TAT use (7). Debridement led to a significant decrease in the 
resistance of the bioburden to TAT for as long as 24 h, with resistance increasing to reach the original 
resistance levels at 72 h.
Our current study using a rat model replicates the current debridement protocol for infected 
diabetic ulcers (53). Initial debridement (day 4) removed a cellular burden of dead and senescent 
cells and excessive bacterial load; additional maintenance debridement (days 5 and 8) maintained 
the wound environment and the readiness of the wound bed for healing. The effects of debridement 
are manifest in our model: first, by limiting the increase in the size of the wound area after day 4, 
and second, by accelerating wound-healing kinetics as revealed by the inflections in the infected-
wound healing curve, which becomes parallel to the control curve from the third debridement 
onwards. In the current study, macroscopic wound closure showed a similar trend when compared 
with that of the EG and DG measured in histologic specimens among the control and infected 
groups. There was not, however, a statistically significant difference in GT area among groups. This 
result is probably related to an increase in collagenolytic activity in the wound, generating increased 
feedback synthesis (54). Qualitative differences in GT between groups may exist, and additional 
studies, such as complementary breaking-strength measurements, would be of interest. From the 
analysis of the planimetry and histologic data, we can conclude that in our model, the best time to 
evaluate differences between the infected and control groups is day 9, and TAT studies probably will 
not benefit from a longer period of evaluation. In addition, DG closure is a better parameter than is 
GT area for evaluating the histologic level of contraction of the wound.
In summary, we optimized a new wound infection model in chemically induced diabetic Wistar rats. 
This model can be used to investigate new approaches to TAT. The model has numerous benefits: 
the necessary materials and techniques are simple, reproducible, and practical for experiments with 
large sample sizes. Furthermore, in light of the analogies to human-infected wound healing and 
treatment, this model can serve as a valid alternative for applied research.
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Chapter 4: In vivo topical bacteriophage therapy of infected diabetic wounds
Specific framework
The use of animal models is a fundamental part of pharmaceutical research and development in 
the field of chronic wound infections. In the case of BT, after the pioneering work of Smith et al. 
(1-4), many reported the examination of bacteriophage preparations efficacy against experimental 
infections by S. aureus (5, 6), P. aeruginosa (5, 7), and A. baumannii (5), as well as other infectious 
agents in various animal models. Although the potential of BT for the treatment of infections was 
well established in these animal models, the reported outcomes varied dramatically, depending on 
the infectious agents, the animal model of infection, and the lytic potency of the bacteriophages 
used. Thus, the clinical application of BT requires case-by-case in vivo experimental validation. We 
developed a protocol to investigate in vivo the antimicrobial activity and wound-healing capability 
of topically delivered bacteriophage solutions against wounds with chronic S. aureus, P. aeruginosa, 
and A. baumannii infections. For this purpose, we used our previously optimized rodent wound 
infection model in chemically induced diabetic Wistar rats (Figure B4.1-1), as well as a pig wound 
infection model in animals with chemically induced DM (8) (Figure B4.1-2), which suited our needs. 
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Figure B4.1-1 – Topical bacteriophage therapy protocol in the rodent diabetic chronic wound 
infection model. The previously optimized rodent wound infection model in chemically induced 
diabetic Wistar rats was used. Briefly, diabetes mellitus (DM) was chemically induced in specific 
pathogen-free male Wistar rats. Eight days later, following DM confirmation, 42 diabetic rats were 
anesthetized. Hair was removed, a full-thickness wound extending through the panniculus carnosus 
was created in the interscapular region of the upper back using a punch biopsy instrument, and a 
silicone splint was fixed to the skin. Wounds were photographed using a mounted digital microscope, 
covered with a semi-occlusive, non-woven polyester dressing, and then maintained in place with 
a jacket made from adhesive tape. The rats were then randomly divided into 7 groups: negative 
control (n = 6), S. aureus-inoculated control (n = 6) and test (n = 6), P. aeruginosa-inoculated control 
(n = 6) and test (n = 6), and A. baumannii-inoculated control (n = 6) and test (n = 6). The wounds of 
the animals in the negative control group were injected with sterile saline, whereas the wounds of 
the inoculated groups (test and control) were injected with 2 × 106 cfu of S. aureus, P. aeruginosa, or 
A. baumannii resuspended in sterile saline. On days 4, 5, and 8 post-wounding, the semi-occlusive 
dressing was cut off, and the wounds were debrided. All test groups underwent a bacteriophage 
treatment protocol that consisted of an induction phase and a maintenance phase. The induction 
phase occurred after the first debridement (post-wounding day 4) and was comprised of six primary 
bacteriophage cocktail administrations (every 4 hours). The maintenance phase was from day 5 to 
day 8 and consisted of twice-daily (every 12 hours) primary bacteriophage cocktail administrations. 
If debridement was performed, bacteriophage administration followed. The control groups received 
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sterile saline at the same frequency. On days 4, 5, and 8 post-wounding and after debridement, 
microbial load was evaluated by using the sterile-swab, one-point method. Prior to sacrifice on 
day 9 post-wounding, the wounds were photographed using a mounted digital microscope for the 
macroscopic evaluation of wound closure. All animals were sacrificed on day 9 post-wounding, and 
the ulcers were collected for the histologic evaluation of wound closure. 
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Figure B4.1-2 – Topical bacteriophage therapy protocol in the pig chronic wound infection model. 
A previously optimized pig wound infection model in animals with chemically induced DM (8) was 
modified to fit our needs. Three animals (negative control, inoculated-control, and inoculated-test) 
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with a total of 48 excisional wounds (12 negative control wounds, 12 S. aureus-inoculated wounds, 
12 P. aeruginosa-inoculated wounds, and 12 A. baumannii-inoculated wounds) were used in this 
study. Diabetes mellitus (DM) was chemically induced in 3 female Yorkshire pigs. Blood glucose was 
measured on a daily basis, and the pigs received daily, subcutaneous insulin injections. Fourteen days 
after DM induction, the pigs were anesthetized and mechanically ventilated. Hair was removed and 
full-thickness excisional wounds were created on each side of the paraspinal area (18 in total for each 
of the inoculated pigs, and 12 in total for the negative control pig) using a punch biopsy instrument. 
The wounds were photographed using a mounted digital microscope. A modified adhesive chamber 
made from a colostomy bag was placed over each wound, which was covered with a semi-occlusive, 
non-woven polyester dressing. In the inoculated animals, wounds were divided into 3 subgroups: S. 
aureus (2 × 6 ulcers); P. aeruginosa (2 × 6 ulcers), and A. baumannii (2 × 6 ulcers), and inoculated with 
2 × 106 cfu of the respective pathogen. Whereas, in the negative control group (12 ulcers), wounds 
were injected with sterile saline. On days 4, 5, and 8 post-wounding, the semi-occlusive dressing was 
cut off, and the wounds were debrided. All test groups underwent a bacteriophage treatment protocol 
that consisted of an induction phase and a maintenance phase. The induction phase occurred after 
the first debridement (day 4 post-wounding) and was comprised of 6 primary bacteriophage cocktail 
administrations (every 4 hours). The maintenance phase was from day 5 to day 8 and consisted of 
twice-daily (every 12 hours) 100 µL primary bacteriophage cocktail administrations. If debridement 
was performed, bacteriophage administration followed. The control groups received sterile saline 
with the same frequency. On days 4, 5, and 8 post-wounding and after debridement, microbial load 
was evaluated by using the sterile-swab, one-point method. In the negative control group, ulcers with 
more than 103 cfu/swab on any given day were considered critically colonized and were excluded 
from further analysis. Prior to sacrifice on day 9 post-wounding, the wounds were photographed 
using a mounted digital microscope for the macroscopic evaluation of wound closure. All animals 
were sacrificed on day 9 post-wounding, and the ulcers were collected for the histologic evaluation 
of wound closure. 
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Abstract
Chronic wounds that fail to heal are a common complication of diabetes mellitus and the most 
common precipitating reason for nontraumatic lower limb amputation. Unfortunately, the bacterial 
species that cause these infections are becoming more resistance to antibiotics, making them 
increasingly difficult to treat. We assessed the feasibility of combating chronic bacterial infections 
with a topically delivered bacteriophage cocktail in two animal models of diabetes mellitus. 
Microbiological, planimetric, and histological parameters were compared in debrided infected 
wounds with or without topical bacteriophage treatment. We determined that bacteriophage 
treatment effectively decreased bacterial colony counts and improved wound healing, as indicated 
by smaller epithelial and dermal gaps, in S. aureus and P. aeruginosa infections but was not as 
effective against A. baumannii. Although the improvements were more significant in the rodent 
model than in the porcine model, our results suggest that topically administered bacteriophage 
treatment may be effective in resolving chronic infections, especially when applied in conjunction 
with wound debridement. These findings have important implications for the feasibility of using 
topical antimicrobial therapies to safely treat chronic infections in diabetes mellitus patients.
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Introduction
Diabetic foot infections (DFIs) are a frequent and serious complication of diabetes mellitus (DM) 
and are the world’s leading cause of nontraumatic lower limb amputation (1). In current clinical 
practice, DFI treatment includes debridement and systemic antibiotics (2). However, because of 
deficient vascularization and insufficient local antibiotic concentrations, these treatments are often 
ineffective (3). In addition, multi-drug resistant organisms, such as methicillin-resistant S. aureus and 
pan-drug-resistant nonfermenting Gram-negative bacilli, threaten the efficacies of these therapies 
in both community-dwelling and hospitalized patients (4, 5). Thus, it is necessary to identify new 
therapeutic strategies for DFIs. Topical treatment is advantageous because it avoids adverse effects 
from systemic treatment, increases target site concentration, and allows the use of agents that are 
not suitable for systemic therapy. Mechanical debridement remains pivotal to this strategy because 
it significantly reduces the bioburden, and as elegantly demonstrated by Wolcott et al. (6), opens a 
time-dependent therapeutic window for topical antimicrobial therapy (TAT). Nevertheless, no TAT 
agent has been proven to effectively treat DFI to date (7).
Bacteriophages are small viral entities, existing as nucleic acids packaged within a protein capsid, 
that specifically infect bacteria. Depending on their nature, after injection of their nucleic acids inside 
the bacteria, bacteriophages can either reside as a stable element called prophage inside the host cell 
as a free plasmid molecule or integrated into the host chromosome (temperate bacteriophages), or 
induce lysis of the bacterial host with the release of newly formed viral particles (lytic bacteriophages) 
(8). If appropriately complemented by adequate mechanical debridement, lytic bacteriophages could 
be efficient TAT agents in selected clinical environments because of their specificity and efficiency in 
lysing pathogenic bacteria, including those associated with multi-drug resistance (9). Moreover, they 
are not pathogenic in animals or humans (10), effectively eliminate bacteria in biofilms, and are 
active even in microaerophilic environments with high bacterial loads (11). 
Bacteriophage therapy is widely used and generally accepted as safe and beneficial in some parts 
of the world (12), and recent trials in animal models have demonstrated their potential to improve or 
heal bacterial skin infections following both internal (13) and external application (14, 15). However, 
there is little experimental evidence demonstrating that bacteriophages can cure chronic infections 
established for more than several hours (16).
The aim of this study was to investigate the antimicrobial activity and wound-healing capability of 
topically delivered bacteriophage solutions against wounds with chronic S. aureus, P. aeruginosa, 
and A. baumannii infections in two animal models of DM (rat and porcine).
Materials and methods
This study was approved locally by the Animal Ethics Committee of the Instituto de Medicina 
Molecular and nationally by the Portuguese General Directorate of Veterinary Services (Direcção 
Geral de Veterinária), in accordance with Portuguese law. All animals were maintained in accordance 
with European Directive 86/609/EC (17), Portuguese law (Portaria 1005/92) (18), and the Guide for 
the Care and Use of Laboratory Animals (NRC 2011) (19).
Bacterial strains
S. aureus, P. aeruginosa, and A. baumannii strains were isolated from clinical skin wound samples 
that were collected from patients and identified in Lisbon-area hospitals. All host strains were stored 
in tryptone soy broth (Biokar Diagnostics, Pantin Cedex, France) with 15% glycerol (w/v) at -70°C until 
needed. For all experiments, single colonies were grown overnight on tryptone soy agar (TSA, Biokar 
127
Section b
Diagnostics) at 37°C. After 24-h incubation, bacterial cells were suspended in saline (NaCl 0.9%, 
Applichem, Darmstadt, Germany) and adjusted to McFarland’s scale 0.5 (bioMérieux, Craponne, 
France) with a subsequent 1:10 dilution, producing a final solution concentration of 2.0 × 107 cfu/mL. 
Bacteriophages
S. aureus F44/10 and F125/10, P. aeruginosa F770/05 and F510/08, and A. baumannii F1245/05 
lytic bacteriophages were isolated from sewage water from the Lisbon area. Standard methods (20) 
for bacteriophage isolation and amplification were employed using the host strains described above. 
To produce bacteriophage stocks in sufficient quantities for experiments, a previously described 
protocol of amplification, concentration by high-speed centrifugation, and purification on a cesium 
chloride gradient (21) was used. Final concentrations were determined with double agar overlay 
plaque assays (22).
Three primary cocktails (S. aureus cocktail, P. aeruginosa cocktail, and A. baumannii cocktail) and 
one final cocktail were prepared using different concentrations and relative proportions of purified 
bacteriophages (Figure B4.2-1).
Figure B4.2-1 – Schematic depicting bacteriophage cocktail preparation.
Rodent model 
A previously optimized rodent wound infection model in chemically induced diabetic Wistar 
rats was employed to investigate new approaches to TAT (23). Briefly, specific pathogen-free male 
Wistar rats [Crl:WI(Han)], weighing 250-350 g (8-10 weeks old) were obtained from Charles River 
Laboratories (L’Arbresle, Cedex, France). The animals were housed in an approved animal care center, 
and all surgical procedures were performed in a sanitized surgery room using autoclave-sterilized 
instruments. DM was chemically induced as described by Wu et al. (24). Eight days later, following 
DM confirmation, 42 diabetic rats were anesthetized. Their dorsal surface hair was trimmed with an 
electric clipper, remaining hair removed using cold wax strips. Four days later, the animals were again 
anesthetized, and a round wound was inflicted by making a 6-mm diameter single full-thickness 
incision extending through the panniculus carnosus muscle in the interscapular region of the upper 
back of each rat using a punch biopsy instrument. Immediate-bonding cyanoacrylate glue was used 
to fix an oval-shaped silicone splint to the skin, and interrupted 3-0 nylon sutures were placed to 
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maintain its position. Before dressing, wounds were photographed from a standard 1.5-cm distance 
using a mounted digital microscope (SuperEyes 200× USB Digital Microscope, Shenzhen Tak and 
Assistive Technology, Shenzhen, China). Wound and surrounding area were covered with a previously 
tailored, semi-occlusive, non-woven polyester dressing, and maintained in place throughout the 
entire course of the experiment with a jacket made from adhesive tape. 
After applying the dressing but before the animals were conscious, they were randomly divided 
into seven groups: negative control (n = 6), S. aureus-inoculated control (n = 6) and test (n = 6), P. 
aeruginosa-inoculated control (n = 6) and test (n = 6), and A. baumannii-inoculated control (n = 6) 
and test (n = 6). Wounds of the animals in the negative control group were injected with 100 µL 
sterile saline, whereas wounds of the inoculated groups (test and control) were injected with 100 
µL cultured S. aureus, P. aeruginosa, or A. baumannii resuspended in sterile saline by inserting a 
27G/19-mm needle attached to a 1-mL disposable syringe through the silicon splint at a 45º angle. 
On days 4, 5, and 8 post-wounding, the semi-occlusive dressing was cut off, and the wounds were 
debrided. Debridement consisted of the strict, aseptic, mechanical removal of the scab, defined as a 
crust of dried blood, serum, and exudate. 
All test groups underwent a bacteriophage treatment protocol that consisted of an induction 
phase and a maintenance phase. The induction phase occurred after the first debridement (post-
wounding day 4) and was comprised of six 100-µL primary bacteriophage cocktail administrations 
(every 4 hours). The maintenance phase was from day 5 to day 8 and consisted of twice-daily (every 
12 hours) 100 µL primary bacteriophage cocktail administrations. If debridement was performed, 
bacteriophage administration followed. The control groups received 100 µL sterile saline with the 
same frequency.
On days 4, 5, and 8 post-wounding and after debridement, a liquid Amies elution swab (eSwab 
Collection and Preservation System, Copan, Corona, CA) was used to collect and transport swab 
cultures. Bacteria collection was performed using the one-point method described by Sullivan et al. 
(25). Briefly, a sterile swab was used to scrub the center surface of each wound by rotating the swab 
three times clockwise with enough manual pressure to produce a small amount of exudate. The 
swab was then inserted into the tube and transported to the laboratory for immediate processing. 
The swab collection tube was vortexed (with the swab inside) for 5 seconds, and a 100-µL aliquot of 
the resulting suspension was used for serial dilutions. Quantification was performed using the 10-
fold serial dilution method (26). In the inoculated groups, 100 µL of each dilution was plated onto 
the respective selective media plates: Chapman mannitol salt agar (Biokar Diagnostics) for S. aureus, 
cetrimide agar (Merck Chemical) for P. aeruginosa and CHROmagar Acinetobacter for A. baumannii 
(CHROmagar, Paris, France). In the A. baumannii-inoculated and negative control groups, 100 µL of 
each dilution was simultaneously inoculated onto TSA media plates (Biokar Diagnostics). The plates 
were incubated under aerobic conditions at 37°C for 24 hours, at which time colony counts were 
performed. The isolates grown on Chapman mannitol salt agar were presumptively identified as S. 
aureus based on colony morphology and mannitol salt agar fermentation (27). The isolates grown on 
cetrimide agar were presumptively identified as P. aeruginosa based on colony morphology (28). The 
isolates grown on CHROmagar Acinetobacter were identified as A. baumannii based on red colony 
color (29). Prior to sacrifice on post-wounding day 9, wounds were photographed from a standard 
1.5-cm distance using a mounted digital microscope as previously described. Wound kinetics were 
quantified using image-processing software (ImageJ, National Institutes of Health, Bethesda, MD) 
to measure the wound area by planimetry, and wound area was expressed as a percentage of the 
initial wound area. All animals were sacrificed by an i.p. injection of pentobarbital (200 mg) on day 
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9 post-wounding, and each ulcer and the surrounding 0.5-cm skin border was harvested with sterile 
surgical scissors and placed in a tube. The samples were fixed in 10% buffered formalin solution, 
and after overnight fixation, they were trimmed and cut through at the widest margin, embedded 
in paraffin, and sectioned in 3-µm increments. Sections were made perpendicular to the anterior-
posterior axis and perpendicular to the wound surface. For each wound, two serial sections were 
placed on a slide and stained with hematoxylin and eosin. The sections were photographed using a 
motorized inverted bright-field microscope (Zeiss Axiovert200M, Göttingen, Germany) equipped with 
a color camera (Leica DM2500, Leica Microsystems GmbH, Wetzlar, Germany) at 50× magnification. 
Panoramic cross-sectional digital images of each wound were prepared with automated microscopy 
software (MetaMorph, MDS Analytical Technologies, Sunnyvale, CA) and image-processing software 
(ImageJ). Each image was analyzed for epithelial gap (EG) and dermal gap (DG) using the same 
image-processing software. EG was defined as the distance between the advancing edges of clear, 
multi-layered neoepidermis (30, 31), and its size was measured in millimeters; a completely re-
epithelialized wound corresponded to an EG score of zero. DG was defined as the distance between 
uninjured dermis on both sides of the wound (30, 31) and was measured in millimeters. All wound 
kinetics and histological measurements were done with the investigator blinded as to sample origin 
(test or control).
Pig model 
A previously optimized pig wound infection model in animals with chemically induced DM (32) was 
modified to fit our needs. Three animals (negative control, inoculated-control, and inoculated-test) 
with a total of 48 excisional wounds (12 negative control wounds, 12 S. aureus-inoculated wounds, 
12 P. aeruginosa-inoculated wounds, and 12 A. baumannii-inoculated wounds) were used in this 
study.
Three female Yorkshire pigs weighing approximately 60 kg at arrival were allowed to acclimatize 
for 1 week prior to the experiment. Animals were housed individually in cages, had free access to 
water, and were fed twice daily with a standard diet. Pigs were kept in a containment device during 
all procedures. Pigs were fasted for 12 hours before DM induction. On the day of the procedure, 
the animals were weighed and given intramuscular anesthesia with xylazine hydrochloride and 
ketamine hydrochloride. While they were under anesthesia, a 21-gauge intravenous (i.v.) catheter 
was inserted into an ear vein. Streptozotocin (150 mg/kg body weight diluted in 10 mL/g sterile 
saline and sterilized by filtration) was administered through the catheter over 1 min. After recovering 
from anesthesia, post-procedural anti-emetic therapy with metoclopramide was administered. Pigs 
were continuously observed for the first 3 hours, and then food was offered ad libitum to prevent 
hypoglycemia. Blood glucose was measured on a daily basis, and pigs received daily, subcutaneous 
injections of 16 IU pre-mixed neutral suspension of neutral (30%) and isophane insulin (70%) (Mixtard 
30, Novo Nordisk, Bagsværd, Denmark) to keep blood glucose concentrations between 250 and 400 
mg/dL. Fourteen days after DM induction, pigs received induction anesthesia as previously described. 
They underwent endotracheal intubation and were mechanically ventilated with a volume-limited, 
time-cycled ventilator (Mark 9; Bird Corporation, Palm Springs, CA) on a mixture of room air and 
titrated isoflurane (0.5% to 1.5%). The tidal volume was set at 12 mL/kg, and the ventilator rate was 
12 breaths/minute. Prior to surgery, the dorsal surface hair was trimmed with an electric clipper, 
the remaining hair was removed with cold wax strips, and the paraspinal area was thoroughly 
disinfected using 10% povidone-iodine paint and washed with 70% isopropanol 15 minutes later. 
For the inoculated pigs, nine full-thickness excisional wounds (6-mm diameter, 6-mm depth) were 
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created on each side of the paraspinal area (18 in total) using a 6-mm diameter biopsy punch. For 
the negative control pig, only six excisional wounds were created on each side of the paraspinal 
area (12 in total). Subsequently, sterile forceps and a surgical blade were used to remove the full-
thickness skin flap, and sterile gauze was used to remove coagulated blood and control bleeding. The 
wounds were photographed from a standard height using a mounted digital microscope. Afterwards, 
a modified adhesive chamber made from a colostomy bag (two-piece 35-mm Ostomy, Hollister Inc., 
Libertyville, IL) was placed over each wound, covered with a semi-occlusive, non-woven polyester 
dressing, and secured in place with surgical staples (Manipler AZ, B. Braun, Tuttlingen, Germany) 
and adhesive bandages. In the inoculated animals, wounds were divided into three subgroups: S. 
aureus (2 × 6 ulcers); P. aeruginosa (2 × 6 ulcers), and A. baumanni (2 × 6 ulcers). To immerse the 
enclosed surface, wounds were respectively inoculated with 2 × 106 cfu of S. aureus, P. aeruginosa, 
or A. baumanni in 100 µL total solution (sterile 0.9% saline). In the negative control group (12 ulcers), 
wounds were injected with 100 µL sterile saline. After recovering from anesthesia, post-procedural 
anesthesia (buprenorphine 0.005 mg/kg) and anti-emetic therapy was given every 12 hours for 48 
hours. On days 4, 5, and 8 post-wounding, the semi-occlusive dressing was cut off, and the wound 
debrided as described for the rodent model.
A two-part bacteriophage treatment protocol similar to that employed in the rodent model was 
used. The induction phase began after the first debridement (post-wounding day 4) and consisted 
of 100 µL final bacteriophage cocktail administrations every 4 hours for 24 hours. The maintenance 
phase took place between days 5 to 8 and consisted of twice-daily (every 12 hours) 100 µL final 
bacteriophage cocktail administrations. Bacteriophage administration followed every debridement 
session. The control groups received 100 µL sterile saline at the same time.
We employed a microbiological analysis protocol similar to the rodent study. On days 4, 5, and 8 
post-wounding and after debridement, a liquid Amies elution swab was used to collect and transport 
swab cultures, which were processed using the same methods described for the rodent study. 
Bacteria collection was performed using the one-point method described by Sullivan et al. (25). The 
swab was then inserted into the tube and transported to the laboratory for immediate processing. 
Quantification was performed using the 10-fold serial dilution method (26). In the inoculated group 
samples, 100 µL per dilution was plated onto their respective selective media plates: Chapman 
mannitol salt agar, cetrimide agar, and CHROmagar Acinetobacter. In the negative control group 
samples, 100 µL of each dilution was inoculated onto TSA media plates. The plates were incubated 
under aerobic conditions at 37°C for 24 hours, after which colony counts were performed. The 
isolates were presumptively identified as previously described. In the negative control group, ulcers 
with more than 103 cfu/swab on any given day were considered to be critically colonized and were 
excluded from further analysis. Wounds were again photographed on post-wounding day. Wound 
kinetics were quantified using image-processing software as described above. Wound area was 
expressed as a percentage of the initial wound area. All animals were sacrificed by i.v. injection of 
pentobarbital on day 9 post-wounding, and each ulcer (including a 0.5-cm skin border) was entirely 
harvested using sterile surgical scissors and placed in a tube. For histological studies, the samples 
were processed and photographed, and the images were analyzed for epithelial gap (EG) using the 
same methods as described above.
Statistical analysis
All quantitative microbiological results are presented as the mean ± standard deviation and 
expressed as logarithm-transformed values [log(cfu/swab) for swab samples and log(cfu/ulcer) for 
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tissue samples]. The data were compared using a logarithmic scale because of wide variations in cfu/
swab among samples. Planimetric and histological results are expressed as the mean ± standard 
deviation. For all datasets, comparisons between groups were performed using two-tailed Student 
t-tests, and P values < 0.05 were considered significant. All data was entered into a spreadsheet 
program (Excel, Microsoft, Redmond, WA) for statistical analysis. Analytical statistics were performed 
by Analyse-it, version 2.21 Excel 12+ (Analyse-it Software, Leeds, UK), a statistical add-in program for 
Excel.
Results
Rodent model
The results of the microbiological study are presented in Figure B4.2-2 A. Before treatment (t0), 
the average swab colony count in selective media for the S. aureus-inoculated, P. aeruginosa-
inoculated, and A. baumannii-inoculated groups were 5.62 ± 0.28 log(cfu/swab), 5.55 ± 0.34 log(cfu/
swab), and 2.80 ± 0.68 log(cfu/swab), respectively. The average colony count in non-selective media 
for the A. baumannii-inoculated groups was 5.95 ± 0.23 log(cfu/swab). There were no statistically 
significant differences between the test and control subgroups. After induction therapy (t1), there 
was a statistically significant difference in colony count in selective media between control and test 
subgroups in S. aureus-inoculated [control, 5.43 ± 0.49 log(cfu/swab); test, 2.47 ± 1.41 log(cfu/swab); 
P < 0.01], P. aeruginosa-inoculated [control, 4.91 ± 0.55 log(cfu/swab); test, 0.69 ± 0.67 log(cfu/
swab); P < 0.01], and A. baumannii-inoculated groups [control, 2.70 ± 0.77 log(cfu/swab); test, 0.79 
± 0.95 log(cfu/swab); P = 0.01]. There was no statistically significant difference in average colony 
count in non-selective media between the A. baumannii-inoculated test and control subgroups. On 
day 4 after treatment initiation (t4), there was a statistically significant difference in colony count in 
selective media between control and test subgroups for S. aureus inoculation [control, 5.02 ± 0.62 
log(cfu/swab); test, 2.40 ± 0.50 log(cfu/swab); P < 0.01], P. aeruginosa inoculation [control, 2.56 
± 0.94 log(cfu/swab); test, 0.00 log(cfu/swab); P < 0.01], and A. baumannii inoculation [control, 
3.03 ± 0.45 log (cfu/swab); test, 0.00 log(cfu/swab); P < 0.01]. There was no significant difference 
between the A. baumannii-inoculated test and control subgroups. From t0 to t4 in the S. aureus and 
P. aeruginosa-inoculated control subgroups, there was a tendency for microbial load reduction, but 
statistical significance was only obtained in the P. aeruginosa-inoculated group (P < 0.01).
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Figure B4.2-2 – (A) Average swab colony count in infected rats. Wounds were swabbed at t0, t1, 
and t4, and the number of bacterial colony-forming units were compared between control and test 
conditions for each group. The bacteriophage-treated animals showed significantly lower counts than 
the control animals in all three groups on t1 and t4. C, control, T, test; White bars, selective media; gray 
bars, non-selective media; *P < 0.05; (B) Wound closure kinetics in rats. Wound area was assessed on 
t1 and t9, and the differences between the two timepoints were calculated. Bacteriophage treatment 
only reduced wound size in S. aureus- and P. aeruginosa-infected wounds. C, control, T, test; *P < 0.05.
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The wound closure kinetics (planimetric) results are presented in Figure B4.2-2 B. There was a 
statistically significant difference in wound area between the negative control group and all inoculated 
control subgroups (negative control, 24.3 ± 1.8%; S. aureus-inoculated control, 68.2 ± 14.6%, P < 
0.01; P. aeruginosa-inoculated control, 77.3 ± 6.4%, P < 0.01; A. baumannii-inoculated control, 62.3 
± 13.3%, P < 0.01). There was a statistically significant difference between control and test subgroups 
wound areas in the S. aureus-inoculated (test, 33.7 ± 6.7%, P < 0.01) and P. aeruginosa-inoculated 
groups (test, 38.7 ± 11.1%, P < 0.01). Although there was a tendency for wound area reduction 
between control and test subgroups, it did not reach statistical significance in the A. baumannii-
inoculated group (test, 42.9 ± 10.2%).
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Figure B4.2-3 – Histological wound analysis in rats. Epithelial gap (EG) and dermal gap (DG) were 
measured in harvested ulcers. Significant differences were only observed in bacteriophage-treated 
wounds infected with S. aureus and P. aeruginosa. C, control, T, test; *P < 0.05.
The results of the histological study are presented in Figure B4.2-3. There was a statistically 
significant difference between the negative control group and all inoculated control subgroups for 
both EG (negative control, 0.11 ± 0.13 mm; S. aureus-inoculated control, 1.65 ± 0.36 mm, P < 0.01; P. 
aeruginosa-inoculated control, 1.90 ± 0.23 mm, P <0.01; A. baumannii-inoculated control, 1.60 ± 0.64 
mm, P < 0.01) and DG (negative control, 1.67 ± 0.32 mm; S. aureus-inoculated control, 2.97 ± 0.52 
mm, P < 0.01; P. aeruginosa-inoculated control, 3.30 ± 0.23 mm; A. baumannii-inoculated control, 
2.85 ± 0.39 mm, P < 0.01). There was a statistically significant difference for EG between control 
and test subgroups in the S. aureus-inoculated (test, 0.14 ± 0.13 mm, P < 0.01) and P. aeruginosa-
inoculated groups (test, 0.30 ± 0.25mm, P < 0.01). In DG, the difference between test and control 
subgroups only achieved statistical significance in the P. aeruginosa-inoculated group (test, 42.9 ± 
10.2%, P = 0.02). There were no significant differences between control and test subgroups with 
regard to EP or DG in the A. baumannii-inoculated group.
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Pig model
The results of the microbiological study are presented in Figure B4.2-4 A. Before treatment (t0), 
the average swab colony count for the S. aureus-inoculated, P. aeruginosa-inoculated, and A. 
baumannii-inoculated groups were 5.94 ± 0.69 log(cfu/swab), 4.81 ± 0.18 log(cfu/swab), and 3.61 ± 
1.87 log(cfu/swab), respectively. There were no statistically significant differences between the test 
and control subgroups. After induction therapy (t1), there was a statistically significant difference 
in colony count in selective media between control and test subgroups in the S. aureus-inoculated 
[control, 6.02 ± 0.29 log(cfu/swab); test, 3.28 ± 1.84 log(cfu/swab); P = 0.02] and P. aeruginosa-
inoculated groups [control, 4.81 ± 0.80 log(cfu/swab); test, 2.49 ± 1.46 log(cfu/swab); P = 0.03]. 
Although there was a tendency for microbial load reduction in average colony count for the A. 
baumannii-inoculated test and control subgroups [control, 2.52 ± 2.29 log(cfu/swab); test, 1.41 ± 
1.65 log(cfu/swab)], the difference was not statistically significant. At day 4 after treatment initiation 
(t4), there was a significant difference in colony count between control and test subgroups in the 
S. aureus-inoculated [control, 5.93 ± 0.66 log(cfu/swab); test, 2.20 ± 1.14 log(cfu/swab); P < 0.01] 
and P. aeruginosa-inoculated [control, 4.81 ± 0.80 log(cfu/swab); test, 1.71 ± 1.05 log(cfu/swab); P 
= 0.02] groups. No such difference was observed for the A. baumannii-inoculated test and control 
subgroups. 
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Figure B4.2-4 – (A) Average swab colony count in infected pigs. Wounds were swabbed at t0, t1, and 
t4, and the number of bacterial colony-forming units were compared between control (C) and test 
(T) conditions. The bacteriophage-treated wounds showed significantly lower counts for wounds 
infected with S. aureus and P. aeruginosa. *P < 0.05; (B) Wound closure kinetics in pigs. Bacteriophage 
treatment did not significantly decrease wound size for any of the three conditions. However, S. 
aureus and P. aeruginosa infections both resulted in larger significantly larger wounds. *P < 0.05.
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The wound closure kinetics (planimetric) results are presented in Figure B4.2-4 B. Wound closure 
kinetics statistically differed between the negative control group (24.1 ± 6.0%) and the S. aureus-
inoculated (46.3 ± 15.5%, P = 0.02) and A. baumannii-inoculated (39.6 ± 7.1%, P = 0.01) control 
subgroups, but this was not verified for the P. aeruginosa-inoculated control subgroup. Wound 
closure kinetics were not significantly different between any inoculated control and test subgroups 
for the three bacteria strains.
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Figure B4.2-5 – Histological wound analysis in pigs. Epithelial gap (EG) values were measured in 
harvested wounds. Significant differences were only observed in S. aureus and P. aeruginosa 
bacteriophage-treated wounds. C, control, T, test; *P < 0.05.
The results of the histological study are presented in Figure B4.2-5. The analysis revealed a 
statistically significant difference with regard to EG between the negative control group and all the 
inoculated control subgroups (negative control, 1.80 ± 0.33 mm; S. aureus-inoculated control, 4.23 
± 0.14 mm, P < 0.01; P. aeruginosa-inoculated control, 3.02 ± 0.23 mm, P <0.01; A. baumannii-
inoculated control, 3.43 ± 0.60 mm, P < 0.01). We also found statistically significant differences for EG 
between control and test subgroups in the S. aureus-inoculated (test, 3.38 ± 0.59 mm, P = 0.02) and 
P. aeruginosa-inoculated groups (test, 2.20 ± 0.05 mm, P = 0.02). No such difference was observed 
for A. baumannii-inoculated wounds.
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Discussion
Current DFI treatment protocols employ debridement and systemic antibiotics (2), which are 
often ineffective in promoting wound healing (3). In addition, bacterial resistance to antibiotics 
renders these therapies less effective. Novel therapeutic regimens are needed to successfully treat 
DFIs. Although TATs are an attractive alternative, current formulations have not been successfully 
implemented for DFIs (7). The addition of lytic bacteriophages may enhance the utility of TAT agents; 
they are safe for human use (10) and can effectively combat drug-resistant bacteria (9). Although 
these bacteriophages have been used to treat acute bacterial infections (16), no study has assessed 
their ability to ameliorate chronically infected wounds.
Previously published studies have not assessed the effects of bacteriophage cocktails in chronic 
wounds; most examined outcomes after only a few hours of infection (16). In addition, most results 
came from burn models (33). We have investigated the ability of bacteriophages combined with 
debridement to improve microbiological, planimetric, and histological wound parameters in diabetic 
animal models.
Based on previous rodent studies (23) we knew that the bacterial colony counts in tissue cultured 
from infected wounds at t4 were, on average, 7.54 ± 0.19 log(CFU) per ulcer. We used high 
bacteriophage doses (108 to 109 pfu per administration), which yields a multiplicity of infection of 10 
to 100. This initial dose is sufficiently in excess of the target bacterium population to cause reductions 
without the need for bacteriophages to replicate and complete their life cycle. This is in contrast 
with previous bacteriophage therapy studies (34) that employed relatively low bacteriophage doses 
and mainly relied on active therapy, which involves phage infection/replication cycles to reduce 
the target bacterium. These processes of active and passive bacteriophage therapy have been well 
described for in vitro and in vivo studies (35, 36).
All three outcomes were improved by bacteriophage treatment in animals that were infected 
with S. aureus and P. aeruginosa, but only bacterial reduction was observed in those infected with 
A. baumannii. This is potentially justified by a study (37) in which the presence of Acinetobacter 
spp. in a biofilm community was found to facilitate surface colonization by other species, namely 
Staphylococcus spp. Indeed, our microbiological data are in line with this finding. We determined that 
excess bacteria growing in non-selective media in A. baumannii-inoculated groups were primarily 
Staphylococcus spp. 
Bacterial counts were assessed at t4, and colony counts were significantly different for S. aureus 
and P. aeruginosa test conditions compared to control. This difference was particularly pronounced 
for the latter. This finding is in agreement with our previously published optimization study (23). It 
is also in line with results reported by Fazli et al. (38), who used confocal laser scanning microscopy 
of clinical wound-biopsy specimens to demonstrate that the distance from P. aeruginosa aggregates 
to the wound surface was significantly greater than that of S. aureus aggregates, which led to an 
underestimation of the former in swab samples. This observation supports the possibility that 
factors intrinsic to each pathogenic bacterial strain can contribute to differences among studies that 
compare cultures grown from swabs and tissue samples.
Planimetric assessments revealed statistically significant differences between the control and 
test groups treated with S. aureus and P. aeruginosa. Although the same trend was observed 
for A. baumanni, the difference was not significant. These results were similar to the EG and DG 
measurements in harvested histological specimens. However, only the P. aeruginosa test group 
showed a significant difference. This was likely due the smaller standard deviation value in that 
group.
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Although rodent models are useful, we wanted to assess the utility of bacteriophage treatment 
in pigs, which are considered the ideal large animal model for studying cutaneous disease (39).The 
results obtained in the rodent model were largely corroborated by experiments in swine. In both 
models, there was a significant reduction of bacterial counts at both time points (t1 and t4) for S. 
aureus and P. aeruginosa infections, but this was not verified for A. baumannii infections. A possible 
explanation for this difference is the low initial (t0) bacterial counts, which limited evaluation power. 
An alternative possibility for discrepant results between the two models is different host-microbe 
interactions between species, which may limit the establishment of bacterial infection in swine (40).
Although the planimetric results were not significantly different in the swine model, we did find 
differences among the negative control and S. aureus and A. baumannii control groups. Notably, 
the P. aeruginosa test group was not significantly different from the control group. It is possible 
that this was because that bacterial strain causes a deeper infection, and the damage was localized 
further beneath the dermis, resulting in a smaller ulcerated surface area (38). Despite the discrepant 
bacterial counts, there was no statistically significant difference between the A. baumannii and S. 
aureus group planimetries. However, both were significantly different from the negative control 
group. This may also be justified by the coaggregation of Acinetobacter spp. and other species, 
namely Staphylococcus spp. 
We did observe significant results in the S. aureus-inoculated and P. aeruginosa-inoculated test 
animals with regard to EG measurements. However, the results for the A. baumannii-inoculated 
test group were not different from those of the control. A possible reason for this result is that the 
bacteria failed to successfully infect the wound.
There are several limitations inherent to the study design. We used swabs rather than biopsies 
to quantify bacterial counts. This method was chosen because we also evaluated planimetry and 
histology, both of which would have been influenced by biopsies. Moreover, the swab technique 
was previously optimized and shown to correlate with the invasive method for the rodent model 
(23). Secondly, we did not investigate resistance of bacterial strains to the bacteriophage cocktail, 
which may have played a role in the A. baumannii-inoculated groups. This variable will be studied 
in future investigations. Finally, we did not grow all the samples in non-selective media cultures; it 
was not feasible to simultaneously grow such a large number of samples in the lab without risking 
cross-contamination. Finally, the porcine experiments only included a single pig per group. Although 
this decreased the power of the statistical analysis, previously published findings suggest that the 
large degree of interindividual variability makes it necessary to make comparisons within individual 
animals (41). 
To our knowledge, this is the first study to assess the microbiological, planimetric, and histological 
efficacies of topical bacteriophage therapy in animal models. It is important that the treatment was 
performed in conjunction with sharp debridement, as there is currently no clinical or experimental 
rationale for using TAT products in its absence (23). Debridement leads to a significant decrease in the 
resistance of the bioburden to TAT for up to 24 hours and enhances cicatrization (6). Collectively, the 
results of this study suggest that bacteriophage-containing TAT may be a viable treatment for DFIs, 
including infections caused by drug-resistant bacteria. Although additional studies are necessary, it 
may be an effective and novel therapeutic approach for addressing the serious problems associated 
with DFIs and other chronic skin and soft tissue infections.
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General Discussion
Chronically infected wounds, such as DFIs, are a major source of morbidity. Treatment of these 
wounds involves considerable economic cost (1). In addition to debridement, effective treatment 
includes the use of high local concentrations of effective antimicrobials to suppress the growth of 
pathogenic bacteria (2). The efficacy of systemic antibiotic therapy is decreased by poor wound 
vascularization and the presence of biofilm-associated bacteria (3, 4). Systemic drugs may be unable 
to penetrate the affected areas at concentrations high enough to control the infection. Theoretically, 
this problem may be addressed by using a topical therapy capable of delivering high levels of 
antimicrobials to the infection site (5). In this particular clinical environment, lytic bacteriophages 
could be efficient antimicrobial agents because of their specificity and efficiency in lysing biofilm-
associated pathogenic bacteria, including those that are MDR (6). Evidence from animal studies 
supports the hypothesis that topical BT is more effective than topically applied antimicrobials. Using 
a burn wound animal model, Kumari et al. (7) found that the level of protection from antimicrobials 
(i.e., silver nitrate and gentamicin) was lower compared with the protection provided by BT. BT has 
been, and continues to be, used for wound treatment in some countries (8). 
A personalized (sur-mesure or bacteriophage bank-derived monophage) strategy is used in the 
countries where BT is applied to wounds (9). This strategy has theoretical benefits (10), and animal 
studies have provided evidence that it is effective (11), but we chose to develop a preformulated 
single cocktail (prêt-à-porter) strategy. One advantage of this strategy is that it allows early 
presumptive treatment, which maximizes the potential efficacy of the preparation. This concept was 
evaluated by Biswas et al. (12) using a mouse animal model of vancomycin-resistant Enterococcus 
faecium infection. They found that the mice who received bacteriophage treatment up to 5-hours 
post-infection recovered from the infection. However, only some of the mice who were treated after 
5 hours recovered from the infection. There are also fewer problems associated with this model in 
terms of BT regulatory approval (9). It is a good fit with the combination of constraints imposed by 
drug regulation and typical medical practice (13). 
In accordance with this model, we used a poly-bacteriophage cocktail for topical application. 
Our objective was to increase the utility of the formulation, and prevent the development of 
bacteriophage-resistant bacterial mutants during individual treatments (13). Our results have been 
positive, and similar to the results of recent animal (7, 14-19) and human (20-22) studies that used 
bacteriophage cocktails. This success is in contrast with the modest outcomes obtained when single 
bacteriophage topical preparations are used (23). 
Bacteriophages are narrow-spectrum antibacterials and are often not effective against all strains, 
even within a single bacterial species (24). Therefore, the first challenge was to develop a formulation 
that contained the bacteriophage diversity needed to have a spectrum of activity that included the 
most relevant DFI bacterial pathogens. Even for a specific application, there are also geographic 
and epidemiological differences that may affect pathogen diversity, so information about the local 
epidemiology should be obtained. The results of Bourdin et al. (25) illustrate the importance of 
these geographical variations. They tested a cocktail consisting of 3 to 14 T4-like bacteriophages 
against four collections of diarrhea-associated E. coli isolates from different geographical origins, 
serotypes, pathotypes, epidemiological settings, and years of isolation. They found a maximum of 
61% coverage against any of the four collections. We chose to overcome this issue by designing 
an epidemiological study to obtain information about bacterial targets and to aid in the assembly 
of a bacterial library against which to test the bacteriophages. We mostly isolated aerobic 
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gram-positive cocci from acute infections. Complex microbiotas that included gram-negative and 
anaerobic bacteria were found in the patients in our study. S. aureus, alone or as a component of a 
mixed infection, was the most frequently isolated pathogen. This result was similar to the results of 
studies performed in western countries (26, 27). But, there were some differences compared with 
the results from studies performed in India and other Asian countries (28). Our results reflect only 
the clinical and microbiological profiles of inpatients and outpatients in the Lisbon area. Care must 
be taken when these results are extended to other geographic areas, because patterns of microbial 
infections in DFUs vary worldwide. 
Based on the results of the epidemiological studies, we selected S. aureus, P. aeruginosa, and A. 
baumannii/calcoaceticus as the bacterial targets. S. aureus (including MRSA) was selected because it 
was the most common cause of DFIs in our study population. We selected P. aeruginosa because it was 
associated with multi-drug resistance and antibiotic failure. A. baumannii/calcoaceticus was selected 
not only because it was associated with multi-drug resistance and antibiotic failure, but also because 
of its clinical relevance. The isolation of this pathogen is a marker of severe disease in hospitalized 
patients, but A. baumannii is not necessarily a more virulent organism (29). The medical community 
is concerned about its high rates of antibiotic resistance, especially in diabetic patients (30). 
Technophage, S.A., previously isolated two S. aureus bacteriophages (F44/10 and F125/10), two P. 
aeruginosa bacteriophages (F770/05 and F510/08), and one A. baumannii bacteriophage (F1245/05) 
from environmental samples. These bacteriophages have been morphologically and genetically 
characterized. They have characteristics that increase their suitability for use for BT (31). They are 
incapable of lysogenically infecting bacteria and they do not encode bacterial virulence factor genes.
To assess their infectivity on target bacteria, these bacteriophages were tested against bacterial 
isolates that included 44 DFI isolates from the epidemiological study. The bacteriophage spot test 
procedure was used (32). This strategy did not differ from current BT cocktail preparation strategies. 
However, many environmental isolates that are sensitive in spot tests are unable to support plaque 
formation and have poor sensitivity (i.e., a very high bacteriophage concentration is needed for 
growth inhibition). The method and the concentrations that we used were acceptable (33). However, 
new strategies using highly quantitative methods based on the Bio-screen C microbial growth 
analyzer have been shown to be more stringent, compared with these traditional methods (34). 
We formulated a bacteriophage cocktail with a sufficient spectrum of activity to cover the most 
relevant bacteria causing DFIs. However, as with any antimicrobial therapy, it was crucial to evaluate 
the in vitro and in vivo efficacy of the cocktail. This was necessary even after a topical application 
strategy was proved to be effective in multiple animal models of wound infection with common 
pathogens (35-37), including those targeted in our study. The clinical application of BT requires 
case-by-case experimental validation because outcomes vary by infectious agent, animal model of 
infection, and bacteriophage lytic potency. The current BT dosage regimens are mainly empirical 
or are based on complex mathematical models developed using parameter (adsorption constant, 
latent period, and burst size) values obtained in vitro (38). These models have been unable to predict 
the in vivo behaviour of bacteriophages and pathogens (39). 
We developed a set of in vitro and in vivo studies and used the results to design a high-titer (109–
1010 pfu/ml), multiple-dose, topical, BT protocol. In some respects, this pharmacologically-informed 
dosage regimen contrasted with the current protocols used in recent human clinical efficacy trials 
(20, 22), and in the clinical setting (40). These current protocols have produced modest results that 
are below expectations. One noteworthy example is the study published by Wright et al. (22). These 
investigators reported clinical and microbiological efficacy results for the first controlled double-blind 
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phase I/II clinical trial of a bacteriophage cocktail. The formulation contained six  bacteriophages 
at 105 pfu and was applied topically to treat P. aeruginosa-associated chronic otitis after the site 
was prepared. Site preparation consisted of a thorough cleaning and debridement of the external 
auditory canal. Significant clinical improvements (measured by the subjective visual analogue scale) 
were reported for the treated group. However, those improvements were accompanied by only 
modest reductions in bacterial load (<1 log change, at specified time points up to 42 days). This BT 
model was based on an active therapy (41) characterized by a lower initial bacteriophage dosage. 
It is dependent on bacteriophage in situ replication to achieve a minimum inhibitory concentration 
capable of bacterial control. Our protocol was based on a passive therapy (41). Bacteriophages were 
supplied in numbers (high-titer dosing) sufficient to ensure that a minimum inhibitory concentration 
was exceeded. This peak in bacteriophage density was followed by a decline due to a combination 
of metabolism and decay. This decline can be avoided by repeated dosing. When this strategy is 
used, bacteriophages can still display in situ self-amplification (i.e., auto dosing) during antibacterial 
activity (41). Although not guaranteed to occur, this mechanism can provide a margin of safety 
toward attaining BT efficacy (42).
The desire for a high bacteriophage titer is based on the theoretical “multiplicity of 10 rule” (43, 
44). If the goal is significant reduction in bacterial density, then approximately 10 bacteriophages 
should be available to adsorb to the average bacterium. We, along with others (41, 45), considered 
that a bacteriophage dose sufficiently in excess of the target bacterium population should be given 
to account for bacteriophage loss, dilution (associated with absorption and distribution), decay, and 
inefficiencies of bacteriophage adsorption to bacteria (e.g., inefficiencies in penetration into biofilms 
in vivo). This concept has been experimentally validated in studies of topical BT. Goode et al. (46) used 
lytic bacteriophages to reduce the contamination of chicken skin by Salmonella and Campylobacter 
spp. Kumari et al. (47) used a specific bacteriophage for the treatment of burn wounds infected with 
K. pneumoniae B5055. The investigators from both studies concluded that low-titer bacteriophage 
administration (IMs lower than 10) is unlikely to be successful. 
We also used multiple doses divided into two phases, induction (every 4 hours for 24 hours) and 
maintenance (every 12 hours). The induction scheme was based on in vitro studies that found 
that an every 4 hours dose schedule is effective for limiting re-growth of all bacteria, except 
A. baumannii. The maintenance scheme was based on the current clinical standard used at the 
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of 
Sciences. This multiple dose scheme was similar to the scheme used by Huff et al. (14). Using an 
animal model of E. coli respiratory infection, they found that multiple applications of bacteriophages 
are more effective than a single dose. The same observation was reported by Bardina et al. (15). 
Using different treatment schedules, they evaluated the effectiveness of a bacteriophage cocktail 
for the reduction of Salmonella typhimurium concentration in two animal models. Their results 
indicated that frequent treatment is required to achieve effective bacterial reduction over time. 
Other investigators have reported that compared with single dose treatment, multiple dose 
treatment does not improve the outcome. However, the principles and methodologies used in these 
studies were different from our studies. Vieira et al. (16) evaluated the ability of BT to inactivate P. 
aeruginosa in vitro and ex vivo (human skin). They found that the application of a second dose of 
bacteriophage does not increase the efficacy of the therapy. They used only one bacteriophage, 
and their results were similar to the results of our A. baumannii studies, in which we used only one 
bacteriophage. In in vitro experiments, Hall et al. (17) used P. aeruginosa and four bacteriophages 
to test whether simultaneous or sequential application of bacteriophage was more effective at 
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reducing bacterial densities and minimizing resistance emergence. Across different bacteriophage 
combinations, simultaneous application was consistently equal or superior to sequential application 
in terms of bacterial count reduction. There were also no differences in terms of minimization of 
resistance. These investigators did not use repeat applications of different bacteriophages, which is 
one important difference between their work and ours. 
The design of our studies had some limitations. Wound healing outcome depends on the bacterial 
count, the species involved, and the presence of potentiating factors (e.g. biofilm). The outcome also 
depends on the intrinsic or acquired virulence of the organisms, the numbers of different species 
present, and the host immune response (48). We compared the efficacy of different bacteriophages 
against different planktonic bacterial species. Using metabolic activity as a measure of cell viability, we 
also examined efficacy against bacteria within established biofilms. However, we did not specifically 
study other outcome variables. 
One major limitation of our studies was that we did not test surviving bacteria for bacteriophage 
resistance and retention of pathogenicity. The results of the in vitro studies indicated that regrowth 
was apparent at 5 hours, and more significantly, at 24 hours. This result was expected because of 
the high initial bacterial inoculum (5x107 cfu/ml). O’Flynn et al. (49) found resistance frequencies of 
10-6 to 10−4 for single-bacteriophage and 10−6 for double-bacteriophage treatment in vitro. However, 
the evolution of bacteriophage resistance in vitro does not seem relevant to in vivo results. Bacteria 
replicate more slowly in in vivo conditions, and are challenged by environmental variability. This 
difference was illustrated by results obtained by Capparelli et al. (50). They reported an average 
resistance frequency of 10-8 for S. aureus treated with bacteriophages in vitro, but were unable to 
isolate any bacteriophage-resistant S. aureus strains in vivo. Moreover, even when BT does not clear 
the bacterial infection, it may indirectly impair growth by causing resistance mutations that are 
costly to fix, and that can reduce bacterial growth and virulence. Hall et al. (17) used a wax moth 
larvae infected by P. aeruginosa model. They found that resistance has a fitness cost. This result is 
similar to the results of other studies. Bacteriophage-resistant E. coli mutants that emerge during 
infections of mice and cattle are less virulent (32, 33).  
Another study limitation was that the efficacy of the bacteriophage cocktail was not evaluated 
in a wound infected by multiple microorganisms. This limitation is important because in the 
epidemiological study, polymicrobial cultures were obtained from 83.7% of patients, and the isolation 
rate was 3.0 ± 1.4 bacteria per patient. In theory, various interference phenomena may occur (51), 
but the clinical outcomes of mono- and poly-microbial infections are similar (40). This outcome may 
occur because some therapeutic bacteriophages encode lytic enzymes that degrade the bacterial 
polymeric components (52). It may also occur as a result of bactericidal effects on specific pathogenic 
or co-aggregative species grown in a polymicrobial biofilm. We did not specifically study this issue, 
but in our animal studies we found that A. baumannii was a potential co-aggregator of the bacteria 
biofilm community. Contrary to expectations, F1245/05 (a therapeutic bacteriophage capable of 
reducing A. baumannii bacterial counts in vivo) was unable to limit the growth of Staphylococcus 
spp., and wound healing did not occur. The effect of BT on polymicrobial wound healing cannot be 
easily predicted. The outcome depends on complex interactions among the bacteriophages, the 
microbial species, and the infected host.
We did not address some aspects of the association between BT and the modulation of the host 
immune response, and between BT and cytotoxicity. These effects are important because they may 
condition the effectiveness of BT, and are often used as an argument against its use (10). It is well-
accepted that intravenously administered bacteriophages may evoke a substantial immune response 
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(53), but few articles describe results for topical applications. Because the kinetics of bacteriophage 
action are much faster than the production of neutralizing antibodies, the development of neutralizing 
antibodies should not be a significant obstacle during the initial treatment of acute infections (54). 
We used prolonged BT schemes whose efficacy may be conditioned by this immune response. 
However, this effect may have been mitigated by the frequently repeated administration or by 
high local bacteriophage concentrations. The results from many studies indicate that in addition to 
pathogen eradication, BT exerts its effects by immune enhancement. The most expressive immune 
modulatory phenomenon is the enhancement of granulocyte phagocytosis (55). A reduction in 
bacterial count occurred in our in vivo studies. We did not specifically study the mechanisms, but a 
partial involvement of a weak immune response stimulated by the bacteriophage solution cannot be 
ruled out. The literature describing the results of cytotoxicity studies is also insufficient, particularly 
for wound models. The results from our rodent and porcine animal models clearly indicated that BT 
resulted in wound healing. However, we did not specifically evaluate cytotoxicity. This is important 
because minor interference by bacteriophage preparations could greatly affect clinical outcomes 
during the wound healing process.
There are currently no clinical or experimental rationale for the use of topical antimicrobials 
without debridement (56). Therefore, we did not evaluate the efficacy of BT without debridement. 
Using a lagomorph model, Seth et al. (57) found that topical BT was therapeutically ineffective in the 
absence of debridement. Also, BT should not be considered as a stand-alone therapy. It should be 
used in combination with approved treatments, especially with antibiotics. Chibber et al. (58) found 
that MR-10 lytic bacteriophage was effective for the resolution of hindpaw foot infection in diabetic 
mice. Co-therapy with linezolid was more effective for arresting the entire infection process in vivo.
In conclusion, antibiotic therapy with debridement is the standard first-line therapy for most 
DFIs. However, increasing numbers of patients present with antibiotic-resistant infections, and the 
identification and development of an alternative therapy is crucial. Our multi-faceted assessment 
of topical BT using methodologically different phases was a meaningful way to address this issue. 
These studies have enabled us to develop an antimicrobial product comprised of a combination 
of five lytic bacteriophages. We also developed a high IM (≥10) and multiple dose (every 4 hours 
for 24 hours) protocol for topical BT application. Our product and protocol represent a potentially 
effective therapeutic approach for treatment of diabetic wounds infected with different pathogens. 
The efficacy results obtained in our studies represent the first step in the development of a fully 
regulated human clinical trial that explores the potential for the use of BT for the treatment of DFIs 
and other chronic skin and soft tissue infections. 
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Future prospects
The results obtained in these experimental studies are not limited to BT. Based on the microbial 
isolates of the epidemiological study, we started a structured project that involves the collaboration 
of a network of national and international academic, clinical, and industry-related institutions with 
the objective of characterizing the microbiological isolates and their interactions in DFI. This project 
includes the genetic typing and phenotypic and genotypic evaluations of antimicrobial resistance 
patterns in the S. aureus and P. aeruginosa isolates, in addition to the assessment of their biofilm 
expressions and the characterization of their quorum sensing systems. Furthermore, although it 
was developed for BT, our wound infection model of diabetic rodents can be used to test other TAT 
agents. 
This study used a practical approach to the design of a bacteriophage treatment protocol with 
potential efficacy in diabetic wound chronic infections. The approach did not focus on some 
aspects that could be targeted in future studies to reveal insights into the population dynamics of 
bacteriophage-bacteria interactions under conditions relevant to BT: 
– The clinical application of topical BT in the context of DFIs would probably be more important 
in severe infections involving the deep layers of the foot, particularly the bone. Animal models 
of osteomyelitis are available (59), so future animal studies should be envisaged.
– In Western clinical practice, the topical application of bacteriophages in the absence of other 
systemic antibiotics would be highly unlikely. A synergistic effect has already been identified 
(60); however, systematic studies in this area have never been carried out, and bacteriophages 
are so specific in their actions that it is difficult to predict where these interactions may occur. 
Therefore, these interactions should be addressed in future in vitro and in vivo studies. 
– In all studies, we found either the regrowth or the incomplete eradication of bacteria. 
Although the evolution of bacteriophage resistance in vitro does not seem relevant in vivo 
where bacteria replicate more slowly and are challenged by a greater set of environmental 
conditions (50), the biological basis (genotypic and/or non-heritable mechanisms) of these 
findings should be investigated in further studies.
– A practical clinical application of bacteriophage has to be developed. There is emerging 
evidence that NPWT devices enhance wound healing, although its effect on reducing the 
bacterial load is debatable (61, 62). Thus, the efficacy of bacteriophage preparations instilled 
into the wound using medical devices, particularly NPWT devices with an infusion port, should 
be investigated in appropriate, optimized animal models (63). 
On the other hand, scientific discoveries must be translated into practical applications for 
the improvement of human health (64). Thus, the goal of this study is ultimately to transform 
BT into a realistic, everyday strategy for treating DFIs. We have maintained an open dialogue 
with the institutions responsible for regulating human trials in Portugal (Autoridade Nacional 
do Medicamento e Produtos de Saúde [INFARMED]) and abroad (EMA and US FDA), which 
have resulted in the need to conduct toxicology studies in a good laboratory practice (GLP) 
environment using batches of industrially produced bacteriophages. TechnoPhage, S.A. (which 
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holds the patents of the bacteriophages used in this study) and its commercial partners decided 
to outsource these services. If their results are suitable, we will be able to accomplish a fully 
regulated human trial. Furthermore, the knowledge gained about the biology and pharmacology of 
bacteriophages will be harnessed in the future development of new non-systemic formulations with 
potential applications in BT. For example, the application of inhalation technologies to BT has been 
one of the most recent advances within the field (65) and seems the next logical step. 
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